Archive for the ‘CEOcast’ Category

January 4th CEOcast Weekly Newsletter

Monday, January 4th, 2010

Companies featured in this edition of the newsletter: CUR, DKAM, HYTM, IWEB, PHC

Markets finished the last week of 2009 moderately in negative territory, as it was a quiet week that saw the absence of many major market participants and almost no sizable moves to speak of until a sell off late in the day on Thursday led the major indices into negative territory to finish the year. All told, the Dow surrendered 92 points to close at 10428, down 0.9% on the week, but finishing the year up 18.8%. The Nasdaq lost 0.7%, continuing its outperformance relative to the rest of the major indices, closing at 2269 while finishing the year up a healthy 43.9%. The S&P 500 and Russell 2000 finished the week down 1.0% and 1.4% respectively, ending the year up 23.5% and 25.2%.

The most significant story on the week was the lack of developments; volume was anemic throughout much of the week’s session with many investors taking advantage of the holiday season. Markets traded largely sideways for the bulk of the week until late Thursday when indices dipped sharply, largely due to the lack of market participants to absorb end of the year tax selling. In economic news, Consumer Confidence figures posted a slightly better than expected showing for December, perhaps suggesting a surprise waiting for the market in the form of better than expected holiday retail numbers when investors return to work in the new year. On the labor front, weekly initial jobless claims continued their slide, dropping to 432,000 from 454,000 the prior week, and handily beating consensus estimates calling for 460,000 jobs to be shed; both economic developments were largely ignored by the broader market, as the positive news failed to provoke a reaction due to the lack of market participants.

What should investors look for this week? Earnings reports pick up slightly; on Wednesday morning, look for results from Family Dollar (NYSE: FDO), and Monsanto (NYSE: MON), followed that afternoon by Bed Bath & Beyond (NYSE: BBY).

Economic releases for the week begin with Construction Spending for November and ISM Index for December released together at 10:00am on Monday. On Tuesday, Factory Orders and Pending Home Sales for November will be released at 10:00am, followed at 2:00pm by Truck and Auto Sales for December. On Wednesday, Challenger Job Cuts for December are due to be released at 7:30am, followed by ADP Employment for December at 8:15am, ISM Services at 10:30am, and weekly crude inventories at 10:30am. On Thursday morning, labor market data will be released which will most likely be sharply at the forefront of investors’ attention: look for weekly initial jobless and continuing claims, due out together at 8:30am. Average Workweek, Hourly Earnings, Nonfarm Payrolls and the Unemployment Rate, all for December, will be released at 8:30am, followed at 10:00am by Wholesale Inventories for November at 10:00am and Consumer Credit for November at 3:00pm that afternoon.

Conference schedules pick up this week as well. On Wednesday, Pritchard Capital Partners will hold its two day Energize Conference in San Francisco, along with the Citi Global Entertainment, Media, and Telecommunications conference, which is also being held in San Francisco. Goldman Sachs will host their CEO Unplugged Conference in New York that same day.

With New Year’s being a time for resolutions, we thought we would highlight two healthcare services companies which could benefit from meeting objectives that they expressed a high confidence level in attaining. PHC, Inc. (NYSE AMEX: PHC) stated that it expected to receive receiving CMS Medicare certification at its Seven Hills Facility in Henderson, Nevada, which could increase census. The company comes off several quarters of improved operating results, as Seven Hills and its Capstone Facility in Michigan have contributed to stronger revenue growth, as well as GAAP profitability. Shares surged 8% on Friday on twice average volume to close at $1.13.

Could this be the year that healthcare services company Hythiam, Inc. (NASDAQ: HYTM) finally lands a managed care deal? The company inked a deal during the second half of the year with Ford Motor Company, perhaps suggesting that its Catasys offering is beginning to gain traction. HYTM said it expected to begin to recognize revenue from the agreement during the first quarter of this year. Shares ended the week at $0.44, down 1 cent.

Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord, announced in a regulatory filing last week that it had completed a private placement transaction in which it received $1.5 million in gross proceeds; CUR sold 646,551 shares to one accredited investor at a price of $2.32 per share. The company will file a registration statement covering the resale of the shares by March 21, 2010. Shares gained seven cents on the week to close at $1.79.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it will hold a conference call on Tuesday, January 26, 2010 at 11am to discuss its fiscal 2010 second quarter. The company also plans to provide an update on its 2010 fiscal third quarter, in addition to commenting on progress in the execution of its business strategy. The company recently announced its intention to expand internationally, and has shipped new orders to distributors in Ontario, Canada and Israel. Shares remained unchanged on the week at just over a penny.

IceWEB (OTCBB: IWEB), a leading provider of purpose built appliances and building blocks for cloud storage networks, announced last week that Canadian Health has deployed IceWEB high performance Graphic Information System (GIS) technology to track the spread of the H1N1 swine flu. The company also issued a letter to shareholders last week highlighting its goals for the upcoming year and plans to continue to expand shareholder value through a number of different avenues. Management plans to continue the growth of its sales channel worldwide by marketing its IceWEB and Iplicity brands synonymously with cloud storage computing while further enhancing its customer service operations. The company also plans to continue to extend protection around its intellectual property and has indicated that it expects to provide updates on research, development and patent protection efforts in coming weeks and months. IWEB also announced its intention to grow revenue to $25 million within the next 24 months with profit margins of 60%, which it expects will be attainable as a result of its current product mix, customer base and partner network. Shares remained unchanged at just over $0.12 on the week.

December 28th CEOcast Weekly Newsletter

Monday, December 28th, 2009

Companies featured in this edition of the newsletter: NWCI, PSID, XCR, XSNX

Markets sailed to fresh highs for ’09 during this holiday shortened week, largely on the strength of better than expected data from the housing sector and news that labor markets had shed their lowest number of jobs since the fall of 2008, which helped lead all the major indices into positive territory after consecutive weeks of mixed finishes. All told, the Dow ended the week up 1.9%, gaining 191 points to close at 10520, extending its yearly gains to 19.9%. The Nasdaq posted a strong 3.3% gain on the week, closing at 2285, up 44.9% on the year, while the S&P 500 and Russell 2000 managed to end the week up 2.2% and 3.8% respectively, extending their YTD gains to 24.7% and 27.0%.

With a lack of significant corporate catalysts on the calendar due to the holiday shortened week, economic data was squarely in focus and provided some encouraging news in the form of better than expected existing home sales and a drop in weekly initial jobless claims. The drop in weekly claims from 480,000 the prior week to 450,000 this week, versus consensus estimates calling for 470,000, marked the number’s lowest level since the fall of 2008, and suggests that despite the continued weakness still displayed in labor markets, that they are in fact stabilizing.

Despite the unequivocally positive news extrapolated from the drop in weekly jobless claims, data from housing markets were decidedly mixed, as existing and new home sales came in at opposite ends of the spectrum. Existing home sales rose by a better than expected 7.4% for the month, but were offset by an 11.3% drop in new home sales from November. Investors seemed to focus in on the positive existing home sales however, and the less than stellar new home sales failed to provoke much of a reaction.

What should investors look for this week? There will be no notable earnings releases or conferences scheduled due to the holiday shortened week, but there will be a few pieces of economic data released, beginning on Tuesday with Consumer Confidence for December due out at 10:00am. On Wednesday look for Chicago PMI for December at 9:45am, and weekly crude inventories at 10:30am, followed on Thursday by weekly initial jobless claims and continuing claims at 8:30am.

PositiveID Corp. (NASDAQ: PSID), a provider of unique health and security identification tools to protect consumers and businesses, announced last week that it has entered into a strategic partnership with HealthScreenDirect (HSD), to create a comparative clinical study that will seek to address improving disease management through the use of appropriate, concise, and up-to-date patient health information available to practitioners caring for diabetic, hypertensive and obese patients utilizing PSID’s Health Link electronic medical record system; Health Link will also be offered to the 120,000 plus members of the HSD service. HSD provides millions of Americans direct access to diabetes and cholesterol screenings and educational content. These important health screenings are offered through a convenient process at nationally recognized, certified labs that provide confidential results for the patient through HSD’s secure web site and by mail. HSD also provides a more comprehensive wellness program for corporations, associations and organizations across America, which includes onsite health screenings and testing for diabetes, cholesterol, high blood pressure and obesity. PSID management expects that forging additional partnerships with organizations similar to HSD who represent large patient populations will enable them to cost effectively extend the reach of their Health Link personal record system. Shares gained just under four cents on the week to close at $0.979

NewCardio (OTCBB: NWCI), a cardiac diagnostic and services company, announced last week that its Vice President and Chief Medical Officer, Dr. Ihor Gussak, will be presenting at the 4th Annual Cardiac Safety Assessment Summit being held in Washington DC on January 12 and 13, 2010. NewCardio will also be one of the sponsors of the event, which will feature discussions on how to measure and manage cardiac safety issues such as Arrhythmia, Ischemic Heart Disease, Cardiomyopothy and drugs that effect heart rate and blood pressure. Dr. Gussak will participate in a panel discussion on the Clinical Validation of Automated ECG Reading Methods, where he will discuss NewCardio’s technology platform, including QTinno, the company’s automated cardiac safety solution which was recently demonstrated to provide highly accurate results with reduced intrinsic variability relative to currently used diagnostic methods in clinical validation studies. Shares lost ten cents on the week to close at $0.65.

XsunX (OTCBB: XSNX), a developer of advanced, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, released a letter to shareholders last week, announcing the completion of its first fully functional CIGS thin film solar device. The announcement marks a significant milestone in the company’s technological development process, as the production of a fully functional device serves to validate its revolutionary manufacturing process incorporating equipment from the Hard Disk Drive manufacturing process to develop a scalable, cost effective method of producing high performance thin film solar cells. Management believes that reaching this milestone ahead of its previously announced year-end deadline further strengthens its position and will allow it to more ably benefit from the tremendous growth anticipated in the thin-film photovoltaic market over the next decade. Shares gained a penny on the week to close at $0.16.

Xcorporeal, Inc. (OTC: XCRP), a development stage medical device company that is developing an extra-corporeal platform of products that might be used in devices to replace the function of various human organs, announced last week that it has signed an asset purchase agreement with National Quality Care and Fresenius USA, to sell substantially all of its assets for an aggregate cash purchase price of $8 million, in addition to certain additional royalty payments relating to the Wearable Artificial Kidney (WAK) and supersorbent technology due to XCR for the remainder of the life of the company’s relevant patents on the devices. The purchase price is payable in three installments and is expected to close on or before February 28, 2010 subject to approval by a majority of XCR shareholders. Management has expressed its satisfaction with the transaction, as it feels that Fresenius is the best possible partner for its innovative dialysis platform, and expects that the terms of the agreement represent the best approach to maximizing shareholder value. Shares gained just under three cents on the week to close at $0.10.

December 21st CEOcast Weekly Newsletter

Monday, December 21st, 2009

Companies featured in this edition of the newsletter: CUR, DKAM, ENZ, IWEB, NXOI, OMCM, ONBI, PSID, SIHI

Markets finished the year’s last full week of trading mixed for the second consecutive week, as the Fed’s policy announcement, the deterioration of Greece’s credit rating and strong earnings reports from several big tech names combined to lead the major indices in opposite directions. All told, the Dow surrendered 142 points to close at 10328, down 1.4% on the week, reducing its yearly gains to 17.7%. The Nasdaq performed significantly better, posting a 1.0% gain on the week, bringing its YTD gains to 40.2%, while the S&P 500 lost 0.4% and the Russell 2000 gained 1.7%, bringing their yearly gains to 22.1% and 22.2% respectively.

Volatility returned to equity markets early in the week, ahead of the FOMC’s December meeting, as a slight sell off on Tuesday was recouped ahead of Wednesday’s policy announcement. The announcement remained largely unchanged from statements made in prior months, with the exception of a slightly more optimistic tone regarding developments in the labor market; the Fed again announced its intention to keep rates at historically low levels for, an extended period of time.

The week’s only significant news came on Thursday, when markets reacted badly to the announcement late Wednesday that Standard & Poor’s had cut Greece’s credit rating, dropping it one level from A- to BBB+, citing the country’s need to address its status as the holder of the European Union’s largest budget deficit. In corporate news that same day, better than expected results from Research in Motion and Oracle helped buoy the tech sector and led to the Nasdaq’s outperformance. Following the week’s activities, seven of the ten sectors comprising the S&P 500 finished in negative territory, led by Telecom, down 2.3%, and Consumer Staples, down 2.1%, while IT led all gainers with a 1.1% addition on the week on the strength of the aforementioned earnings reports.

What should investors look for this week? Earnings reports will be very limited due to the holiday shortened week, but look for results from ConAgra (NYSE: CAG) before the bell on Monday, followed after the close by Jabil Circuit (NYSE: JBL).

Economic releases for the week begin with Existing Home Sales for November due out at 10:00am on Tuesday. On Wednesday, look for Personal Income and Spending, and PCE and Core PCE Prices, all for November, released together at 8:30am. Revised Michigan Sentiment for December follows at 9:55am, with New Home Sales for November due to be released at 10:00am, followed by weekly crude inventories at 10:30am. The week wraps up on Thursday with weekly initial jobless claims and continuing claims, along with Durable Goods Orders for November at 8:30am.

There are no conferences of note scheduled due to the holiday shortened week.

Rodman & Renshaw healthcare analyst Reni Benjamin, Ph.D, released a research update on vertically integrated life sciences company Enzo Biochem (NYSE: ENZ) last week, in which he reaffirmed his support for the company’s long term prospects. In the report, Dr. Benjamin reiterated the “Market Outperform/Speculative Risk” rating on the stock, and put a 12 month price target of $14 on the shares which are currently trading at $5.69, based on a 2015 discounted earnings per share and revenue per share analysis. Benjamin cited the recent addition of two widely used, high margin diagnostic tests to the company’s portfolio -colorectal screening test ColonSentry and cervical cancer screening test oncoFISH which represent a shift in the company’s strategy towards high end molecular diagnostics that have the potential to create substantial upside due to synergies created between the company’s clinical labs and life sciences divisions. He concluded his opinion by stating that, “Enzo has the potential to generate significant value for the long-term investor interested in a fundamental revenue story, augmented by considerable potential upside from a burgeoning therapeutics pipeline.” Shares gained two cents on the week to close at $5.69.

PositiveID Corp. (NASDAQ: PSID), a provider of unique health and security identification tools to protect consumers and businesses, announced last week that technology developed by its partner, Receptors, LLC, has been featured in the Journal of the American Chemical Society, a peer reviewed journal devoted to the publication of fundamental research papers in all areas of chemistry. The article, entitled Small Molecule-Based Binding Environments: Combinatorial Construction of Microarrays for Multiplexed Affinity Screening, documents the construction of Receptors’ patented CARA (combinatorial artificial receptor array) technology, which has been licensed to PSID for inclusion in the development of the company’s glucose-sensing RFID microchip and rapid virus detection system for the H1N1 virus and other pandemic viruses. Shares lost fourteen cents on the week to close at $0.94.

Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord,announced last week that it had received approval from the Emory University Institutional Review Board (IRB) to commence a Phase I clinical trial investigating the use of the its proprietary neural stem cells to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), a debilitating neurodegenerative condition affecting roughly 30,000 people in the U.S. The trial, which was approved by the FDA in September, will take place at the Emory ALS Center under the direction of Dr. Jonathan Glass M.D., Director of the Emory ALS Center, who will serve as the site’s Principal Investigator. The trial will study the safety of Neuralstem’s cells and the surgical procedures and devices required for multiple injections of the cells directly into the grey matter of the spinal cord. Shares lost five cents on the week to close at $1.79.

SinoHub (AMEX: SIHI) a company providing world-class supply chain management services with transparent information access for participants in the electronic components supply chain in China, had coverage initiated with a “Buy” rating by analysts from Canaccord Adams last week. Canaccord joins Global Hunter Securities in covering the company, with a median price target between the two organizations of $6.00, on the shares which are currently trading at $3.62. Recently, SinoHub announced that it has signed a new three-year lease, expanding its warehouse facilities in Hong Kong nearly three-fold to 79,500 square feet to support its growing business operations. The company’s current facility encompasses 26,900 square feet and processes nearly $70 million a month in electronic components; management expects that the newly expanded facilities will allow it to process approximately $200 million per month, assuming a similar business and product mix.Shares lost eighty eight cents on the week to close at $3.62.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it has expanded into Ontario, Canada, and has sold $50,000 of Trump Super Premium Vodka to the Liquor Control Board of Ontario (LCBO). The sale marks the initial launch of the brand in Toronto markets, and expands the offering outside of existing Canadian distribution channels within the provinces of Alberta and Manitoba. International penetration for the iconic spirits has been increasing of late, as the company recently announced $150,000 in new orders to be shipped to Israel in addition to the Canadian expansion. Management believes that the increased international demand demonstrated by the new orders for the brand is a direct result of the worldwide recognition of the Trump name, and expects to see increased order flow as it continues to roll additional iconic brands out in overseas markets. Shares remained unchanged at just over a penny on the week.

IceWEB (OTCBB: IWEB), a leading provider of purpose built appliances and building blocks for cloud storage networks, announced last week that it has expanded on the original deployment of its high-density storage platform with U.S. Department of Agriculture’s Agricultural Research Service (ARS). The TruEnterprise product line has been utilized by the ARS for several years for both regular data storage functions, and to ingest Geospatial raster and vector images from their field teams; the platform’s versatility provides significant ROI by drastically reducing IT costs associated with storing and processing large volumes of data, which has been rewarded with the expanded deployment. In other news last week, the company also announced that it has begun manufacturing ESRI’s latest version of the ArcGIS Data Appliance, expanding on the more than 1 Petabyte of ArcGIS Data Appliances which IWEB has already developed as part of an agreement to produce purpose built data appliances pre-loaded with imagery, which ESRI delivers to clients worldwide. Shares remained unchanged at $0.13 on the week.

Next One Interactive (OTCBB: NXOI), an interactive media company specializing in Digital Media with a focus on Travel and Real Estate, announced last week that it will begin airing the “American Outdoorsman” on the Resort & Residence Network. The show is one of the most popular and well recognized outdoor adventure/travel series airing today, and will also begin airing commercials promoting their new American Outdoorsman Outdoor Adventure Travel Club and American Outdoors TV series for kids.Members who join the new American Outdoorsman Adventure Club will be offered a cruise incentive purchased through Next One Interactive; under the arrangement between the two entities, Next One Interactive’s travel division, Extraordinary Vacations, will be the exclusive travel booking partner for the American Outdoorsman Adventure Club’s Celebrity Trips and American Outdoorsman weekends. With projections calling for a minimum of 2000 travelers for each outing, the partnership is expected to generate over 20,000 trips for Extraordinary Vacations during 2010. Management from both companies expect that the relationship will add significant revenue streams to their bottom lines from a number of channels, including travel bookings, advertising, sponsorships, production, and membership fees. Shares gained four cents on the week to close at $1.05.

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, announced last week that it has been selected by a West Coast biopharmaceutical company specializing in small molecule medicines across a number of therapeutic areas, to provide its TrialMaster EDC solution in association with a 9 month Phase I study which is expected to enroll over 80 subjects across 2 sites. Management has indicated that Trialmaster was selected due to its ability to quickly build studies while remaining within budgetary constraints, and as a result of the platform’s support of the client’s internal data standard. Shares remained unchanged at $0.18 on the week.

One Bio (OTCBB: ONBI), a company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced last week that it has appointed Dr. Jian Ming Chan, the company’s Chief Scientist and current Chair of the Department of Environmental Science & Engineering at Fudan University, to its newly created Advisory Board. Dr. Chan will work with the Company’s Board of Directors to identify respected members of the bio-science community who would be strong additions to the newly created Advisory council, and will be responsible for educating Directors on developments and research relating to natural supplements, herbal and chemical extracts, and organic products; Dr. Chan will also be making recommendations to the company regarding potential additions to the company’s product line. Shares remained unchanged at $6.10 on the week.

December 14th CEOcast Weekly Newsletter

Monday, December 14th, 2009

Companies featured in this edition of the newsletter: DKAM, ENZ, FMTI, HYTM, IMUC, IWEB, NXOI, ONBI, PHC, PSID, SRCO

Markets finished this relatively quiet week much where they began, as a lack of significant catalysts left markets trading mostly sideways and led to the major indices closing decidedly mixed following the week’s activities. All told, the Dow ended the week moderately in positive territory, gaining 82 points to close at 10471, up 0.8% on the week and 19.3% on the year. The Nasdaq lost 0.2% on the week, closing at 2190 bringing its YTD gains to 38.9%, while the S&P 500 finished the week flat but still up 22.5% on the year and the Russell 2000 lost 0.4%, stemming its yearly gains to 20.2%.

Despite the slow week, markets opened sharply lower on Tuesday after ratings agency Moody’s indicated that the US and UK would need to take steps towards reducing deficits in order to avoid threats to their triple A credit ratings, which sent many investors heading for the exits early in the session. Tuesday’s downward move was offset however by a higher open on Thursday following better than expected trade deficit data for October which led to the mixed performance on the week.

Despite the slow week for market driving news, there were further signs of moderate continued recovery, as retail sales for November, Preliminary Michigan Sentiment for December, and October business inventories all managed to beat consensus estimates by modest margins. As a result of the lack of definitive direction on the week, the S&P 500 finished largely mixed, but was led by Utilities, up 3.6%, with Financials leading the laggards, down 1.6%.

What should investors look for this week? Earnings releases pick up moderately; expect results from Best Buy (NYSE: BBY) on Tuesday before the bell, followed after the close by Adobe Systems (NASDAQ: ADBE). On Thursday morning Carnival Cruise Lines (NYSE: CCL), Discover Financial Services (NYSE: DFS), Fed Ex (NYSE: FDX), Morgan Stanley (NYSE: MS) and Rite Aid (NYSE: RAD) are expected to report, followed after the close by Accenture (NYSE: CAN), Nike (NYSE: NKE), Oracle (NASDAQ: ORCL), Palm, (NASDAQ: PALM) and Research in Motion (NASDAQ: RIMM).

Economic releases for the week begin with PPI and Core PPI for November along with Empire Manufacturing for December at 8:30am on Tuesday, followed at 9:00am by Net Long-term TIC Flows for October and Capacity Utilization and Industrial Production for November at 9:15am. On Wednesday, look for Building Permits, Housing Starts, CPI and Core CPI, all for November, released together at 8:30am, followed by weekly crude inventories at 10:30 am and the FOMC Rate decision at 2:15pm. The week wraps up on Thursday with weekly initial jobless claims and continuing claims at 8:30am followed by Leading Indicators for November and Philadelphia Fed data from December at 10:00am.

Conference schedules for the week will be light, beginning on Tuesday in San Francisco with the Roth Capital Partners Medical Device Conference. On Wednesday Credit Suisse hosts their New York Retail Roundup while Raymond James will hold their IT Supply Chain Conference which is also being held in New York.

Enzo Biochem (NYSE: ENZ), a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, reported results for its first fiscal quarter of 2010 for the period ended October 31, 2009. During the period, ENZ posted significantly improved results, posting operating revenues of $25.2 million, a 19% improvement in operating revenues compared to the comparable period in the previous year along with a Gross profit increase of 63%, to a record $13.3 million. Organic core product sales growth in the company’s Life Sciences division topped 26%, while the Clinical Labs division posted a 36% increase in revenues and improved gross margins. Net loss of $1.8 million, or ($0.05) per share for the period was reduced by more than 70%, compared to the year ago period where net loss was $6.4 million, or ($0.17) per share. In other news last week, the company announced that it has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc. relating to Ikonisys’ proprietary oncoFISH cervical test, a laboratory developed test for cervical cancer prevention. Enzo Clinical Labs will market the assay to physicians requesting advanced analysis of specimens from liquid based Pap tests to assist them in evaluating cytologic reports. Ikonisys will conduct the evaluation of the specimen using its proprietary CellOptics platform on the Ikoniscope Digital Microscopy System for the interpretation of molecular signals. Shares lost 43 cents on the week to close at $5.48.

Volume Alert: Shares of healthcare services company Hythiam (NASDAQ: HYTM) soared 68% on Friday on more than seven times average volume. The lack of news to explain the outsized gain may have left investors wondering whether the company could be close to inking a deal with a healthcare services company. The company previously said that it expected to land such a deal, which could provide validation for the company’s Catasys offering and a significant source of revenue. During the third quarter the company entered into a deal with Ford Motor Company to provide the Catasys integrated substance dependence solution to certain of Ford’s hourly employees in Michigan. Shares ended the week at $0.48, up 18 cents.

Forbes Medi-Tech Inc. (NASDAQ: FMTI), a life sciences company focused on evidence-based nutritional solutions, announced last week that its proprietary cholesterol-lowering ingredient Reducol, will be included in a new pineapple juice being launched in the Philippines by Del Monte Philippines, Inc. This latest inclusion marks the continued expansion of the Reducol product line, and is a significant step towards management’s goal of increasing market penetration of the cholesterol lowering product further into Southeast Asia. Shares gained 2 cents on the week to close at $0.30.

PositiveID Corp. (NASDAQ: PSID), a provider of unique health and security identification tools to protect consumers and businesses, announced last week that it has entered into a strategic partnership with the Health Network of the Palm Beaches to further the technological development, implementation and distribution of PositiveID’s Health Link personal health record within the medical facilities participating in the Southern Florida Regional Heath Information Organization (RHIO). RHIOs are the micro level organizations tasked with consolidating medical records on local levels so that they may be incorporated down the line into a proposed National Health Information Network that would provide a national database of medical records. Management expects that ensuring seamless communication between Health Link and the electronic medical record systems currently in use in doctors’ offices and hospitals throughout the state, will enable the company to gain significant traction in the product’s roll-out. Shares lost 9 cents on the week to close at $1.08

Volume Alert: Shares of behavioral healthcare provider Pioneer Behavioral Health (AMEX: PHC), gained 6% on over three times average volume on Friday. Recently, the company reported improved results for its 2010 first quarter for the period ended September 30, 2009, where it managed to report its third consecutive quarter of profitability, increasing net patient care revenue by 11.4% on the strength of increased census at the company’s Seven Hills Behavioral Institute in Las Vegas, and its Capstone facility in Detroit which is expected to continue in the current period. The stock ended the week at $1.05, down 3 cents.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it has sold $150,000 of spirits to its partner, H. Pixel International Trade Ltd., in Israel. In addition to the first order, the companies have come to terms on a final contract under which DKAM will receive a guaranteed minimum of $175,000 in fees and payments annually for the next 15 years totaling approximately $3 million, with potential for additional revenue in the form of incremental bonuses for additional volumes or product additions. Management has indicated that it plans to seek similar arrangements from other distributors and strategic partners. Shares remained unchanged at just under two cents on the week.

ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it has entered into a definitive agreement with an accredited investor to sell up to $10 million of the company’s non-convertible Preferred Stock to the investor over a two year period. Proceeds from the sales are expected to provide working capital, in addition to funding further clinical activity, including planned future clinical trials for the company’s ICT-109 and ICT-121 cancer vaccine candidates for the treatment of glioblastoma. In other news last week, IMUC announced the appointment of three new members to its Scientific Advisory Board: Colonel George Peoples, M.D. Director of the Cancer Vaccine Development Program and Deputy Director of the United States Military Cancer Institute (USMCI), Dr. Constantine Ioannides, Professor of Immunology at the M.D. Anderson Cancer Center, and Dr. Cohava Gelber, Chief Scientific & Technology Officer of ATCC. The recommendations were made with the strong support of IMUC’s Board of Directors, who cited these individuals’ impressive research credentials and leadership within the field of immunotherapeutics and cancer research as reasons for the appointments. Shares lost fifteen cents on the week to close at $0.90.

IceWEB (OTCBB: IWEB), a leading provider of purpose built appliances and building blocks for cloud storage networks, announced last week that it has added a built-in, no-charge virus scanning capability based upon the widely accepted ClamAV software to its Iplicity Unified Storage Platform. ClamAV contains nearly 700,000 virus signatures and is updated in real-time by a broad cross section of the worldwide open-source community in order to protect against malicious code such as viruses, worms, Trojan horses; the new functionality will be made available as a no-charge software Plug-In for current and future Iplicity customers. Shares remained unchanged at just under eleven cents on the week.

Volume Alert: Shares of Next One Interactive (OTCBB: NXOI), an interactive media company specializing in Digital Media with a focus on Travel and Real Estate, gained just under 15% on almost three times average volume last week, following the announcement that its subsidiary Resort & Residence TV has launched Extraordinary Vacations, a travel shopping show now airing on the network. The show is a 30-minute, response driven program showcasing a wide array of travel offers from around the globe including hotel packages, all inclusive resorts, cruises, specialty tours, destination specific vacations and more. The show will allow travel industry organizations such as cruise lines and resorts to market their services directly to consumers via a cost effective channel dedicated to vacation programming. Shares rose 12 cents on the week to close at $1.01.

One Bio (OTCBB: ONBI), a company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced last week that its chemical and herbal extract division has launched its “Complete Beauty and Treatment Series” over-the-counter product line. The new series of therapeutic products has been developed to target salons and nutrition retail locations, and was officially launched at the 5th Cross-strait Forestry Expo and Fair for Investment and Trade in Sanming City, China to an audience of more than 80,000 people and companies from 15 countries who attended the event. The line will include various skin care treatments and weight management and energy supplements derived from ONBI’s natural herbal extracts and organic products. Shares remained unchanged at $6.10 on the week.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated to the powersports industry, announced last week that it has signed a Letter of Intent to acquire the assets of a Denver-based consumer finance company, with assets including a portfolio of performing motorcycle loans in excess of $14 million, inventory, cash and other assets; Sparta has indicated that it expects the transaction to close by January 31, 2010. The acquisition is subject to the completion of a definitive purchase/sale agreement, Sparta’s completion of due diligence, the receipt of audited financials, and certain other factors. The ultimate purchase price is subject to adjustment at closing based on the value and performance of the portfolio to be acquired. Shares ended the week at $0.04, down 1 cent.

December 7th CEOcast Weekly Newsletter

Monday, December 7th, 2009

Companies featured in this edition of the newsletter: ACTC, CVM, ENZ, HYTM, IMUC, IWEB, NXOI, ONBI, PSID, SIHI, XSNX

Markets hit fresh highs for ’09 yet again this week, as decreased concerns regarding the Dubai debt restructuring announcement and news that the US labor market is showing signs of recovery spurred broad based buying which led all of the major indices higher. All told, the Dow ended the week up 0.8%, gaining 79 points to close at 10388, extending its yearly gains to 18.4%. The Nasdaq gained 2.6% on the week, closing at 2194, up 39.1% on the year, while the S&P 500 and Russell 2000 gained 1.3% and 4.4% respectively, bringing their YTD gains to 22.4% and 20.7%.

Concerns stemming from the post-Thanksgiving announcement that Dubai was attempting to restructure debt subsided early in the week, as investors recognized that US exposure to the debt was minimal, and developments would be ongoing for some time. With these fears allayed, investors focused in on economic news in the absence of any market moving earnings releases, and were not disappointed, as the seemingly endless streak of negative headlines associated with US labor markets was finally snapped when unequivocally upbeat employment reports were released late in the week. Employers shed only 11,000 jobs during the month of November, handily beating estimates calling for 125,000 cuts and marking the labor market’s best performance since December of 2007. Unemployment figures also dropped unexpectedly, declining to 10.0% in November from 10.2% the prior month.

In corporate news, Bank of America announced plans to repay $45 billion in TARP funds which sparked buying in financials and helped the sector to a 2.3% gain on the week, while gold continued its run, hitting a new high at $1226 per ounce before losing 4.6% on Friday to close at $1161 an ounce. Following the week’s activities, nine of the ten sectors comprising the S&P 500 finished the week in positive territory, lead by utilities at 3.9% and telecom at 2.4%.

What should investors look for this week? Earnings reports will continue to trickle in slowly; expect results from AutoZone (NYSE: AZO) and supermarket operator Kroger (NYSE: KR) Tuesday before the bell, followed by Costco (NASDAQ: COST) pre-market on Thursday.

Economic releases for the week begin on Monday with Consumer Credit for October due out at 2:00pm, followed on Wednesday by Wholesale Inventories for October at 10:00am and weekly crude inventories at 10:30am. On Thursday, expect weekly initial jobless and continuing claims at 8:30am, along with Trade Balance data for October. The week wraps up on Friday with Import and Export Prices for November, released along with Retail Sales for November at 8:30am, followed at 9:55am by Preliminary Michigan Sentiment for December and October Business Inventories at 10:00am.

Conference schedules will be busy again this week, beginning on Monday with the three-day UBS Media & Communications Conference in New York. On Tuesday, RBC Capital Markets hosts their Software-as-a Service One on One Symposium in New York, alongside the two day Bank of America Securities and Merrill Lynch Industrials Conference and Goldman Sachs US Financial Services Conference, both of which are also being held in New York; also beginning on Tuesday is the three day Barclay’s Technology Conference, being held in San Francisco. The week wraps up on Wednesday with Wells Fargo hosting their Global Real Estate Securities Conference in New York.

Earnings Preview: Enzo Biochem (NYSE: ENZ), a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, is set to release results for its first fiscal quarter of 2010, for the period ended October 31, 2009, on Thursday after the close; the company will hold a conference call on Friday to discuss the results. During the fourth quarter of ’09, Enzo reported a 16% increase in total operating revenue, to $24.5 million, and a 19% increase in gross profit, to $10.6 million, compared to the corresponding year ago period. The increased results were attributed to greater product sales and acquisitions at its Enzo Life Sciences subsidiary, in addition to higher testing throughput at its Enzo Clinical Labs division, but were offset by higher selling, general and administrative expenses amounting to 48% of net operating revenues. As a result of the widened costs, ENZ reported a net loss of $5.3 million or ($0.14) per share for the period, compared to a year ago net loss of $3.3 million, or ($0.09) per share; investors are likely to focus on the company’s ability to narrow net loss and continue to grow revenue from its Life Sciences and Clinical Labs divisions, which has recently expanded service offerings and product lines to include several new testing kits and diagnostic tools designed to expand marketability. Shares jumped over 14% on the week, gaining 75 cents to close at $5.91.

Hythiam (NASDAQ: HYTM), a company providing behavioral health management services to health plans, employers and unions through a network of licensed and company managed healthcare providers, announced last week that it has been granted eligibility to continue listing on the Nasdaq Exchange subject to HYTM’s ability to meet certain requirements. Continued listing is subject to the company’s ability to demonstrate either stockholders’ equity of at least $10 million or a market value of its listed securities of at least $50 million, on or before February 24, 2010. Shares lost six cents on the week to close at $0.30.

PositiveID Corp. (NASDAQ: PSID) , a provider of unique health and security identification tools to protect consumers and businesses, announced last week that it has entered into a strategic alliance with Innovations Avocare to develop PositiveID’s Health Link personal health record within the medical facilities participating in the State of Florida regional health information organizations (RHIO). The companies will also work to advance compatibility between their Health Link system and the state Electronic Medical Record systems utilized by RHIOs. Avocare connects healthcare within a community through the Regional Health Information Networks, a hardware and software system that brings medical information together through a secure Physicians Portal website dedicated to offering a more efficient, private and secure replacement to paper, fax and phone communications between health care providers. In other news last week, PSID announced its intention to expand its exclusive license agreement with partner RECEPTORS, to include Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors,” to use in conjunction with PositiveID’s Patent No. 7,125,382 entitled “Embedded Bio-Sensor System†to develop an in vivo glucose-sensing radio frequency microchip for animals, primarily dogs and cats. Shares lost 4 cents on the week to close at $1.17.

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that it has retained the services of an international Contract Research Organization (CRO) to run its upcoming Phase III clinical trial in advanced primary head and neck cancer with lead product candidate, Multikine. This CRO is considered to be one of the world’s top CRO’s for running global oncology studies, and will manage the study which is expected to enroll up to 800 patients with advanced primary head and neck cancer in multiple countries around the world. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve patients’ overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck. Shares lost eight cents on the week to close at $1.21.

SinoHub (AMEX: SIHI) a company providing world-class supply chain management services with transparent information access for participants in the electronic components supply chain in China, announced last week that it has signed a new three-year lease, expanding its warehouse facilities in Hong Kong nearly three-fold to 79,500 square feet to support its growing business operations. SinoHub’s Hong Kong facility serves as its gateway for processing all electronic component imports into China. Currently, the company’s facility, which includes a procurement-fulfillment hub, bonded warehouse and transshipment hub, totals 26,900 square feet and processes nearly $70 million in monthly processing volume of electronic components; management expects that the expanded warehouse facilities will increase the value of electronic components that it can handle to a potential processing volume of approximately $200 million per month, assuming a similar business and product mix. Shares gained forty two cents on the week to close at $3.77.

Stem cell developer Advanced Cell Technology (OTCBB: ACTC) received encouraging news last week, as it was announced that the Obama administration has approved the first human embryonic stem cells for experiments by federally funded scientists in a move designed to expand government support for the up and coming science of regenerative medicine. The National Institute of Health authorized 11 lines of stem cells that will be eligible for federal research grants that would allow scientists to begin tapping millions in federally appropriated funds earmarked to advance the study of stem cells. While private funds are still required to be used in development of new embryonic stem cell lines beyond those eligible for grants from the NIH, proponents of the research are hailing the move as a long awaited step towards removing significant impediments put in place by the Bush administration; it is expected that the announcement is the first in a series of what will ultimately be a vastly expanded bank of stem cell lines eligible to be studied using federal funds. Shares ended the week unchanged at $0.105.

ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated significant abilities to target and destroy CSCs in pre-clinical animal models. The technology being licensed is an immunotherapy targeting cancer stem cells using abnormal Notch and Numb pathways, two mechanisms implicated in many common solid tumors including breast, colon and ovarian cancers. Research indicates that cytotoxic T cells induced by these peptides preferentially target cancer stem cells derived from breast cancer, ovarian cancer and pancreatic cancer; expression of these peptides has been demonstrated on clinical samples from ovarian cancer patients. This latest addition serves to further increase IMUC’s ability to specifically identify and destroy CSCs by targeting additional pathways that were not addressed by its current portfolio. Shares gained eight cents on the week to close at $1.05.

IceWEB (OTCBB: IWEB), a leading provider of purpose built appliances and building blocks for cloud storage networks, announced last week that its Iplicity Unified Storage Platform has successfully passed a series of tests established by Citrix, and has been verified as Citrix Ready, a certification designed to help customers identify third-party solutions that add the greatest value in Citrix Delivery Center Infrastructure solutions. Iplicity provides highly scalable virtualized storage to Citrix deployments and is simple to deploy and manage. From server virtualization projects to Virtual Desktop deployments, Iplicity adds value to Citrix customers by reducing their storage costs, providing lightening fast performance, and easing the burden of administering a complex SAN or NAS storage solution. As a result of the recently granted certification, Iplicity products will carry the Citrix Ready logo, and will be featured in an online catalog along with other products carrying the certification, which management expects will greatly enhance visibility to Citrix customers and channels. Shares gained a penny and a half on the week to close at $0.135

Next One Interactive (OTCBB: NXOI), an interactive media company specializing in Digital Media with a focus on Travel and Real Estate, announced last week that its Resort and Residence (R&R) TV network has completed the first episode of its original series Yacht TV, which will debut December 15. The series will be sponsored by The Sacks Yacht Group, a 25-year-old luxury yacht vacation and sales company, and NXOI’s wholly owned subsidiary, Maupintour, a leader in tour packages for over 50 years, who will leverage the forum to market yacht charters to their customer base, making them one of the only traditional tour companies to offer yacht vacations. The show will feature Sacks Group’s luxury vessels ranging from 70 to 150 feet located in a variety of destinations worldwide, and is expected to generate revenue through several channels including, referrals, booking fees, advertising and sponsorships enhanced with interactive applications; Yacht TV has deals in place that are expected to generate over $60,000 a month from a combination of revenue streams. In related news, NXOI announced last week that it has entered into a partnership with Elite Island Resorts, a premier group of beachfront resort properties in the Caribbean, to feature the company’s Antigua properties in programming for the Resort and Residence TV network; R&R will feature The Verandah Resort and Spa, The St. James’s Club and Villas and Galley Bay Resort and Spa, in addition to providing viewers with a tour of Antigua. Shares lost twelve cents on the week to close at $0.89.

One Bio (OTCBB: ONBI), a company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced last week that its subsidiary, Green Planet Bioengineering, has secured key certifications on its recently leased land in Sanming China, to initiate botanical extractions of highly demanded and highly profitable herbs. The land includes 1,270 acres for the cultivation of Sarcandra Glabra, a valuable plant whose extracts are used in traditional Chinese medicine for many treatments including bruising, bone fractures, arthritis, nausea, internal pain, and cough. In addition, the lease includes 480 acres for the cultivation of Polygonum Cuspidatum, which yields Resveratrol, a highly demanded raw extract believed to have various health benefits which is extensively used for treatment and research of various cancers and Alzheimer’s disease. Shares gained ten cents on the week to close at $6.10.

XsunX (OTCBB: XSNX), a developer of advanced, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, released a letter to shareholders last week highlighting the presentation given last week by its CTO, Robert Wendt, at the second annual Thin-Film Solar Summit in San Francisco. At the conference, which attracts a wide array of solar industry professionals including scientists, engineers, manufacturers and project developers, Mr. Wendt presented an overview of the company’s technological platform and highlighted the benefits of the platform, citing low risk, speed to market and economic viability as reasons for its revolutionary potential. The presentation is available on the XSNX website, and can be accessed by visiting http://www.xsunx.com/pdf/Thin%20Film%20Summit_Final_2009_11_24.pdf Shares remained unchanged at $0.17 on the week.

November 30th CEOcast Weekly Newsletter

Monday, November 30th, 2009

Companies featured in this edition of the newsletter: ACTC, ENZ, NWCI, OMCM, ONBI, PHC, XSNX

Markets continued to display strength early on during this holiday shortened week, only to be led lower on Friday by concerns stemming from the announcement that the UAE was attempting to restructure debt with potentially adverse effects on lenders, chiefly, European banks. All told, the Dow finished marginally in negative territory, losing 0.1% on the week, surrendering 8 points to close at 10309, up 17.5% on the year. The Nasdaq performed slightly worse, losing 0.4% to close at 2138, while the S&P 500 finished the week flat and the Russell 2000 lost 1.3% to put their yearly gains at 20.8% and 15.6% respectively.

Stronger than expected Existing Home Sales reported on Monday helped indices climb to their highest levels of the week, as sales in October rose 10.1% to 6.1 million homes, handily beating forecasts for 5.7 million, on the strength of incentives created by the first-time buyers tax credit. Markets held Monday’s gains in two quiet sessions leading up to the Thanksgiving break, but as investors returned to action on Friday, they were greeted by news that European and Asian markets had reacted badly to the announcement of debt restructuring plans by the UAE, which ultimately led markets into negative territory on the week.

With US markets closed on Thursday, their Asian and European counterparts plunged on concerns about the potential effects of restructuring up to $20 billion in UAE debt coming due in the next 18 months. As many European banks are among those with the most exposure to the loans, markets reacted badly, with the FTSE declining over 3% on Thursday despite rebounding on Friday.

What should investors look for this week? Earnings reports will be light, but expect results from retailer Aeropostale (NYSE: ARO) on Wednesday after the close, followed on Thursday pre-market by home builder Toll Brothers (NYSE: TOL), with software developer Novell (NASDAQ: NOVL) reporting after the close that same day.

Economic releases for the week begin on Monday with the Chicago PMI due out at 9:45am. On Tuesday morning, look for Construction Spending and Pending Home Sales for October along with the ISM Index for November at 10:00am, followed by Truck and Auto Sales for November at 2:00pm. Challenger Job Cuts for November will be released on Wednesday morning at 7:30am, followed by ADP Employment for November at 8:15am, weekly crude inventories at 10:30am, and the Fed Beige Book for November at 2:00pm. On Thursday, weekly initial jobless claims and continuing claims will be released at 8:30am along with Revised Q3 Productivity and Q3 Employment Cost Index, followed at 10:30am by ISM Services for November. The week wraps up with Nonfarm Payrolls, the Unemployment Rate, Average Workweek and Hourly Earnings, all for November, due out at 8:30am, followed at 10:00am by Factory Orders for October.

Conference schedules pick up following the holiday; Piper Jaffray hosts their two-day Healthcare Conference in New York beginning on Tuesday along with the Citigroup Global Markets Basic Materials Conference. On Wednesday, the Jeffries Energy Summit begins in New York along with the Morgan Stanley Transportation Corporate Access Day, JP Morgan SMid Cap Conference, and two-day Bank of America and Merrill Lynch Credit Conference. Advanced Cell Technology (OTCBB: ACTC), ImmunoCellular Therapeutics (OTCBB: IMUC) and NewCardio (OTCBB: NWCI) present Thursday at the LD Micro Conference in Los Angeles, which brings together 75 presenting companies with over 100 institutions focused on investing in small and micro cap companies across a breadth of industries. Credit Suisse Group hosts its Technology Conference in Phoenix on Thursday.

Pioneer Behavioral Health (AMEX: PHC), a provider of inpatient and outpatient behavioral health services, announced last week that it has been awarded a contract renewal from the Detroit-Wayne County Community Mental Health Agency representing total commitments in excess of $10 million if all option years are exercised. PHC was the incumbent bidder for the contract, having serviced the residents of Wayne County for over five years prior to being awarded the new multi-year contract, which began on May 1, 2009. Under the terms of the contract, PHC will provide Access and Eligibility Services, Crisis Intervention, and Information and Referral, including an array of services delivered via Call Center operations and electronic review of records, change of level of services, credentialing and related behavioral services designed to help residents of Wayne County make informed behavioral health choices. Shares lost sixteen cents on the week to close at $1.00.

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, announced last week that its TrialMaster EDC solution has been chosen by Beardsworth, a full service contract research organization, to assist in a Phase II vaccine study that will enroll approximately 340 patients at ten sites over the course of three years. OmniComm and Beardsworth plan electronic imports of data to TrialMaster utilizing OmniComm’s native template matching subsystem. Electronic exports from TrialMaster EDC to Beardsworth’s BNet portal will be achieved utilizing OmniComm’s new RESTful Web Services, Application Programming Interface (API). This API technology, developed using a RESTful Web Services architecture, leverages CDISC standards and allows for easy integration with external data sources like BNet. The agreement adds Beardsworth to the list of clients participating in OMCM’s already successful CRO preferred program. Shares remained unchanged at $0.20 on the week

One Bio (OTCBB: ONBI), a company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced last week that its subsidiary, Green Planet Bioengineering, has entered into a distribution agreement with The Chinese Society of Traditional Chinese Medicine, under which, the Society has agreed to include ONBI’s recently launched over-the-counter natural and health supplements and beauty products to its network, distributing traditional and herbal medicine products throughout China, the US and European markets. Management expects to see improved sales of over-the-counter natural and health supplements as a result of the Society’s 30,000 points of sale in China and 3,000 in the United States; the agreement marks a key step in the company’s aggressive distribution strategy. Shares lost 40 cents on the week to close at $6.10.

XsunX (OTCBB: XSNX), a developer of advanced, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, announced last week that its Chief Technology Officer, Robert Wendt, has been invited to address over 300 senior thin-film experts at the second annual Thin-film Solar Summit in San Francisco, CA on December 1. Mr. Wendt will be part of a panel discussion on thin-film breakthrough technology along with several industry leading scientists, and will discuss the latest in cell and module innovation from a technical perspective, specifically advancements in high-rate single cell deposition of CIGS layers. The Thin-film Solar Summit U.S. attracts highly respected solar industry professionals including manufacturers, investors, engineers, scientists, project developers, researchers and key service providers looking to push the thin-film industry forward. Shares gained just over a penny on the week to close at $0.175.

On the Wires: Vertically integrated biotechnology company Enzo Biochem (NYSE: ENZ), announced last week that its Board of Directors has approved the termination of Shahram K. Rabbani’s as the company’s Secretary and Treasurer; Mr. Rabbani will continue to serve as a Director of the company. The board has appointed Dr. Elazar Rabbani to serve as Secretary and Barry W. Weiner to serve as Treasurer, effective immediately. Dr. Rabbani currently serves as the company’s Chairman of the Board and Chief Executive Officer and Mr. Weiner currently serves as the President, Chief Financial Officer, Principal Accounting Officer and as a member of the Board of Directors.

SPECIAL SITUATIONS:

NewCardio, Inc. (OTCBB: NWCI) $0.70

With all the attention surrounding health care reform and generally improved medical practices of late, companies with products that can facilitate more efficient patient care have been receiving increased attention from investors. NewCardio is a company seeking to incorporate novel, state-of-the-art technology to improve the diagnostic accuracy and precision of the analysis of signals from electrocardiograms (ECGs) in order to better diagnose heart conditions. The company’s focus on improving one of the most commonly employed medical diagnostic tests in use today presents investors with an opportunity to consider a company engaged in serving an extremely robust market at a time when improving efficiencies within the health care space is at the forefront of public policy initiatives.

What makes NewCardio’s technology unique is that it takes the standard 12 lead ECG input performed over 250 million times annually in the developed world, and displays the signals in a three dimensional output, providing significantly increased sensitivity, accuracy and precision to the potentially lifesaving diagnostic tool. In addition to providing for a more thorough, accurate diagnosis of potential heart conditions, it allows for the capability to automate what has historically been a more costly and labor intensive process. In order to more fully capitalize on the multibillion dollar a year potential market, the company is currently developing three unique solutions addressing distinct and rapidly growing segments of the industry, which it expects will greatly enhance its ability to diversify its revenue stream.

Initially, NewCardio has implemented its technology in cardiac toxicity testing done in conjunction with FDA mandated clinical trials for new drug development. Utilizing the 3D technology, the company expects that it will significantly reduce the costs associated with cardiac safety trials and will accelerate the drug development process, as clinical trial service providers, such as Contract Research Organizations (CROs) and drug companies will be able to automate the traditionally time consuming and costly manual or semi-automated processes typically done in conjunction with these trials; estimates put the potential market on cardiac toxicity testing near $$750 million annually for early and late-state drug testing. The company’s product offering targeted at facilitating clinical ECG activities, called QTinno, has already been licensed by several top tier CROs to deliver fully automated safety analysis of cardiac safety in drug development just months after its launch in August, with agreements expected to follow from additional leading CROs, ECG core labs, Phase I units and pharmaceutical companies.

Along with clinical applications, the company expects that use of its improved diagnostic tool VisualDX will have similarly positive effects on hospital operations, as the ability to more accurately and expeditiously diagnose heart conditions in Emergency Departments has the potential to save thousands of lives annually, in addition to significantly reducing costs associated with unnecessary hospital admissions resulting from inaccurate ECG readings. With 70 million ECGs performed in ERs in the US alone each year, the potential market for hospital applications has been estimated to be in excess of $2 billion annually. In addition to clinical and hospital applications, the company also plans to employ the technology in home monitoring of chronic heart conditions, which could potentially revolutionize the way patients monitor their disease outside of a healthcare facility. A unique, wireless hand held device (CardioBip) that could transmit heart information remotely to doctors is currently in development which would enable complete cardiac assessment outside of the immediate care of a physician, allowing for round the clock observation without the high costs associated with hospital stays.

To complement its innovative technology platform, the company also has a strong management team with backgrounds across a breadth of industries that serve to guide both product development and corporate operations. Spearheaded by Chairman Mark Kroll, the most prolific inventor of electrical medical devices in the world with over 280 patents to his credit, management includes veterans from the medical device, technology, CRO, biotechnology and finance industries, including high ranking executives from organizations such as Intel and St. Jude Medical with extensive experience in designing and marketing cutting edge medical devices. Along with leading technological development and attracting early adoption agreements for QTinno with several major CROs, management and Board have recently demonstrated their commitment to both the technological concept and the company itself, by buying up more than half of a recent $2.9 million private placement offering that, when coupled with a $3 million dollar line of credit, is expected to sufficiently fund operations into the second half of 2010, by which time management expects considerable strength in the sales of QTinno.

According to a regulatory filing, the company has begun to explore strategic relationships with one or more partners, to provide capital and to enhance the development and marketing of its products, with a primary focus on its 3-D Technology platform, specifically Visual3Dx for the urgent care market and CardioBip for cardiac monitoring applications. By the second half of next year, the company expects activity in clinical trials to drive acceptance of its automated cardiac safety tool.

With strong technological improvements made to an already well established medical test enabling reduced costs and improved diagnostic capabilities for one of the leading causes of death worldwide, NewCardio appears to be well positioned to capitalize on the growing trend towards providing better care while improving efficiencies within the healthcare system. The ability of their platform to provide more accurate readings in a less time consuming and less labor intensive manner has the potential to allow for better care and reduced cost across a wide breadth of applications, making it an extremely intriguing and timely prospective investment as the focus on more efficient healthcare continues to attract significant national attention.

November 23rd CEOcast Weekly Newsletter

Monday, November 23rd, 2009

Companies featured in this edition of the newsletter: ACTC, CUR, CVM, DKAM, ENZ, IMUC, MFGD, NXOI, OMCM, ONEZ, PSID, XSNX

Markets continued to carry momentum during the early stages of last week, as the absence of significant economic news led to a continuation of the upward trend characterizing the past few weeks, until an earnings miss from Dell on Thursday led to a selloff in the technology sector which caused the major indices to end the week mixed. All told, the Dow ended the week in positive territory, gaining 47 points to close at 10318, up 0.5% on the week and 17.6% on the year. The Nasdaq surrendered 1.0% to close at 2146, paring its YTD gains to 36.1%, while the S&P 500 and Russell 2000 lost 0.2% and 0.3% respectively, reducing their yearly gains to 20.8 and 17.1.

Things got off to a strong start on Monday, with the performance of the prior week fresh in the minds of investors, helping to spur outsized gains which were largely eroded throughout the course of the week. Economic news was mixed, as weekly initial jobless claims met expectations but remain elevated above the 500,000 mark, while retail sales for October handily beat consensus estimates, growing by 1.4%. These relatively positive developments were offset however by news of weakness in the housing sector, in the form of significantly worse than expected housing starts, which fell by 10.9% in October.

In corporate news, the few retailers reporting last week posted generally positive results, as Gap, Limited Brands, Sears Holdings and Target all managed to beat consensus EPS estimates. The lone disappointment on the earnings side last week was Dell, which disappointed both revenue and EPS. The news was not well received by investors, as shares of Dell traded 7.2% lower the following day, despite the announcement that the company was seeing generally improved demand for IT services. The Dell miss weighed heavily on the tech sector, which ended up underperforming the rest of the S&P’s ten sectors, leading the laggards with a loss of 1.4% on the week, with healthcare leading the way with a gain of 1.9%.

What should investors look for this week? Earnings reports will continue to trickle in slowly during this holiday shortened week; expect results from Tyson Foods (NYSE: TSN) on Monday premarket, followed after the bell by Hewlett Packard (NYSE: HPQ). Barnes & Noble (NYSE: BKS) report Tuesday morning along with HJ Heinz (NYSE: HNZ) and Medtronic (NYSE: MDT) with Deere (NYSE: DE) reporting Wednesday morning before the bell to close out the week. Of course, markets will be closed on Thursday for Thanksgiving and will trade until 1 p.m. on Friday.

Economic releases for the week begin with Existing Home Sales for October due out at 10:00am on Monday, followed on Tuesday by Preliminary Q3 GDP and Preliminary Chain Deflator at 8:30am, with Consumer Confidence for November at 9:00am and FHFA Home Price Index figures for September at 10:00am. Wednesday will be a busy day, as Personal Income and Spending for October will be released along with PCE and Core PCE Prices for October at 8:30am. Also due out at 8:30am that morning are weekly initial jobless claims and continuing claims and Durable Orders for October, followed by Revised Michigan Sentiment for November at 9:55am and New Home Sales for October at 10:00am; weekly crude inventories round out the week at 10:30am.

There are no conferences of note scheduled due to the holiday shortened week.

Enzo Biochem (NYSE: ENZ), a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, announced last week that it has entered into an agreement with GeneNews, of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey. Enzo expects that the test will be available in the second half of 2010, following the completion of requisite state regulatory processes in New York and New Jersey. The test offers a novel, non-invasive option for determining an individual’s current risk for colorectal cancer and helps prioritize patients at greater risk for the disease; Enzo is currently the only US provider of the test and will provide an important segment of the eligible US population with the diagnostic tool. Shares gained sixteen cents on the week to close at $5.90.

PositiveID Corp. (NASDAQ: PSID), a provider of unique health and security identification tools to protect consumers and businesses, announced last week that it has formed a new animal health division, PositiveID Animal Health, to focus on diagnostic/clinical response and source food safety products and applications. Randolph K. Geissler, founder of Destron Fearing and former CEO of Digital Angel Corporation, a specialist in managing companies and technologies involved in the veterinary science field, will serve as CEO of the newly formed entity. The Animal Health division will address the growing concern of animal health through diagnostic/clinical response products, applications and test kits, and will seek to apply the patents recently obtained from its partnership with RECEPTORS LLC relating to the in-vivo glucose sensing microchip technology to animals. The company also plans to seek out applications similar to its recent virus triage detection system for H1N1 and other pandemic viruses in humans, for detection of viruses such as bird flu and mad cow disease in animals. Shares lost twenty six cents on the week to close at $1.35.

Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord, announced results for its third quarter ended September 30, 2009 last week, and provided an update on its clinical program, including the proposed Phase I trial in Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s Disease, for which the company was recently granted approval of its IND from the US FDA. Phase I trials to treat ALS with its spinal cord stem cells are expected to commence during the first quarter of 2010 and will be conducted under the supervision of world renown ALS researchers at the University of Michigan and Emery University. In addition to providing a clinical update, the company also released results for its third quarter; during the period, CUR reported a net loss of $5,096,983, or $0.15 per share, compared with a net loss of $3,177,957 or $0.10 per share, for the comparable 2008 period. Net loss attributable to common stockholders for the first nine months of 2009 was $7,380,751 or $0.22 per share, compared with $8,410,081, or $0.26 per share, for the comparable period in 2008, resulting from a year to date gain in accounting for warrants, partially offset by increases in non-cash stock-based compensation expense, R&D and legal fees. Shares gained twelve cents on the week to close at $1.82.

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that it has commenced its first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine. The initial study will involve taking blood from 20 hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS-H1N1 investigational therapy in order to assess the cells’ response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol; the study will also investigate the effects of LEAPS on the blood of 20 non infected patients as a control group. Shares lost two cents on the week to close at $1.30.

Volume Alert: Shares of stem cell developer Advanced Cell Technologies (OTCBB: ACTC) gained 8% on twice average volume following the announcement last week that it has filed its Investigational New Drug (IND) application with the US FDA to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Stargardt’s is an Orphan disease and is one of the most common forms of juvenile macular blindness; Age-related Macular Degeneration (AMD), another degenerative retinal disease similar to SMD, is one of the leading causes of untreatable blindness. The proposed treatment for eye disease uses stem cells to re-create a type of cell in the retina that supports the photoreceptors needed for vision. These cells, called retinal pigment epithelium (RPE), are often the first to die off in SMD and AMD, which in turn leads to loss of vision. In pre-clinical animal models, implantation of RPE cells resulted in 100% improvement in visual performance in subjects with degenerative retinal conditions over untreated controls without any adverse effects. Following approval from the FDA, a total of twelve patients will be enrolled into the study at three clinical sites, including the Casey Eye Institute in Portland, Oregon, the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts, and the New Jersey Medical School in Newark, New Jersey. In related news last week, ACTC announced that it has entered into definitive agreements on three private placements with institutional and other accredited investors, under which the company has received definitive commitments in excess of $15 million; the agreements are expected to provide proceeds sufficient to fund general operations and working capital for the next two years, including support of the RPE program and the expected Phase I clinical trial relating to the IND application which was just filed. Shares gained $0.008 on the week to close at $0.108.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it has sold and is shipping $250,000 of its spirits brands, including Trump Super Premium Vodka, Willie Nelson’s Old Whiskey River Bourbon, and Olifant Vodka, to distributors nationwide in the first month of its third quarter in preparation for the holiday season. The company has utilized credit facilities now in place in order to begin rebuilding inventories and expects that the effort will be rewarded with higher revenues as inventories return to their pre-downturn levels. Management has indicated that it plans to continue to reduce debt, strategically outsource and aggressively manage overhead to build towards profitability once the higher revenues resulting from the rebuilt inventories are realized. Shares remained unchanged at just under $0.03 on the week.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, had its BUY rating reiterated by analysts from New York based brokerage firm Griffin Securities last week, in addition to a raise in its 12 month price target from $2.50 to $3.25 on the shares which are currently trading around $0.80. The recommendations came in a research update issued last week, in which analysts cited the recent partnership arrangement with Roche in addition to several recent clinical successes, including positive Phase I results for ICT-107, the company’s dendritic cell therapy for glioblastoma, the most common and deadly form of brain cancer, which demonstrated an ability to significantly improve the life expectancy of glioblastoma patients beyond the historical life expectancy. The report also cited the strong potential of IMUC’s maturing product portfolio including ICT-121, the company’s cancer stem cell targeting vaccine which is expected to begin Phase I trials early next year, which have led Griffin to reaffirm their support for the company’s future growth prospects. Shares gained ten cents on the week to close at $0.90.

Volume Alert: Shares of Money4Gold (OTCBB: MFGD), an emerging global leader in direct-from-consumer, reverse logistics specializing in the procurement of precious metals and stones, surged 18% on almost twice average volume last week, following the announcement of record results for its third quarter ended September 30, 2009. The company reported gross revenue of $6.8 million, an increase of 871.4% compared to gross revenue of $0.7 million in the year-earlier period and 460.4% compared to gross revenue of $1.5 million in the previous quarter; gross revenue exceeded the company’s previous guidance of at least $6 million. The increased revenues are primarily attributable to international expansion and higher advertising spending, which drove increased collections of gold, which combined with higher gold prices to improve revenue. During the period, the company was also able to significantly improve its already high margins, posting a gross margin increase from 40.8% in the year-earlier period, to 69.8% in the 2009 third quarter, up from 58.0% in the second quarter of this year. Gross profit for the period was $4.8 million, compared to $0.3 million in the year-earlier period and $0.9 million in the 2009 second quarter. Management believes that the results are indicative of its ability to cost effectively acquire new customers through a combination of highly effective media channels and international expansion. As a result of this ability and a strong month of October, management has indicated that it expects fourth quarter sequential revenue growth of approximately 100%, or about $13.5 million in revenue. Given the strong expected revenue growth and improving margins, the company expects to generate positive EBITDA in the fourth quarter for the first time in its history. Shares gained $0.035 on the week to close at $0.235.

Next One Interactive (OTCBB: NXOI), an interactive media company specializing in Digital Media with a focus on Travel and Real Estate, provided an update last week regarding its Resort and Residence Network which has completed its second week on the air, with the initial launch in over 21 million households, available on satellite and cable. By the end of the 2010 first quarter, the network will be distributed to 40 million subscribers with programming that explores the world’s best vacation destinations, resorts, entertainment and activities around the world, in addition to a real estate lineup that features luxury homes with a connection to the related real estate broker, along with programming that includes home decor, landscape architecture, green living, antique collecting and home improvement projects. In 2010, the network will offer full interactive applications so that viewers will be able to request information, enter promotions and sweepstakes and book vacation travel with just the click of the remote control. In other news last week, the company announced that it has appointed two new executives, Tom Armstrong as Vice President of Advertising Sales and Wendy Borow Johnson as President,to its subsidiary Resort and Residence TV. Ms. Borow Johnson is a veteran in the field of electronic media, having served in key positions in the launch of several targeted lifestyle transactional television networks, including Healthy Living Channel, Beauty and Fashion Network, Brands Shopping Network and the Recovery TV Network. She is also a pioneer in interactive television having served as VP of Marketing for Source Media and launched the first two way digital cable systems in addition to her time as SVP of Turner Media Group where the networks deployed over 200 interactive programming and advertising campaigns. Mr. Armstrong has over 20 years of experience in the travel industry, having worked with several of the most notable travel companies in the world, including experience in the sale of travel related advertising mediums. Shares lost eight cents on the week to close at $1.11.

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, announced last week that its TrialMaster EDC solution has been selected to streamline data collection for a 24-month Phase IV cardiovascular study that will enroll 100 subjects across 7 sites. The collaboration marks a continued working relationship between the two companies, who have worked together on twelve studies in the past five years. In other news last week, OMCM announced that it has opened a new office in Monmouth Junction, NJ, located strategically between Princeton and Rutgers Universities in close proximity to the Route One technology and pharmaceutical research corridor. Management believes that the new location will provide access to the broad talent pool of clinical research and technology professionals located in the area, in addition to helping it better serve the clinical needs of the Northeast region. Shares gained two cents on the week to close at $0.20.

ONE Holdings (OTCBB: ONEZ), a green process manufacturer of high quality health supplements, organic fertilizers and pesticides, announced last week that it has applied for listing on the Nasdaq Capital Markets exchange following the recent shareholder approval of an initiative to complete a 5 to 1 reverse common stock split that it expects will allow it to meet the exchange’s minimum listing requirements; the company also announced that it has changed its name to ONE Bio Corp. and will begin trading immediately under the new symbol ONBI on the OTC Bulletin Board while it awaits approval from the Nasdaq. In other news last week, the company announced strong third quarter results for the period ended September 30, 2009. Revenue for the period was up 57.8% to $4,157,806 compared to $2,634,409 for the same period a year ago. Operating Income was up 22.4% to $1,491,037 compared to $1,218,137 for the same period last year. Net Profit was up 16.2% to $849,970 compared to $731,314 for the same quarter last year. Management is encouraged by the strong turnaround that they have been able to achieve since taking control five months ago and expect that the strong market conditions which currently exist in the Asia Pacific region will provide a viable alternative to US investors seeking to invest in the growth of the Asia Pacific region but wanting a strong US domestic management team coupled with Asian operational expertise. Shares of the new entity are trading at $6.50 following the reverse split.

XsunX (OTCBB: XSNX), a developer of advanced, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, released a letter to shareholders last week highlighting the surge in recent media interest experienced by the company and providing an update on the progress being made in developing a working prototype of a sample CIGS thin film solar cell device. In the latest update to shareholders, the company provided details of its plans to complete a sample device prior to the end of this year thanks to the achievement of developmental milestones relating to the establishment of optimized baselines and validation of various layers comprising the CIGS cells. The completion of a working prototype would be a significant step in development of the technology and should aid significantly in fostering adoption of the technology on a broader scale. In addition to the progress being made in technological development, the company has also made significant strides towards raising its profile within the industry. In another letter to shareholders released earlier this month, the company discussed the recent surge in attention which it has been receiving from industry-focused media outlets, including Solar Industry magazine, which published a cover story in its October issue entitled CIGS Deposition: A Crucial Challenge, that was authored by the company’s Chief Technology Officer, Robert Wendt and discusses potential challenges associated with manufacturing the cells as well as potential methods for overcoming current limitations. The company’s CEO was also recently interviewed by RenewableEnergyWorld.com during the Solar Power International Conference in Anaheim last week where he discussed the company’s decision to shift to manufacturing CIGS cells and why they believe that thin-film solar is the future of the photovoltaic industry. Shares lost a penny on the week to close at $0.16.

November 16th CEOcast Weekly Newsletter

Monday, November 16th, 2009

Companies featured in this edition of the newsletter: ACTC, CVM, CHIP, ENZ, HYTM, IWEB, ONEZ, PHC, SIHI, SRCO

Markets continued their strong performance this week in the absence of any major market driving earnings or economic reports, as the broad based buying that characterized the previous week continued and led to gains in all of the major indices. All told, the Dow added 2.5% on the week, gaining 247 points to close at 10,270, up 17.0% on the year. The Nasdaq posted a 2.6% gain on the week, closing at 2,167 to extend its yearly gains to 37.5%, while the S&P 500 and Russell 2000 gained 2.3% and 1.0% respectively, bringing their yearly gains to 21.1% and 17.4%.

Equity markets carried the momentum from the previous week’s session, as the thin economic calendar and lack of significant earnings reports provided little incentive for investors to slow their buying activities. The dollar remained a strong catalyst in the absence of any other major market driving announcements, which helped lead commodities higher and resulted in the materials sector posting the largest gain of the S&P’s ten sectors, coming in up 4.2% on the week. In related news, gold continued its strong move, hitting another all time high at $1,123.40 an ounce, as investors continue to eye weakness in the dollar and monitor signs of inflation.

What should investors look for this week? Earnings reports will be light again, but expect results from Lowe’s (NYSE: LOW) before the bell on Monday, followed on Tuesday morning by Home Depot (NYSE: HD) and Target (NYSE: TGT). BJ’s Wholesale (NYSE: BJ) reports Wednesday pre-market with Sears Holdings (NASDAQ: SHLD) reporting Thursday before the bell while Dell (NASDAQ: DELL) wraps things up after the close that same day.

Economic releases for the week begin with Retail Sales for October due out at 8:30am Monday morning along with Empire Manufacturing for November, followed by September Business Inventories at 10:00am. On Tuesday, expect PPI and Core PPI for October due out at 8:30am, followed by Net Long term TIC flows for September at 9:00am and Capacity Utilization and Industrial Production for October at 9:15am. On Wednesday, Housing Starts and Building Permits for October will be released in tandem with CPI and Core CPI for October at 8:30am, followed at 10:30am by weekly crude inventories. Things wrap up on Thursday with weekly initial jobless claims and continuing claims at 8:30am, followed by Leading Indicators for October and Philadelphia Fed minutes from the November meeting at 10:00am.

Conference schedules will be full again this week, beginning on Monday with the two day Deutsche Bank Securities G2E Gaming Investment Forum being held in Las Vegas. The Dow Jones Newswires Alternative Energy Conference begins on Tuesday in San Francisco, as does the two day Oppenheimer & Co. Industrials Conference, being held in New York along with the two day Bank of America Merrill Lynch Small & Mid Cap Conference . Enzo Biochem (NYSE: ENZ) will present at the two day Lazard Capital Markets Healthcare conference in New York on Tuesday. On Wednesday, the two day Sidoti & Co. Emerging Growth Institutional Investor Forum begins in New York along with the two day Morgan Stanley Global Consumer & Retail Conference and Citigroup Small/Mid Cap Conference.

Managed care provider, Hythiam (NASDAQ: HYTM), announced results for its third quarter ended September 30, 2009 last week, in addition to providing further details regarding its agreement with the Ford Motor Company. HYTM indicated that it expects to finish implementation of the Ford agreement in the Fourth Quarter of 2009, and expects revenue to begin in the first quarter of 2010. For the 2009 third quarter, the company reported revenues of $268,000 from its continuing operations, compared to revenues from continuing operations of $1.3 million during the comparable period last year. The decrease in healthcare services revenues was primarily attributable to the difficult economy and the company’s decision to streamline operations by reducing operating costs and resources supporting private-pay to focus on managed care opportunities. Loss from continuing operations for the 2009 third quarter was $8.8 million, or $0.16 per share, versus a loss of $6.4 million, or $0.12 per share, in the third quarter of 2008. Shares lost a penny on the week to close at $0.40.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently announced its intention to acquire identity security provider Steel Vault to form PositiveID Corp, announced last week that it has completed the acquisition, and will change its name in accordance with its previously announced plans. The newly formed entity, PositiveID Corp, will trade on the NASDAQ under the symbol PSID, and will provide unique health and security identification tools to protect consumers and businesses, representing the convergence of a pioneer in personal health records and the first and only FDA-cleared implantable microchip for patient identification. PositiveID will initially operate primarily in two areas: HealthID and ID Security, with HealthID focused on bringing innovative health solutions to consumers and businesses based on the company’s intellectual property, specifically a rapid virus detection system for the H1N1 virus and other forms of pandemic viruses, and an in vivo glucose-sensing RFID microchip, both of which are currently under development with partner RECEPTORS LLC. The ID Security division will offer identity theft protection and related services including credit monitoring and reporting through its NationalCreditReport.com website. Under the terms of the agreement, Steel Vault stockholders will receive 0.5 shares of VeriChip common stock for every share of Steel Vault common stock held, with outstanding warrants and options to be converted at the same ratio. Shares gained fourteen cents on the week to close at $1.61.

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, reported on work conducted in collaboration with scientists at the Cleveland Clinic and CEL-SCI investigating CEL-SCI’s LEAPS vaccine technology at the 7th GTCbio Vaccine Conference in Crystal City, Virginia last week. Scientists worked with LEAPS vaccines for herpes simplex virus, HIV, rheumatoid arthritis and most recently, H1N1 influenza, with results demonstrating that LEAPS peptide immunogens can convert precursor cells from mouse or humans into dendritic cells, the cells that direct the subsequent immune response. Results further demonstrated that immunization with a LEAPS-immunogen for the herpes simplex virus activated a protective T cell immune response against the virus in mice while a LEAPS-immunogen for treatment of rheumatoid arthritis (CEL-2000) reduced the production of the pro-inflammatory cytokines to block the progression of disease in mouse models. Management indicated that it is encouraged by the new data, which it feels is supportive of its H1N1 treatment for hospitalized patients where the goal is to produce a specific anti H1N1 immune response, similar to those demonstrated in the herpes and arthritis models, that will steer the immune system towards protection and away from a cytokine storm which may be responsible for many infected patients’ deaths. Shares gained eleven cents on the week to close at $1.32

Pioneer Behavioral Health (AMEX: PHC), a leading provider of inpatient and outpatient behavioral health services, announced results for its 2010 first fiscal quarter last week, for the period ended September 30, 2009. During the period, the company managed to report its third consecutive quarter of profitability, increasing net patient care revenue by 11.4%, while improving net income from continuing operations by $790,000. Among the highlights was an increase in total net revenue from continuing operations, as the company generated $12.6 million for the three months ended September 30, 2009 compared to $11.7 million for the three months ended September 30, 2008, attributable to higher net patient care revenue, which was partially offset by a decline in contract services revenue. Net patient care revenue increased 11.4% to $11.8 million for the three months ended September 30, 2009 from $10.6 million for the three months ended September 30, 2008 and 8.7% from $10.8 million for the quarter ended June 30, 2009; the gains are the result of increased census at the company’s Seven Hills Behavioral Institute in Las Vegas, and its Capstone facility in Detroit. Income from operations improved $790,717 to $355,898 for the 2010 fiscal first quarter compared to a loss of $434,819 in the same period a year ago. Net income applicable to common shareholders was $223,604, or $0.01 per diluted share, compared to a net loss of $332,703 or $0.02 per share in the fiscal 2009 first quarter. Shares lost eight cents on the week to close at $1.05

Earnings preview: Chinese electronics supply chain management company SinoHub (AMEX: SIHI) is set to release third quarter earnings on Monday before the bell, and will hold a conference call to discuss results that morning at 10:30am EST. During the company’s second quarter, it demonstrated robust growth including a nearly six-fold increase in net income and revenue growth of more than 137%, compared with the 2008 second quarter. Net income for the 2009 second quarter grew substantially to $3.2 million, or $0.13 per share, from $540,000, or $0.03 per share in the corresponding year ago period. Total revenues for the 2009 second quarter also rose significantly, to $31.4 million from $13.2 million for the 2008 second quarter. Investors will likely focus on the company’s ability to maintain sustained growth and profitability as China emerges from the global economic slowdown; parties interested in the conference call can access a live broadcast via the company’s website. Shares lost five cents on the week to close at $4.80.

Advanced Cell Technologies (OTCBB: ACTC), a company engaged in the development of regenerative therapies utilizing stem cells, announced that its Chief Scientific Officer, Robert Lanza, M.D., was chosen to give an opening Plenary Lecture at the 3rd International Conference on Cell Therapy, which was held in Seoul, Korea last week. Dr. Lanza delivered a presentation titled “Embryonic and Induced Pluripotent Stem Cells – Moving from the Bench to the Bedside.” During the presentation, Dr. Lanza discussed the company’s various preclinical programs, including its retinal pigment epithelium (RPE) technology, which the company plans to file an Investigation New Drug (IND) application for this quarter to begin human clinical trials. Shares remained unchanged on the week at $0.10.

IceWEB (OTCBB: IWEB), a leading provider of purpose built appliances and building blocks for cloud storage networks, announced last week that it has been chosen to provide key servers used by security personnel at the 2010 World Summit in Canada. IWEB will provide its Modular Lightweight Portable (MLP) server, which will serve as the primary mobile command center for an array of security and infrastructure protection forces tasked with providing a safe environment for the major gathering of international world leaders. The server’s ability to deploy mission critical content and connectivity typically limited to a headquarters based network, in combination with its standing as a high performance, scalable solution, engineered as a field deployable package, has lead it to become a top choice for security details tasked with protecting high profile international events. Shares lost two cents on the week to close at $0.15.

ONE Holdings (OTCBB: ONEZ), a green process manufacturer of high quality health supplements, organic fertilizers and pesticides, announced last week that it has signed an agreement with one of Japan’s largest supermarket operators, Kobe Bussan Supermarkets, to expand its organic food product line offered through Kobe’s supermarket stores, marking a continued collaborative arrangement between Kobe and ONEZ’s subsidiary United Green Technology, Inc. The expanded product lineup will include fresh bamboo health products, organic bamboo, vegetable products, and the company’s newly developed organic convenience packs. The expanded agreement is expected to contribute an additional $8 million per annum to sales within the next two years. Shares lost four cents on the week to close at $1.22.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated to the powersports industry, continues to improve its balance sheet, as it announced last week that it has closed on the sale of additional preferred stock and warrants. The purchase was made by Optimus Capital Partners, and brings the total amount to date invested by Optimus to $1,570,000. In addition to this latest purchase, Optimus has also exercised warrants to purchase 13,500,000 shares of common stock at an exercise price of $.09 per share for $1,215,000. Sparta has also converted or received written agreements to convert an additional $945,000 of notes and accounts payable to equity, in addition to the $6 million in note and accrued interest conversions previously announced. This leaves approximately $100,000 in notes payable remaining on the company’s balance sheet as compared to $5.5 million at the end of its fiscal year April 30, 2009. The company expects that the $9.7 million that it has been able to raise in new equity and converted debt over the past three months will position it to begin utilizing the initial $25 million under its previously announced secured senior credit facility, which would significantly enhance its ability to expand its financing operations. Shares remained unchanged at $0.05 on the week.

November 9th CEOcast Weekly Newsletter

Monday, November 9th, 2009

Companies featured in this edition of the newsletter: ACTC, CHIP, CVM, DKAM, ENZ, IWEB, MBCI, MFGD, PHC

Markets rebounded last week, on the strength of upbeat productivity and manufacturing reports that led to solid gains in all of the major indices. Despite news that the unemployment rate had hit its highest levels in 25 years, the Dow managed to end the week up 310 points, gaining 3.2% on the week to close at 10,023, up 14.2% on the year. The Nasdaq posted a gain of 3.3%, closing at 2112 and extending its yearly gains to 34%, while the S&P 500 and Russell 2000 advanced 3.2% and 3.1% respectively on the week to bring their YTD performance to 18.4% and 16.2%.

Several better than expected economic reports provided buying incentive throughout much of the week, as investors managed to shake off the previous week’s negative bias to send indices into positive territory despite some less than encouraging unemployment data released towards the end of the week. Advance Q3 productivity readings gave investors looking for signs of continued recovery reason to jump back into the markets, as the report showed significantly higher growth than expected, coming in up 9.5% versus consensus estimates calling for an increase of only 6.5%. The unexpected surge marked the largest productivity gain since 2003, a fact which was not lost on investors as the news helped spur the week’s biggest gains, leading the Dow higher by almost 200 points following the announcement on Thursday. Further good news was extrapolated from ISM Manufacturing data for October which also came in better than expected, as did September construction spending and pending home sales which served to further soothe investor sentiment. In light of these positive developments, news that the unemployment rate had reached its highest level in 25 years, coming in at 10.2% versus a forecast calling for 9.9%, did little to temper enthusiasm, as even a tepid employment report couldn’t keep markets from finishing in positive territory following the announcement.

The Fed’s decision to leave its benchmark rate unchanged at historic lows also served to stoke buying sentiment on the week, and on the corporate front, earnings reports were generally positive, as Cisco managed to beat estimates while providing a strong forecast and announcing that the company had authorized the repurchase of up to $10 billion of its stock; other notable earnings beats on the week included CVS, Kraft and Qualcomm. Commodities also continued their run last week, as gold gained 6% to hit a new record high before retreating to close at just under $1100 an ounce, and oil posted a modest gain of 1% in volatile trade. Thanks to the preponderance of positive developments on the week, all ten sectors of the S&P managed to finish the week in positive territory, led by Industrials at 6.1% and Consumer Discretionary at 4.7%.

What should investors look for this week? There will certainly be considerable discussion about Healthcare Reform, after President Obama’s healthcare bill passed in the House by a razor-thin margin of 220-215. Earnings reports slow considerably, but look for results from Macy’s (NYSE: M) pre-market on Wednesday, followed by Dendreon (NASDAQ: DNDN) and Applied Materials (NASDAQ: AMAT) after the bell. Kohl’s (NYSE: KSS) and Wal-Mart (NYSE: WMT) report before the open Thursday, with Walt Disney (NYSE: DIS) set to release their results after the close. JC Penney (NYSE: JCP) rounds out the week on Friday morning before the bell.

Economic data will be light on the week, but look for weekly initial jobless claims along with continuing claims on Thursday at 8:30am, followed by weekly crude inventories at 11:00am and the Treasury Budget for October at 2:00pm. Import and Export Prices for October will be released at 8:30am Friday morning along with Trade Balance data for September, followed at 9:55am by Preliminary Michigan Sentiment for November.

Conference schedules will be considerably busier this week with things set to begin in New York on Monday with the Stifel Nicolaus Aerospace, Defense and Airline Conference. On Tuesday, the Bank of America/Merrill Lynch Banking and Financial Services Conference kicks off in New York along with the Deutsche Bank FinTech Senior Executive Forum, and the Jefferies Healthcare Summit which is being held in Boston; Piper Jaffray holds their Global Internet Summit in Menlo Park, CA that same day. Citigroup will hold their Industrial Manufacturing & Transportation Conference in New York on Thursday and Credit Suisse hosts their two day Healthcare Conference beginning that same day in Phoenix.

Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, reported on its therapeutic platforms utilizing oral immune regulation for immune mediated diseases at the Bio-Europe 2009 15th Annual International Conference in Vienna, Austria last week. Management commented on the therapies which include Alequel, an individualized therapy for treatment of Crohn’s disease, and Optiquel, an oral, novel peptide for autoimmune uveitis, in addition to progress made in the development of its drug screening platform that has yielded orally delivered small molecules having potentially significant effects for bone disorders and diabetes. In other news last week, Enzo reported that favorable results of the company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH), the most common form of chronic liver disease in the Western world, were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was designed to evaluate safety and efficacy of the drug and reported no treatment-related adverse events; in addition, data supported the role of NKT-based immunotherapies in patients with insulin resistance and NASH, and were consistent with Enzo’s pre-clinical and clinical studies involving the development of new therapeutic platforms for immune mediated diseases according to management. Shares gained fifteen cents on the week to close at $5.66.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently acquired identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, announced last week that it has been selected as a finalist for the South Florida Business Journal’s 2009 Technology Awards in the Hardware category. The awards were created to honor the area’s best technology-based companies, the CEOs or CIOs leading the way, and the companies making the best use of a technology in South Florida, and look for growing start-up companies, trendsetting innovations, products and services to highlight. Shares lost seven cents on the week to close at $1.47

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that it had been granted clearance to proceed with its first clinical study evaluating the efficacy of its LEAPS H1N1 investigational therapy on the blood of hospitalized H1N1 patients by an Institutional Review Board of The Johns Hopkins University School of Medicine. In order for the FDA to consider a next-stage clinical trial to evaluate LEAPS-H1N1 treatment of hospitalized patients with laboratory-confirmed H1N1 Flu under an Exploratory IND, the FDA has asked CEL-SCI to submit a detailed follow-up regulatory filing with extensive additional data. CVM is working actively with its CRO in conjunction with Johns Hopkins to prepare submissions to the FDA in order to support the fastest and most effective way to conduct clinical trials going forward for this unique investigational treatment. Shares gained seventeen cents on the week to close at $1.22.

Earnings Preview: Pioneer Behavioral Health (AMEX: PHC), a leading provider of inpatient and outpatient behavioral health services, is scheduled to announce results from its 2010 fiscal first quarter on Wednesday, November 11th before the market opens, and will hold a conference call to discuss the results at 9:00am that day. For the fourth fiscal quarter of 2009, the company managed to increase net revenue from continuing operations to $11.7 million for the three months ended June 30, 2009 from $11.5 million for the three months ended June 30, 2008. Income from operations was $381,661 for the 2009 fiscal fourth quarter compared to $97,540 for the 2009 fiscal third quarter, and $394,571 for the fiscal 2008 fourth quarter. Net income before taxes for the 2009 fiscal fourth quarter improved approximately $305,000 sequentially to $317,086. Investors are likely to focus on the company’s ability to maintain profitability and increase demand at its Capstone and Seven Hills Behavioral Facilities. Investors will also likely be focused on top line revenue growth as management had indicated on the company’s Q4 conference call that it expected sequential quarterly revenue and profitability to accelerate. Shares gained sixteen cents on the week to close at $1.18.

Advanced Cell Technologies (OTCBB: ACTC), a company engaged in the development of regenerative therapies utilizing stem cells, presented a corporate overview and update on the company’s upcoming developmental milestones for its therapeutic program last week at the BIO Europe 2009 Conference in Vienna, Austria. Among the milestones mentioned were the reiteration of plans to file an IND for its retinal pigment epithelial program (RPE) prior to the end of 2009, and the company’s goal of becoming one of the first to treat a patient with an embryonic stem cell based therapy, which it hopes to achieve by the third quarter of 2010. Pending FDA approval, ACT hopes to commence Phase I clinical trials for its first IND designation in the summer of 2010, and anticipates filing an IND for an additional retinal indication in a similar timeframe. Shares remained unchanged at $0.10 on the week.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that the company has reduced its debt by 15%, in the aggregate amount of $1,002,450 through agreements reached with the CEO and members of its Board of Directors to satisfy obligations owed to them for a portion of an outstanding loan by issuing them 1.8 million shares of common stock and warrants to acquire 9.8 million shares of common stock exercisable at $0.15. The warrants are priced at a 250% premium to the stock’s current price, with fifty percent of the warrants able to be exercised at anytime during the ten year term while the other 50 percent will only be exercisable after the company has achieved positive EBITDA for two successive quarters. The company believes that pricing the warrants at such a high premium above the stock’s current price while tying 50% of the warrants’ exercisability to a performance based metric such as back to back quarters of profitability will demonstrate their level of commitment to shareholders. Shares remained unchanged at $0.04 on the week.

IceWEB (OTCBB: IWEB), a leading provider of purpose built appliances and building blocks for cloud storage networks, announced last week that it has entered into an agreement with ExxonMobil Global Services Company, an operating division of ExxonMobil, the largest publicly traded international oil and gas company, under which it will design Geographical Information Systems (GIS) and provide technicians to support Exxon’s use of the technology. The company also announced last week that it has been awarded a significant contract by a Federal Agency to provide its Iplicity Unified Storage Platform to support a large Unix environment providing over 100 terabytes of disk capacity that will enable the Agency to capture and archive critical log data. Management indicated that Iplicity was chosen for this contract because of its ease of use, high performance, and advanced data replication capabilities. Shares gained three cents on the week to close at $0.20.

MabCure, Inc. (OTCBB: MBCI), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, announced last week that it has signed a research agreement with AZ Sint Lucas Hospital, in Brugge, Belgium to conduct preclinical research intended to broaden the utility of MabCure’s monoclonal antibodies relating to diagnosis of cancer in tissue specimens. The partnership is designed to expand the current scope of the company’s diagnostic products beyond their current ability to detect malignancies in physiological samples such as urine and serum. Management believes that this partnership has the potential to expand the utility of the company’s portfolio beyond its current multi-billion dollar potential market by allowing them to detect cancer from biopsied tissue samples, allowing them access to a much larger sample base than they are currently able to diagnose. Shares gained six cents on the week to close at $1.13.

SEPCIAL SITUATIONS:

Money4Gold Holdings (OTCBB: MFGD) $0.18

As a result of the recent economic downturn and the quantative easing measures implemented by the government in an attempt to stave off damage to the financial system in the wake of the collapse, many investors have begun to worry about the long term effects that these policies may have on the economy. Foremost among these concerns is the threat of inflation brought on by the aggressive stimulus measures which has led investors towards commodities, and especially gold, as a means of hedging against potential future inflationary pressures. As a result of the explosive demand for gold, producers are experiencing difficulties meeting production demands due to the high costs and hardships associated with extracting these precious resources from the earth, resulting in a need to find a more efficient, dependable method of production. Money4Gold is an emerging leader in the precious metals space that is well positioned to capitalize on the supply problems and record run up of gold prices characterizing markets of late thanks to a unique business model affording it significant advantages over traditional gold producers.

What sets MFGD apart from traditional gold producers is the source from which it obtains its raw materials. Rather than extracting gold and other precious metals from the ground as producers traditionally have, Money4Gold obtains its materials from the general population in the form of unused or broken jewelry, essentially mining from consumers rather than the earth. This strategy offers significant advantages over traditional production methods as it is significantly less costly, more efficient, and environmentally friendly. These efficiencies in combination with a critically important partnership with one of the country’s largest and most respected precious metal refiners allow the company to offer investors dramatically higher margins when compared to traditional precious metal producers.

Despite the fact that Money4Gold is currently the only publicly traded precious metals recycling company in the United States, they are not the only company engaged in this enterprise; however, Money4Gold’s pre-established relationship with refiner Republic Metals, superior marketing and customer service help provide it with significant competitive advantages that keep the company one step ahead of its peers. One of the reasons that the company has such bright prospects is its relationship with Republic Metals, which is one of MFGD’s largest shareholders and also has a representative on the company’s board of directors. Because of this relationship, the company is able to offer consumers significantly higher prices for their jewelry than the competition, due to the fact that they are able to cut out the middle man and deal directly with the refinery. To further improve the situation, Republic services MFGD’s raw gold at cost, with the savings passed on to the consumer in the form of higher payouts than the competition, which in turn leads to happy customers and more gold for the company. In addition to this critically important and unique strategic relationship, the company also owns and operates its own internet lead generation system and aggressively markets its services through a multitude of channels including internet, radio, and television spots featuring world famous pitchman Anthony Sullivan. MFGD has rolled out international service offerings in multiple languages to complement its US operations, expanding the business into Canada, the UK, and most recently Germany, with plans to permeate additional international markets which should serve to greatly enhance the company’s already strong position.

With significant competitive advantages in an industry that is poised for explosive growth due to the ever increasing demand for gold, Money4Gold appears to be well positioned to reap the benefits of investors’ preferences towards hedging against inflation. This increase in demand, in combination with the existing problems that traditional gold producers have displayed in keeping up with supply suggests that the precious metals recycling industry will continue to experience significant growth as suppliers continue to seek out novel sources of obtaining more gold. As one of the emerging leaders in this space, it appears that now is an opportune time for investors to consider MFGD as the company is still operating largely under the radar of the investment community; whether or not they will remain so is still to be determined, but the fact remains that the demand for gold doesn’t appear to be slowing anytime soon while producers continue to struggle to keep pace, making this a tantalizing prospective investment given the current economic climate.

November 2nd CEOcast Weekly Newsletter

Monday, November 2nd, 2009

Companies featured in this edition of the newsletter: CHIP, CICS, CVM, FMTI, IMUC, INRK, IWEB, ONEZ

Weak data on consumer spending and employment once again raised doubts about the strength of the economic recovery, and helped send investors running for the exits this week as markets finished sharply lower following broad based selloffs in all of the major indices. All told, the Dow ended the week down 259 points, losing 2.6% to close at 9712 and reducing its yearly gains to 10.7%. The Nasdaq underperformed significantly on the week, surrendering 5.1% to close at 2045, paring its YTD gains to 29.7%, while the S&P 500 and Russell 2000 lost 4.0% and 6.3% respectively, bringing their yearly gains to 14.7% and 12.7%. While the Russell 2000 was by far the worst performing index for the week, microcap stocks below the level of the Russell were even hit harder, as investors shunned risk.

While the strengthening dollar appeared to be the main driving force on the week, the Q3 GDP reading released on Thursday seemed to excite investors initially, as markets rallied sharply on Thursday after the GDP Report showed a 3.5% increase in the third quarter, moderately better than expectations calling for 3.2%, and significantly better from a sequential perspective than the 0.7% contraction that was seen in Q2. However, after a day of analysis, investors recognized that much of the gains were driven by stimulus programs such as Cash for Clunkers, and reflected an economy that was still struggling.

What should investors look for this week? Earnings reports begin to wind down as the majority of companies with market moving potential have already reported, but expect results from Ford Motor Co. (NYSE: F) and Sysco (NYSE: SYS) on Monday before the bell. Tuesday morning, look for results from Amerisource Bergen (NYSE: ABC) and Viacom (NYSE: VIA), with Kraft Foods (NYSE: KFT) reporting after the close. Comcast (NASDAQ: CMCSA) and Time Warner (NYSE: TWX) report before the open on Wednesday followed after the close by Cisco Systems (NASDAQ: CSCO), News Corp (NASDAQ: NWSA), Prudential (NYSE: PRU) and Qualcomm (NASDAQ: QCOM). Cablevision (NYSE: CVC), DirecTV (NYSE: DTV) and Thomson Reuters (NYSE: TRI) report before market Thursday, followed after the close by CBS Corp (NYSE: CBS), Starbucks (NASDAQ: SBUX), Sun Micro (NASDAQ: JAVA) and Sunoco (NYSE: SUN).

Economic data for the week begins with Construction Spending and Pending Home Sales for September along with the ISM Index for October at 10:00am Monday, followed on Tuesday by Factory Orders for September at 10:00am, with Auto and Truck Sales for October due out at 2:00pm. On Wednesday, expect Challenger to report on Job Cuts for October at 7:30am, followed at 8:15am by the ADP Employment Report for October, ISM Services for October at 10:00am, Weekly Crude Inventories at 10:30am and the FOMC’s Rate Decision at 2:15pm that afternoon. On Thursday, look for Preliminary Q3 Productivity at 8:30am along with weekly initial jobless claims and continuing claims. Things wrap up on Friday with a slew of labor market data that will most likely be sharply in focus; Nonfarm Payrolls, Average Workweek, Hourly Earnings and the Unemployment Rate, all for October, will be released together at 8:30am followed by September Wholesale Inventories at 10:00am and Consumer Credit for September at 2:00pm.

Conference schedules pick up this week; on Monday Goldman Sachs will host the two day Borse Dubai International Investor Conference in New York and Wedbush Morgan Securities begins its two day Clean Tech & Industrial Growth Conference in San Francisco. The Oppenheimer & Co. Healthcare Conference starts Tuesday in New York while Goldman Sachs hosts a two day Global Industrials Conference beginning on Wednesday in New York. The World Energy Engineering Conference begins that same day in Washington DC and the Lazard Capital markets Technology & Media Best Ideas Investor Day is being held in San Francisco on Friday.

Earnings Preview: interCLICK, Inc. (OTC: INRK), a rapidly growing Internet marketing network, will report results for its third quarter ended September 30th on Wednesday after the market closes. Last week, the company completed a 1-for-2 reverse split in preparation for a Nasdaq listing. Investors will be watching to determine whether the company will be able to continue its torrid growth, and follow the success of some of the larger Internet marketing companies that already reported results. In the second quarter, the company grew revenue by 128% to $10.6 million, which also increased 26% sequentially from the 2009 first quarter. EBITDA was $0.2 million, compared to an EBITDA loss of ($1.6) million in the year-earlier period.The third quarter is seasonally usually stronger than the first two. At the time of the Q2 release, interCLICK said it expects third quarter revenue to exceed $12.5 million and gross margin to approach 50%. For the month of July, interCLICK had revenue in excess of $4 million. Since reporting Q2 results, shares of INRK have gained 28%. The stock closed Friday at $5.43, up 17 cents.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently announced its intention to acquire identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, announced last week that it will present developments regarding its in vivo glucose-sensing RFID microchip and virus triage detection system for the H1N1 virus at the ID World International Congress in Milan, Italy, which runs from November 3-5. The ID World International Congress is the most comprehensive showcase on the evolving world of RFID, biometrics and smart card technologies, and is the only international forum that looks at the automatic identification industry as a whole, offering a full-scale and complete vision of social, technological and business aspects related to the deployment of the automatic identification systems. Shares lost 33 cents on the week to close at $1.54.

Forbes Medi-Tech Inc. (NASDAQ: FMTI), a life sciences company focused on evidence-based nutritional solutions, announced last week that the European Union has approved a health claim for plant sterols that supports the company’s current cholesterol reduction claim and further validates the inclusion of Reducolâ„¢ in various food products. This recent Commission Regulation will enable products that incorporate Forbes patented cholesterol lowering ingredient, Reducol, to make a label claim that states, “Plant sterols have been shown to lower/reduce cholesterol. High cholesterol is a risk factor in the development of coronary artery disease.” Reducol is sold in various food products in the EU including margarines, yogurts, yogurt drinks, milks, and cheeses. Shares lost 3 cents on the week to close at $0.40.

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that it has received more than $10 million over the past 60 days from the exercise of warrants by investors to purchase the company’s common stock. These additional funds increased the gross proceeds raised in the last 60 days to approximately $30 million, which the company has indicated that it expects to use towards its pivotal Phase III clinical trial with its cancer drug Multikine and to accelerate the development of its LEAPS compound for the treatment of H1N1 hospitalized patients. Since the beginning of the year, the company has been able to strengthen its balance sheet significantly, raising gross proceeds in excess of $43 million and eliminating its Series K convertible notes which had an initial principal value of $8.3 million. Shares lost 26 cents on the week to close at $1.05.

ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers, announced significant positive results from its Phase I clinical trial evaluating the safety and efficacy of ICT-107, the company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Data for the trial, which was presented at the Congress of Neurological Surgeons annual meeting in New Orleans last week, demonstrated significantly improved median progression free survival time compared to the current standard of care. Patients in the trial demonstrated a median progression free survival time of 19 months 12 months longer than the historical progression-free survival time for GBM patients of 6.9 months. In addition to the significant improvement in median progression free survival time, seven of the 16 patients involved in the trial continue to show no signs of tumor recurrence, while three have gone more than two years with no disease progression. With 80% of patients (13 of the 16) still alive at a median time of 20 months, it is too early to determine the median overall survival time for this trial, but historically, only 26.5% patients survive two years under the current standard of care; ICT-107 was also well tolerated, with no significant adverse events reported during the trial. Shares lost 12 cents on the week to close at $1.02.

Volume Alert: Shares of IceWeb (OTCBB: IWEB), a leading provider of storage solutions and on-line cloud computing application services, gained 6% on almost twice average volume last week following the announcement that it has partnered with Saratoga Data Systems, Inc. to integrate their Flume Data Acceleration product into Iplicity Cloud Storage Appliances. IceWEB will bundle or integrate Flume Network Optimization software into its core Iplicity product suite in order to solve a problem delaying wholesale migration into cloud storage. The problem being addressed relates to the large volumes of data that need to be migrated from private networks to cloud storage which far exceed what can be transferred electronically in a reasonable period of time. By integrating Flume protocols within Iplicity, IWEB has developed a solution that significantly accelerates the transfer of large amounts of data across long distance, high latency networks, in a secure, encrypted, and guaranteed error free fashion. The company believes that this will eliminate the current need that many providers have to rely on manually copying data at the remote customer site and then shipping that data on physical devices to the provider’s location and downloading that data onto their cloud infrastructure. The companies expect that this partnership will make Iplicity a more attractive offering by allowing rapid transfer of large amounts of data simultaneously to multiple distinct cloud storage providers, thus greatly enhancing functionality and overall efficiency. Shares gained a penny on the week to close at $0.17.

ONE Holdings (OTCBB: ONEZ), a green process manufacturer of high quality health supplements, organic fertilizers and pesticides, released consolidated results for fiscal 2008 and the first 6 months of fiscal 2009 for its recently completed acquisitions last week. The consolidated acquisitions generated net income during 2008 and the first 6 months YTD in excess of $7.1 million and $3.4 million respectively, with operating income of $10.5 million and $5 million respectively. Revenue for 2008 and the first 6 months YTD was $35 million and $16.5 million respectively; gross margin was 41% throughout. The company has accrued total assets in excess of $38 million as of June 30, 2009 with shareholder’s equity reaching $28.5 million. Management has indicated that it expects to outperform its first half ’09 results due to the second half of the year being a traditionally busier period. Shares lost a penny on the week to close at $1.24.

Carbonics Capital Corporation (OTCBB: CICS), a company that provides applied engineering and technology transfer services based on clean technology and process innovations that enhance manufacturing efficiencies, announced last week that the company has executed an agreement with Great Plains Oil & Exploration, LLC to lease Carbonics’ oilseed crush plant in Culbertson, Montana. The arrangement is part of a liquidation of the facility ordered by the Montana Department of Agriculture in relation to an outstanding debt that was incurred for an oilseed shipment in 2008 that the company was unable to pay for due to an inability to renew its working capital line of credit during the second half of that year. Great Plains is leasing the facility to further development of their oilseed production program and plans to use the facility as an important hub in their network of camelina growers in eastern Montana and western North Dakota. Shares remained unchanged at under a penny on the week.

October 26th CEOcast Weekly Newsletter

Monday, October 26th, 2009

Companies featured in this edition of the newsletter: CVM, CHIP, GERS, IMUC, IWEB, NXOI, OMCM, ONEZ, SIHI

Volatile trade characterized much of last week as markets searched for direction in the wake of a multitude of earnings reports that left investors wondering as to the overall state of recovery and sent all of the major indices modestly into negative territory. All told, the Dow surrendered 23 points on the week, losing 0.2% to close at 9972, paring its yearly gains to 13.6%. The Nasdaq lost 0.1% on the week, closing at 2154, but still up 36.6% on the year, while the S&P 500 and Russell 2000 surrendered 0.7% and 2.5% respectively on the week, bringing their yearly gains to 19.5% and 20.3%.

Despite the considerable number of companies beating expectations last week, investors took pause and seemed to outweigh the fact that the majority of the beats from companies such as American Express, AT&T, Caterpillar and Yahoo, came as a result of cost cutting measures rather than significant growth in revenue. The emphasis on cost cutting appears to be wearing thin on investors hoping to see top line growth, which was evident by the seeming lack of enthusiasm that was displayed for this latest batch of results. As a result of the less than impressive revenue growth across the board, selling was broad based as only one sector of the S&P managed to finish in positive territory, with IT posting a gain of 1% on the strength of blowout results from Apple and Amazon.com.

Economic data on the week provided no clearer indication of the state of the overall recovery as initial jobless claims climbed to a three week high of 531,000 versus expectations for 515,000, and housing data came in decidedly mixed with Existing Home Sales for September beating consensus estimates but being offset by weaker than expected Starts and Building Permits.

What should investors look for this week? Earnings season continues; on Monday morning Verizon (NYSE: VZ) reports, followed on Tuesday morning by BP (NYSE: BP) and Valero (NYSE: VLO), with McKesson (NYSE: MCK) and Visa (NYSE: V) reporting after the close. On Wednesday before the bell, expect results from Coca-Cola Enterprises (NYSE: CCE), Conoco Phillips (NYSE: COP), General Dynamics (NYSE: GD), Hess (NYSE: HES), Qwest (NYSE: Q) and Wellpoint (NYSE: WLP), with First Solar (NYSE: FSLR) reporting after the bell. Thursday morning will be busy as, Aetna (NYSE: AET), AstraZeneca (NYSE: AZN), Burger King (NYSE: BKC), Colgate-Palmolive (NYSE: CL), Eastman Kodak (NYSE: EK), Exxon Mobil (NYSE: XOM), Motorola (NYSE: MOT), Office Depot (NYSE: ODP), Office Max (NYSE: OMX), Procter & Gamble (NYSE: PG), Royal Dutch Shell (NYSE: RDS), and Sprint Nextel (NYSE: S) all report before the bell followed by MetLife (NYSE: MET) after the close.

Economic releases for the week begin on Tuesday morning with Durable Goods Orders for September due out at 8:30am, followed at 9:00am by Consumer Confidence figures for October and the Case-Shiller Home Price Index for August. On Wednesday, look for New Home Sales for September at 10:00am followed by weekly crude inventories at 10:30am. Thursday will see Advance Q3 GDP and Chain Deflator released along with a slew of other data at 8:30am, including weekly initial jobless claims and continuing claims, Personal Income and Spending for September, and PCE and Core PCE, also for September. Chicago PMI for October is due out at 9:45am, followed by revised Michigan Sentiment for October at 9:55am and Q3 Employment Cost Index at 10:00am.

There are no conferences of note scheduled again this week due to earnings.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently announced its intention to acquire identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, said last week that it had entered into a strategic partnership with the Diabetes Research Institute to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip. The DRI is a recognized world leader in cure-focused research, and expects that the collaboration could potentially improve patient care and compliance among individuals with diabetes. In other news last week, the company hosted an event for the medical, patient and investor communities in New York to unveil details of their virus triage detection system for the H1N1 virus and Phase II development of an in vivo glucose-sensing RFID microchip. Shares lost ten cents on the week to close at $1.87.

CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week that it has presented new rheumatoid arthritis data at the American College of Rheumatology’s annual meeting in Philadelphia. The company said that its rheumatoid arthritis treatment vaccine CEL-2000 acts to prevent or retard the permanent tissue damage caused by rheumatoid arthritis in animals. The statistically significant results were demonstrated by the measurement of four different parameters, suggesting that CEL-2000 appears to block the immune response that causes the autoimmunity which leads to rheumatoid arthritis. The long term results obtained with fewer doses of CEL-2000 vaccine were comparable or better than those seen with Enbrel, a leading treatment for people with rheumatoid arthritis. Shares lost twenty one cents on the week to close at $1.31.

Volume Alert: Shares of SinoHub (AMEX: SIHI) a company providing world-class supply chain management services with transparent information access for participants in the electronic components supply chain in China, jumped 18% on almost 5 times average volume last week following their presentation the week prior at the Roth China Conference in Miami Beach. The move can also be attributed to the recent strong recovery in economic growth demonstrated by China in the form of significantly better than expected GDP growth of 8.9%, spurred in part by resumed growth in the manufacturing sector which SinoHub serves. Shares gained eighty two cents on the week to close at $5.25.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it has filed a provisional patent application with the US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the company’s ICT-109 monoclonal antibody product candidate. The patent application seeks to extend the protection around ICT-109 to include proprietary targets that are uniquely expressed in cancerous cells, which allow ICT-109 to potentially differentiate between antigens present in normal benign tissue cells and those present in tumor cells, enabling the direct targeting of cancerous growths without harming healthy tissue. In other news last week, the company also announced that it has engaged Dr. Peter Brooks of the Maine Medical Center, a specialist in the mechanisms that regulate angiogenesis, tumor growth and metastasis, to explore novel targets and antibodies associated with targeting cancer stem cells (CSCs). The collaboration is designed to produce novel antibodies using the company’s proprietary CSCs isolated from glioblastoma patients to target epitopes primarily present on CSCs, potentially enabling more effective approaches for identifying and treating a wide range of malignant human tumors. Shares gained three cents on the week to close at $1.15.

Volume Alert: Shares of storage and cloud computing solutions provider IceWeb (OTCBB: IWEB), surged 77% on 11 times average volume last week, following the announcement that the company is working with Spot Image Corporation to build and market a turn-key appliance pre-bundled with Spot Image’s imagery served by Google Earth Enterprise. The appliance will be designed to offer a rapidly deployable service that delivers Spot Image’s imagery to customers as pre-built globes served by Google Earth Enterprise. In other news last week, the company announced that it has entered into a partnership whereby Utilipath LLC will provide Iplicity Storage Products and solutions to their nationwide customer base. Utilipath is a leading provider of engineering and construction services to the $20 billion utility infrastructure services segment, and expects that the new partnership will add significant value that they can deliver to their constituents by offering the IceWEB Iplicity solution set for their internal use. It was a busy week for IWEB, as the company also unveiled a new notebook at the GEOINT summit in San Antonio. The new Notebook, called “WorldBook,” has the industry’s largest disk capacity currently capable of storing more than 1.28TB of data. Additional features include optional GPS, 3G Wireless, smart card reader and sunlight readable display. Shares gained just under eight cents on the week to close at $0.177.

Next One Interactive (OTCBB: NXOI), an interactive media company specializing in Digital Media with a focus on Travel and Real Estate, announced last week that its full time programming Network, Resort and Residence TV, will launch as channel 354 on October 28, 2009 part of DirecTV’s basic package reaching over 18.3 million homes, and plans to add distribution on other cable and satellite systems in coming weeks. The initial launch will have a program line-up consisting of 15 distinct series with vacation travel, home improvement and real estate programming; its positioning between the Bloomberg News network and CNBC brings it a highly favorable audience that the company expects will attract the exact demographic group that will appreciate its distinctive programming. Shares lost ten cents on the week to close at $1.28.

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, announced last week that it ranked number 284 on Technology Fast 500(TM), Deloitte LLP’s ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five-year period from 2004-2008. OmniComm grew 455% percent during this period. Shares remained unchanged at $0.20 on the week.

ONE Holdings (OTCBB: ONEZ), a green process manufacturer of high quality health supplements, organic fertilizers and pesticides, announced last week that it will be opening an office in Shanghai. The company plans to open the office within the next few months to consolidate treasury, operations, and sales of ONE Holdings operating units in the Asia Pacific region, giving ONE’s upper management better levels of efficiency and control. The company also announced the hiring of Wei-En Chen, who will be working out of ONE’s Miami headquarters. Wei-En joins with the responsibility of assisting the CFO, maintaining consolidated accounting records, and managing SEC filings. Ms. Chen will work closely with the new Shanghai office, giving the U.S. management team a clear view of its subsidiaries. Shares gained a penny on the week to close at $1.25.

Greenshift (OTCBB: GERS), a company that develops and commercializes clean technologies that facilitate the efficient use of natural resources, announced last week that it has been granted U.S. Patent No. 7,608,729, titledMethod of Freeing the Bound Oil Present in Whole Stillage and Thin Stillage. This latest patent approval builds off of the recently granted patent relating to the company’s core technology that was issued earlier this month, to enhance yield and optimize energy utilization. The issuance of both patents serves to validate the significant resources that the company has invested in the development of its extraction platform which is expected to significantly improve upon the 3.4 million tons of corn oil passed unrecovered through the U.S. ethanol industry during 2008 alone. Shares remained unchanged at less than a penny on the week.

October 19th CEOcast Weekly Newsletter

Monday, October 19th, 2009

Companies featured in this edition of the newsletter: CHIP, ENZ, GERS, IWEB, OMCM, ONEZ, XSNX

Markets hit fresh highs for ’09 yet again last week, as the first round of earnings helped to assuage investor concerns that operating results would underpin robust gains in equities this year. All told, the Dow gained 130 points to end the week at 9995 after briefly cracking the 10,000 mark, gaining 1.3% on the week and extending its gains to 13.9% on the year. The Nasdaq gained 0.8% on the week to close at 2156, up 36.8% on the year, while the S&P 500 and Russell 2000 gained 1.5% and 0.2% respectively, bringing their YTD totals to 20.4% and 23.4%.

Earnings stole the spotlight last week as things got off to a strong start early with JP Morgan handily beating expectations calling for $0.51 per share, reporting earnings of $0.82 per share. Citigroup and Goldman Sachs reported similarly upbeat results, but were not rewarded in kind as selling pressure resulted in losses on the day despite the earnings beats. Google however was rewarded by the market for besting EPS estimates, coming in at $5.89 versus expectations for $5.42; shares gained 3.75% on Friday following the announcement.

Commodity prices also served as a major driving factor this week as weakness in the dollar, which hit a fresh 52 week low, helped boost commodities to record levels. Gold managed to continue its run, hitting an all time high of $1070.20 an ounce and oil surged to $78.75 per barrel, its highest levels of ’09.

Economic data was mostly overshadowed by earnings, but retail sales managed to provide a positive surprise, declining by a modest 1.5%, versus expectations for a drop of 2.5%. Initial jobless claims also managed to moderately outperform expectations, coming in at 514,000, beating estimates for 520,000.

What should investors look for this week? Earnings will be at the forefront of investors’ collective attention again this week as we continue one of the most highly anticipated earnings seasons in recent memory. Things kick off on Monday afternoon with Apple (NASDAQ: AAPL) and Texas Instruments (NYSE: TXN) reporting after the close. On Tuesday morning, expect reports from Caterpillar (NYSE: CAT), Coca-Cola (NYSE: KO), Lockheed Martin (NYSE: LMT), and Pfizer (NYSE: PFE), with Yahoo! (NASDAQ: YHOO) reporting after the close. On Wednesday look for results from Boeing (NYSE: BA), Continental Air (NYSE: CAL), Eli Lilly (NYSE:LLY), McDonald’s (NYSE: MCD), Morgan Stanley (NYSE: MS), Northrop Grumman (NYSE: NOC), and Wells Fargo (NYSE: WFC), with Amgen (NASDAQ: AMGN) releasing results after the bell. Thursday, AT&T (NYSE: T), Bristol-Myers (NYSE: BMY), Dow Chemicals (NYSE: DOW), Delta Airlines (NYSE: DAL), Merck (NYSE: MRK), Phillip Morris (NYSE: PM), UPS (NYSE: UPS), US Airways (NYSE: LCC), and Wyeth (NYSE: WYE), all report before the bell. Amazon.com (NASDAQ: AMZN) and American Express (NYSE: AXP) release after the close on Thursday, and Honeywell (NYSE: HON) and Microsoft (NASDAQ: MSFT) round out the week before the bell Friday morning.

Economic releases for the week begin Tuesday morning with Building Permits and Housing Starts for September, released along with PPI and Core PPI, also for September at 8:30am. Weekly crude inventories are due out at 10:30am Wednesday, followed by the Fed’s Beige Book at 2:00pm that same day. Thursday brings weekly initial jobless claims and continuing claims at 8:30am, followed by Leading Indicators for September at 10:00am along with the FHFA Housing Price Index for August. Existing Home Sales for September finish up the week’s activity at 10:00am Friday.

There are no conferences of note scheduled for this week due to earnings season.

Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture and licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, reported results for its fourth fiscal quarter ended July 31, 2009 last week. Among the highlights were a 16% increase in total operating revenue, to $24.5 million, and a 19% increase in gross profit, to $10.6 million, compared to the corresponding year ago period. The company attributes the increased revenues to greater product sales and acquisitions at its Enzo Life Sciences subsidiary, in addition to higher testing throughput at its Enzo Clinical Labs division. Enzo reported a net loss of $5.3 million or ($0.14) per share for the period, compared to a year ago net loss of $3.3 million, or ($0.09) per share; results were impacted by higher selling, general and administrative expenses amounting to 48% of net operating revenues, compared to 42% a year ago. The company remains in a strong financial position, with no debt, working capital of $60.5 million and cash and short term investments totaling $50.2 million at the end of the period. In other news last week, the company announced that its Life Sciences subsidiary released a new catalog dealing with Epigenetics & Chromatin Modification at the Society for Neurosciences’, Neuroscience 2009 conference, on October 17, in Chicago, Illinois. The catalog provides a portfolio of tools relating to histone- and DNA-modifying enzymes, including enzymes for lysine acetylation/deacetylation (HATs, HDACs and sirtuins), protein methylation/demethylation, DNA methylation and telomerases. Shares lost fifty one cents on the week to close at $6.81.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently announced its intention to acquire identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, provided further scientific and technological details on the development of Phase II of its in vivo glucose-sensing RFID microchip. The company expects that Phase II trials will be completed in the second quarter of 2010 and will build on Phase I, which successfully demonstrated the bench-top format application of the glucose-sensing system to the detection of glucose levels. The company plans to focus on the development of a bench scale system prototype that incorporates all of the critical components necessary to demonstrate glucose sensing in the presence of model blood and interstitial fluid matrices; they expect that the Phase II trial will result in a fully functional, bench scale prototype of the glucose sensing system. In other news last week, the company announced that it will host an event for the medical, patient and investor communities on October 22, 2009, in New York to unveil details of their virus triage detection system for the H1N1 virus and Phase II development of the aforementioned in vivo glucose-sensing RFID microchip. The companies will also provide a product demonstration of the virus triage detection system currently under development. Shares lost fourteen cents on the week to close at $1.97.

Greenshift(OTCBB: GERS), a company that develops and commercializes clean technologies that facilitate the efficient use of natural resources, announced last week that it has been granted U.S. Patent No. 7,601,858, titled “Method of Processing Ethanol Byproducts and Related Subsystems” for the extraction of corn oil. The patent covers processes for recovering corn oil by evaporating, concentrating and mechanically processing thin stillage, a precursor to the distillers grain co-product of corn ethanol production. The patent allows the company to tap into a new reserve of inedible crude corn oil, with an estimated industry-wide output of about 20 million barrels per year. The corn oil is a valuable second generation feedstock for use in the production of biodiesel and renewable diesel, thereby enhancing total fuel production from corn and increasing ethanol plant profits. In related news last week, the company has filed legal action in the United States District Court against GEA Westfalia Separator, Inc. and others in the industry for infringing on GreenShift’s recently awarded patent covering corn oil extraction technology. The suit alleges that Westfalia and others in the industry infringed on the aforementioned patent and that Westfalia solicited several industry members into using the company’s now patented technology well after the patent applications were published. Shares remained unchanged at under a penny on the week.

Volume Alert: Shares of IceWeb (OTCBB: IWEB), a leading provider of storage solutions and on-line cloud computing application services, gained 64% on over four times average volume last week, following the announcement that it will be exhibiting in the GEOINT 2009 Symposium, the preeminent event of the year for the defense, intelligence and homeland security communities. IceWEB’s equipment will also be prominently displayed in six partners’ booths throughout the show, and will include the MLP III, their Iplicity Enterprise suite, and a new, yet to be announced product which will be unveiled at the Symposium. Shares gained just over five cents on the week to close at $0.115.

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, was the subject of a research update from analysts at Emerging Growth Equities that was released last week. In the report, analysts reiterated their Buy rating and put a price target of $0.40 on the shares, which are currently trading at $0.20. Analysts cited, “recent contract wins reflect[ing] OmniComm’s strengthening competitive position and some improvement in the macro environment, in addition to recently completed acquisitions which expanded both the customer base and breadth of available services as reasons for the rating.” In other news last week, the company announced that its new SDTM solution is ready ahead of schedule, and is available to its customers for deployment and implementation into clinical studies. The SDTM update was developed for OmniComm’s flagship EDC product, TrialMaster, and will allow for mapping and exporting of data directly into the CDISC SDTM format, ensuring an accelerated pathway towards electronic submission of clinical data. The update makes OMCM the first EDC company to leverage all of the industry leading reporting standards in a single solution. Shares lost four cents on the week to close at $0.20.

ONE Holdings (OTCBB: ONEZ), an investment company owning majority equity interest in core operating assets in Biotechnology located in the Asia Pacific region, announced last week that its Green Planet Bioengineering Co. Subsidiary has filed a patent application relating to the process and application of extracting Isofraxidin and Flavonoid compounds synchronously from Sarcandra Glabra, a plant native to China that possesses medicinal properties. The new process is expected to dramatically improve the extraction rate and medicinal yield, in addition to significantly increasing the company’s time to market in the high margin over the counter business. The company plans to launch OTC products by the fourth quarter of this year and expects that the product expansion will result in higher net profit. Shares gained a penny on the week to close at $1.24.

Volume Alert: Shares of XsunX (OTCBB: XSNX), a developer of advanced, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, surged over 46% on almost four times average volume last week, following the initiation of coverage by analysts at Beacon Equity research. Coverage was initiated with a Speculative Buy rating and a price target of $2.90 on the shares that are currently trading at just over $0.19. Analysts speculated that the company’s “new technology may produce a replacement for silicon wafers as roughly 80% of solar panels are silicon-based” at half the cost. The company’s CIGS wafers could be integrated into solar panels, adapted to a variety of building materials and even used in consumer products. The report also provides an update on XSNX’s development progress, stating that the company “is currently focusing its development efforts on designing an efficient evaporation source for use in commercial-scale manufacturing of CIGS layers. These design and engineering efforts began in April 2009. XSNX anticipates performing tests of evaporation source designs and adapting these sources to HDD equipment over the next nine to 10 months.” Shares gained just over six cents on the week to close at $0.191.

October 12th CEOcast Weekly Newsletter

Monday, October 12th, 2009

Companies featured in the current edition of the newsletter: CHIP, CVM, DKAM, ENZ, HYTM,NXOI, ICLK, IWEB, SIHI, SVUL

Stocks came roaring back last week, snapping their losing streak as investors anxiously await third quarter earnings season which is set to begin this week. All told, the Dow gained 377 points to close at 9864, up 4% on the week and 12.4% on the year. The Nasdaq gained 4.5% to close at 2139, extending its gains to 35.7% on the year, while the S&P 500 and Russell 2000 posted gains of 4.5% and 6.0% respectively, bringing their yearly gains to 18.6% and 23.1%.

While there were little in the way of significant developments on the week, there were some positive signs that gave investors all the excuse that they needed to buy into the weakness of the past few weeks. Alcoa managed to kick off earnings season with a bang, reporting better than expected results and predicting improved demand for aluminum in the second half of 2009. Further support came from better than expected sales figures, as opposed to cost cutting which had allowed many companies to beat estimates during the second quarter.

Despite the absence of market driving economic reports, Tuesday’s decision by the Reserve Bank of Australia to raise its key lending rate by 25 basis points was interpreted as another sign of global recovery and helped to further stoke bullish enthusiasm. Following the week’s activity, nine of the ten sectors of the S&P 500 finished in positive territory, led by Energy, up 7.5% and Financials, up 6.7%.

What should investors look for this week? Earnings Season begins in earnest on Tuesday morning with results expected from Johnson & Johnson, with chipmaker Intel reporting after the close, followed on Wednesday by Abbott Labs and JP Morgan before the bell. Thursday will be a busy day as Citigroup, Goldman Sachs, Nokia, Safeway and Southwest Air all report before the bell. Advanced Micro, Google and IBM report after the close. Bank of America and General Electric wrap things up Friday morning.

Economic releases for the week begin on Wednesday with Import and Export Prices for September, released along with Retail Sales, also for September, at 8:30am, followed at 10:00am by Business Inventories for August and FOMC Minutes from the September meeting at 2:00pm. On Thursday, look for weekly initial jobless claims, continuing claims, and CPI/Core CPI for September due out together at 8:30am. The October Philadelphia Fed Index is due out at 10:00am that same day along with weekly crude inventories at 2:00pm. The week finishes up on Friday with Net-Long Term TIC Flows for August at 9:00am, Capacity Utilization and Industrial Production for September at 9:15am, and Preliminary Michigan Sentiment for October at 9:55am.

Conference schedules for the week will be light, but Sinohub (AMEX: SIHI) will present at the three-day Roth Capital Partners China Conference beginning on Monday in Miami Beach.

Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture and licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, announced last week that it has added a new apoptosis detection kit for monitoring chromatin condensation to its rapidly expanding CELLestial product line for live cell analysis. Enzo showcased the capabilities of the new assay in a scientific poster presentation at the prestigious 8thCell Death Conference which was held at the Cold Spring Harbor Laboratory in Cold Spring Harbor, N.Y last week. The Nuclear-ID Green Chromatin Condensation Kit is a major breakthrough for the rapid screening of agents that induce apoptotic cell death, which is potentially useful in identifying compounds for the treatment of diseases such as cancer. Potential applications for live-cell studies using the kit include monitoring the stages of chromatin condensation, rapid testing of compounds that induce apoptosis, and as a quick test to determine the health status of cells grown in culture. Shares gained forty six cents on the week to close at $7.34

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently announced its intention to acquire identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, announced last week that it has selected Raytheon Microelectronics Espa to produce its radio frequency identification (RFID) implantable microchips, including its existing VeriChip microchip for patient identification, its new 8 millimeter microchip for use in Medical Components, Inc.’s vascular access medical devices, and its glucose-sensing RFID microchip currently under development with RECEPTORS, LLC. In related news last week, the company also announced that it has received an exclusive license to two RECEPTORS’ Patents related to the development of the aforementioned in vivo glucose-sensing RFID microchip that could potentially negate the need for diabetics to draw blood samples multiple times each day to read their blood glucose levels. CHIP believes that patients implanted with the glucose-sensing microchip, if successfully developed, could get a rapid reading of their blood sugar with a simple wave of a handheld scanner. The company was also featured last week in a special segment of the Glenn Beck show on Fox News dedicated to the H1N1 virus. The show featured VeriChip, its Health Link personal health record and its H1N1 virus triage detection system currently being developed with partner RECEPTORS LLC, as part of the show. Shares lost thirty three cents on the week to close at $2.11.

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, released a letter to shareholders last week highlighting the company’s progress in developing a treatment for the H1N1 swine flu virus. The letter also provided an overview of the disease as explained by one of the company’s outside collaborators, Ken S. Rosenthal, Ph.D., Professor of Microbiology, Immunology and Biochemistry, Northeastern Ohio Universities Colleges of Medicine and Pharmacology. It went on to describe the impending global Phase III trial of the company’s head and neck cancer drug,Multikine, in association with Teva Pharmaceuticals and Orient EuroPharma, as well as the validation of the company’s new manufacturing facility for contract manufacturing operations located in Baltimore, MD which is also nearing completion. Shares lost twenty five cents on the week to close at $1.41.

SinoHub (AMEX: SIHI) a company providing world-class supply chain management services with transparent information access for participants in the electronic components supply chain in China, announced last week that its Chief Executive Officer, Harry Cochran, will present a company overview at the Roth China Conference at 8:00 a.m. ET on Wednesday, October 14, 2009 at the Fontainebleau Hotel in Miami Beach, Florida. Shares gained twenty five cents on the week to close at $4.00, up 7%.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it has received $650,000 in new orders to date from distributors for Spirits during its fiscal second quarter for the period ending October 31, 2009.The figure excludes sale of beer from labels such as Kid Rock’s American Badass Beer, and represents a significant improvement over the corresponding year ago period when Spirit sales were $378,000. The company attributes its robust sales to increased access to new credit facilities which have enabled it to rebuild customer inventories and take advantage of the interest in its brands, particularly Olifant Vodka, which after the twenty two city Snoop Dogg Olifant Vodka Summer Concert Series has continued accelerated growth. Management has indicated that it expects to see sustained revenue growth as they continue to rebuild spirit inventories with distributors which were negatively impacted by constricted credit markets in the wake of the financial crisis. Shares lost half a cent on the week to close at $0.085.

interCLICK, Inc. (OTCBB: ICLK) the leading ad network in data and inventory transparency, announced last week that it is the first ad network to join Bizo’s Premier Data Reseller Program. Bizo is a leading B2B audience targeting platform and network, currently reaching over 45 million targeted business people across thousands of sites on the web. The partnership is exclusive to ICLK through 2009 and fully certifies the company to utilize Bizo’s extensive bizographic targeting dataand grants interCLICK’s advertisers access to more robust targeting data as well as improved optimization, ensuring the most efficient results for B2B advertisers. Several major advertisers are already taking advantage of the partnership by layering Bizo data on top of interCLICK’s publisher inventory to efficiently reach a highly targeted audience of business professionals. In other news last week, ICLK announced that it has retained the services of J.H. Cohn, one of the top 15 accounting and business consulting firms in the United States, as its independent accounting firm. The company cited JHC’s combination of national scale, marketing services industry expertise, and track record with fast-growth emerging companies as reasons for selecting the firm. Shares gained fourteen cents on the week to close at $2.16.

IceWeb (OTCBB: IWEB), a provider of storage solutions and on-line cloud computing application services, announced last week that it has completed the first delivery of systems to the GCS Research Adelos Program. The Adelosâ„¢ sensor system is an advanced covert intelligence and surveillance sensor system protecting high value critical infrastructure, monitoring sensitive perimeters, and securing vulnerable borders; it requires hardware to be fully mobile and self sustained, making IWEB’s INLINE Storage solutions a natural fit. The companies have been collaborating on the hardware requirements for the system for over a year and expect that the research performed on this project will position both companies to deliver field proven replications of this innovative configuration more quickly and affordably than any other solution available. Shares remained unchanged at $0.08 on the week.

Next One Interactive (OTCBB: NXOI), an interactive media company specializing in Digital Media with a focus on Travel and Real Estate, had coverage initiated by Venture Research last week. Coverage was initiated with a strong buy rating and a price target of $4.00 on the shares that are currently trading at $1.30. Analysts cited the strong consumer market that the company has chosen to enter -proposing to capitalize on the over 100 million households with access to cable TV-in addition to the heavy advertising activities characteristic of its targeted real estate and travel segments as reasons for the rating; existing deals with Comcast, Time Warner and DirecTV also factored positively into the evaluation. Shares lost fifteen cents on the week to close at $1.30.

Steel Vault (OTCBB: SVUL) an emerging provider of identity security products and services, announced last week that it has approved November 10, 2009, as the date for its special meeting of stockholders to vote on the merger of Steel Vault and VeriChip Corporation. If the merger is approved, each share of Steel Vault common stock will be converted into the right to receive 0.5 shares of VeriChip common stock which ended the week trading at $2.11. No fractional shares of VeriChip common stock will be issued in connection with the merger; instead, VeriChip will make a cash payment to each Steel Vault stockholder who would otherwise receive a fractional share. Shares gained nine cents on the week to close at $0.89

SPECIAL SITUATIONS:

Hythiam (NASDAQ: HYTM) $0.68

With cost containment at the forefront of the debate among President Obama and Congress, insurance companies are likely to become even more acutely focused on cost containment and return on investments they make in paying for healthcare services. One company that could be well positioned to benefit is Hythiam, as the company’s Catasys Program offers payers the ability to reduce the cost of treating substance abuse, which, when left untreated, can significantly increase the cost of healthcare in the long run. Due to the increased focus on cost reduction, timing could be ideal for companies such as Hythiam to gain adoption for innovative ways to treat substance abuse.

However, it appears that insurance companies are not the only parties focused on reigning in healthcare costs. Last month, the company entered into a three year agreement with Ford Motor Company to provide the Catasys integrated substance dependence solution to Ford’s hourly employees in Michigan enrolled in the National PPO and who meet certain criteria. Eligible employees struggling with alcoholism, stimulant and opiate dependence will be covered under the program, which contains medical interventions including naltrexone, Suboxone and the proprietary PROMETA Treatment Program, and psychosocial and care coaching components across 52 weeks. The company will conduct direct outreach to enroll qualified members, and will also work with UAW-Ford and Ford’s EAP program to ensure the most beneficial treatment pathway for members. Contractual revenues from the agreement are based on a combination of monthly fees for the member population for Catasys, with additional monthly fees for members enrolled into the Catasys program. Operational implementation is expected to begin this quarter.

So what is Catasys? It is an integrated treatment approach, under which Hythiam provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary Prometa Treatment Program for alcoholism and stimulant dependence. The Prometa Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers. The Program works through a combination of behavioral modification treatments designed to correct the mental processes responsible for addictive behavior, a proprietary combination of drugs designed to alleviate physical and mental withdrawal symptoms, and a nutritional component which is designed to promote long term health and recovery through introducing lasting changes in the lifestyles of patients.

Empirical support for Prometa’s effectiveness has been demonstrated in a number of studies in recent years. It has been found to promote a significant difference in use for subjects in active withdrawal in a 2009 alcohol study, in addition to the finding that the Program led to significant differences in use and cravings for subjects with a history of withdrawal and a significantly reduced instance of cravings in patients with methamphetamine addictions. Along with its ability to reduce withdrawal and cravings in substance dependant patients, Prometa has also been demonstrated to significantly reduce costs associated with treating these individuals. In a recent third party payor pilot study, Prometa was found to significantly reduce the costs associated with treating substance dependant individuals, decreasing the behavioral health costs of these individuals by as much as 68%, versus a control group who were not treated with Prometa that demonstrated a 57% increase in cost of care. Recently, the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies. The results are the first to be published in a peer-reviewed scientific journal from a double-blind, placebo-controlled study conducted to assess the impact of the PROMETA Treatment Program on alcohol dependence and could bolster the company’s marketing claims.

With a treatment program proven to positively impact the lives of substance dependant individuals while reducing the overall cost of treatment, Hythiam appears well positioned to capitalize on the much publicized trend towards reducing healthcare costs. The company provides investors with a unique opportunity to invest in a company making great strides in improving the overall state of healthcare in the U.S. by effectively treating repeat abusers who require hundreds of millions of dollars a year in medical treatments. The company itself has recently undergone restructuring which has left it in a significantly improved financial position achieved through a reduction in operating costs and the completion of a $7 million registered direct offering that is expected to enable it to more effectively capitalize on the almost $2 billion market that it serves.

October 5th CEOcast Weekly Newsletter

Monday, October 5th, 2009

Companies featured in this edition of the newsletter: CHIP, ENZ, ICLK, IMUC, IWEB, MBCI, OMCM, ONEZ, ORMP

Markets extended their losses last week as less than encouraging economic news suggesting that the economy might be recovering more slowly than previously anticipated led to sell offs in all the major indices. All told, the Dow ended the week down 177, surrendering 1.8% on the week to close at 9487, paring its YTD gains to 8.1%. The Nasdaq lost 2% on the week, closing at 2048, up 29.9% on the year, while the S&P 500 and Russell 2000 lost 1.8% and 3.1% respectively, bringing their yearly gains to 13.5% and 16.2%.

Employment data weighed heavily on investors’ minds this week, as labor market concerns sparked selling in advance of Friday’s lackluster Nonfarm Payrolls report. The report proved to validate concerns, falling short of even the most negative expectations coming in at -263,000 lost jobs versus forecasts for -175,000. Despite the larger than anticipated decline, markets sold off modestly following the release, as the poor figure appears to have been priced in during the S&P 500′s 2.6% plunge during Thursday’s session. Weak Payroll numbers weren’t the only reason for Thursday’s drubbing, as weekly initial jobless claims released the day before rose to 551,000, more than expectations of 535,000 and ADP employment change also came in worse than expected, declining by 254,000 versus expectations for 200,000.

Despite the poor labor market data, corporate developments left some room for positive interpretation on the week as activity is slowly beginning to return to pre-crisis levels. Several notable mergers and acquisitions took place in addition to several IPO’s which had all but vanished in the months prior. Xerox paid $6.4 billion in cash and stock to acquire Affiliated Computer Services on Monday which helped markets post their largest gains of the week, and Abbott Labs acquired Salvoy Group’s pharmaceutical business for $6.6 billion. Despite these positive signs, nine of the ten sectors of the S&P declined on the week, with consumer staples being the sole winner gaining a modest 0.7%.

Earnings reports will be few and far between again this week, but look for reports from Pepsi Bottling (NYSE: PBG) Tuesday pre-market, and YUM! Brands (NYSE: YUM) after the close that same day. Costco (NASDAQ: COST) and Monsanto (NYSE: MON) report before the market on Wednesday with Alcoa (NYSE: AA) reporting after the close. PepsiCo (NYSE: PEP) and Marriott (NYSE: MAR) finish out the week reporting on Friday morning.

Economic releases for the week begin with ISM Services for September at 10:00am Monday morning. On Wednesday, look for weekly crude inventories at 10:30am followed at 2:00pm by Consumer Credit for August and Treasury Budget for September. On Thursday, weekly initial jobless claims and continuing claims will be released together at 8:30am, followed by Wholesale Inventories at 10:00am. The week wraps up with Trade Balance data for August at 8:30am on Friday.

Conference schedules for the week begin with the two day JMP Securities Healthcare Focus Conference and the Brean Murray, Carret & Co. Consumer One on One Conference, both beginning in New York on Monday along with the William Blair & Co. Emerging Growth Stock Conference. The Johnson Rice Energy Conference begins on Tuesday and is being held in New Orleans, as is the Jefferson Companies New Orleans Investment Conference which begins on Thursday.

Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture and licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, announced last week that its Enzo Life Sciences subsidiary, a world leader in non-radioactive probe technology, and BioTek Instruments, a privately held global leader in the development, manufacture and sale of microplate instrumentation for drug discovery and life science applications, have begun a co-marketing partnership aimed at research institutions, biotechnology and pharmaceutical companies. The collaboration is designed to allow researchers to obtain integrated instrumentation and reagent solutions that are high-performance, yet affordable, by creating a highly reproducible and reliable platform for live cell analysis, offering a cost effective alternative to dedicated microplate imaging-based systems, which often are too costly for investigators to implement. The collaboration will be formally launched next month at MipTec 2009, an international conference focused on drug discovery held in Basel, Switzerland. Shares lost forty nine cents on the week to close at $6.88.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently acquired identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, announced last week that it has regained compliance with NASDAQ’s minimum $1.00 per share bid price requirement and is in compliance with all other NASDAQ requirements for continued listing. In other news last week, the company also announced that it has entered into a definitive agreement for a $10 million investment commitment. Verichip expects to use a portion of the proceeds to fund its development programs with RECEPTORS LLC to develop a virus triage detection system for the H1N1 virus and an in vivo glucose-sensing RFID microchip with the remainder to be used for working capital and general corporate purposes. In related news last week, the company has announced further details regarding the development of its virus triage detection system for the H1N1 virus developed using RECEPTORS’ patented AFFINITY by DESIGN platform, which is intended to provide two levels of virus identification within minutes. Once developed, it is expected that the first level will prep the sample and identify the agent as a flu or non-flu virus, and the second level will sub-classify the flu virus as H1N1 or other types, and alert the user to the presence of pandemic threat viruses. The company believes the influenza triage diagnostic system will be scalable and will be able to be rapidly adapted to identify new strains of influenza and other viruses as they evolve, giving the virus triage detection system value for future testing applications in healthcare. The first phase of development of the virus triage detection system, consisting of the sample prep and flu or non-flu classification, is expected to be completed in four months, with the second phase, which will have the ability to identify the precise pathogen present, expected to take approximately six to eight months. Shares lost seventy eight cents on the week to close at $2.44.

IceWeb (OTCBB: IWEB), a leading provider of storage solutions and on-line cloud computing application services, announced last week that it has partnered with Mezeo Software, the leading provider of deployable cloud storage solutions purpose-built for service providers. The collaboration will provide a solution that enables service providers to quickly and easily deploy their own complete, service-enabled cloud storage offering designed to provide an end-to-end, multi-tenant cloud storage solution that can be easily, rapidly and securely deployed in a centrally managed private storage cloud or in a hybrid public/private cloud configuration. The goal of the collaboration is to create a solution that enables service providers to go to market efficiently and affordably, without the costs and delays of developing a solution from the ground up. Shares lost a penny on the week to close at $0.08.

interCLICK, Inc. (OTCBB: ICLK) the leading ad network in data and inventory transparency, announced last week that it has applied for listing on the Nasdaq exchange. An application was filed in June 2009, at which time Nasdaq indicated that ICLK needed to satisfy the minimum $4.00 price criterion required for new listings. In order to gain compliance with the price requirement, the company’s board of directors authorized a reverse split on September 24, 2009; approval of the measure requires an affirmative majority vote. The company has indicated that it expects the measure to pass due to its anticipation of support from 12 individuals representing 52% of its outstanding shares and will not solicit any proxies in connection with obtaining approval. Upon receiving the requisite vote, management retains the right to determine the required reverse split, or to abandon the proposal as it sees fit. Shares gained two cents on the week to close at $2.02.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109 last week. Data demonstrated that ICT-109 had a statistically significant ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. IMUC plans to conduct additional studies of ICT-109 in combination with other markers to design a sufficiently robust assay for early stage detection of these cancers that could potentially be widely adopted as a diagnostic tool in this field. The company now plans to find a partner within the diagnostic space to further develop and commercialize the approach. Shares gained seven cents on the week to close at $1.20.

MabCure, Inc. (OTCBB: MBCI), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, announced last week that it has developed MAbs to be used in the detection of Colorectal Cancer (CRC), a debilitating form of the disease that is a leading cause of death in men and women over the age of fifty, with a potential US and European diagnostic market estimated by the company to be in the billion dollar range. The company plans to explore options relating to both the early detection of cancer from blood and feces samples as well potential applications related to imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy. Shares lost five cents on the week to close at $1.24.

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, announced last week that Kendle, a leading global clinical research organization (CRO), will add OmniComm’s TrialMaster EDC solution to its current eClinical offerings in a multi-year enterprise-wide agreement. Management from Kendle cited TrialMaster’s ability to, “offer the right mix of functionality to streamline the study development process and drive efficient study operations,†as a reason for the agreement. Kendle is one of the largest, most respected and successful global CROs, with extensive eClinical experience, having conducted more than 250 trials utilizing EDC technologies to expedite the clinical trials process. Share remained unchanged at $0.15 on the week.

Oramed Pharmaceuticals (OTCBB: ORMP), a developer of oral drug delivery systems, was featured in a video on the Forbes.com video network last week. In the clip, Nadav Kidron, CEO of ORMP, highlights the current state of the global diabetes epidemic and discusses how the company’s proprietary oral insulin delivery system may potentially revolutionize the treatment of the millions of people afflicted with diabetes. Mr. Kidron continues on to discuss the benefits of oral delivery versus traditional insulin injections, as well as the drug’s clinical progress and development outlook, highlighting their Phase II trials in South Africa and plans to work with the US FDA in designing trials for the drug to gain approval in the US. The interview can be found on the Forbes website at www.forbes.com. Shares remained unchanged at $0.57 on the week.

ONE Holdings (OTCBB: ONEZ), an investment company owning majority equity interest in core operating assets in Biotechnology located in the Asia Pacific region, announced last week that it has closed on the acquisition of Jianou Lujian FoodsStuff Co. Ltd, an award-winning green-technology enterprise that specializes in the highly profitable production of organic products and fertilizers based on bamboo. The acquisition closed prior to the end of the third quarter as the company had previously indicated that it expected to and marks the third acquisition that the company has made in the past three months, adding $50 million dollars in revenue, $11 million in operating income and $8 million in net income based upon the recent additions’ 2008 results. Shares remained unchanged at $1.20 on the week.

September 28th CEOcast Weekly Newsletter

Monday, September 28th, 2009

Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling for 440,000, while existing home sales missed estimates even more drastically, falling by 2.7% to 5.10 million in August from 5.24 million the month prior, and significantly lower than expectations for 5.35 million. These latest figures coupled with the pending expiration of the first time home buyer tax break, which is expected to be wound down in November, have led many to believe that there is still significant room for improvement in housing markets as increasing unemployment, excess housing inventory and tightening credit standards have created a difficult environment for prospective home buyers. Investors were given further pause later in the week by the news that durable goods orders fell by 2.4%, versus expectations for a gain of 0.4%, most readily attributed to weakness in aircraft and automotive demand resulting from the termination of the cash for clunkers program.

Corporate news was mixed on the week, as shares of Blackberry maker Research in Motion (NASDAQ: RIMM) lost almost 18% following weaker than expected revenue forecasts for Q3 despite reporting in line with expectations for its Q2 numbers. On the more positive side, General Mills (NYSE: GIS) handily beat estimates, reporting EPS of $1.28, significantly better than forecasts calling for EPS of $1.03; the company attributed the better than expected performance to strong consumer demand and raised its full year earnings outlook as a result. Following the week’s action, all ten sectors of the S&P declined, with materials leading the way at 4.8% and financials following with a loss of 3.6%.

What should investors look for this week? Earnings will be slow once again, but look for reports from Walgreen (NYSE: WAG) before the bell on Tuesday, followed after the close the same day by Nike (NYSE: NKE). Pepsi Bottling (NYSE: PBG) reports Wednesday pre-market.

Economic releases for the week begin on Tuesday with Case-Shiller Home Price Index for July and Consumer Confidence figures for September, due out together at 9:00am. On Wednesday, ADP Employment for September will be released at 8:15am, followed by Final Q2 GDP at 8:30am, Chicago PMI for September at 9:45am, and weekly crude inventories at 10:30am. On Thursday morning, expect Personal Income and Spending for August, along with weekly initial jobless claims, and continuing claims at 8:30am. Construction Spending for August, ISM Index for September, and Pending Home Sales for August will be released at 10:00am, followed at 2:00pm by Auto and Truck Sales for September. The week wraps up on Friday with Average Workweek, Hourly Earnings, Nonfarm Payrolls and the Unemployment Rate, all for September, released together at 8:30am, followed by August Factory Orders at 10:00am.

Conference schedules for the week begin on Tuesday with the Maxim Group Conference in New York, followed on Wednesday by the Jefferies Global Clean Technology Conference in London, and the two day Deutsche Bank Securities Leveraged Finance Conference in Scottsdale, AZ. The week wraps up on Thursday with the Thomas Weisel Partners Consumer Conference and the Bank of America Securities Global Real Estate Conference which are both also being held in New York.

Volume Alert: Shares of Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture and licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, gained 4.5% on over twice average volume last week, following coverage being initiated by an analyst at brokerage firm Rodman & Renshaw. Coverage was initiated with a Market Outperform/ Speculative Risk rating and a 12 month price target of $14 on the shares which are currently trading below $8, based on a 2015 discounted earnings per share and revenues per share analysis. The analyst cited the “potential to develop in-house as well as acquire cutting-edge molecular diagnostics tests, creating a synergy between the life sciences division and clinical laboratory that offers substantial upside to investors.” The report also cites “Enzo’s promising therapeutic pipeline that has the potential to drive shareholder value including Optiquel for autoimmune uveitis and Alequel for Crohn’s disease.” In other news last week, Enzo announced that it had entered into a Cooperative Research and Development Agreement with the National Eye Institute (NEI), part of the National Institute of Health, to conduct a human clinical trial of Optiquel. Under the terms of the arrangement, Enzo will provide Optiquelâ„¢ and fund a portion of the studies, while Robert Nussenblatt, MD, Chief of NEI’s Laboratory of Immunology, will serve as the Principal Investigator on this project. In autoimmune uveitis, the body’s own immune system attacks the uvea of the eye, the portion of the eye that lies between the outermost and innermost layers of the eye; it occurs most frequently in people ages 20 to 50, with estimates that more than 30,000 of the 280,000 people in the United States that are affected by uveitis each year, lose their vision as a result of the condition. Shares gained thirty two cents on the week to close at $7.37.

Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently acquired identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, surged 180% on over twelve times average volume last week, following the announcement that the company has been granted an exclusive license to patents related to its partner RECEPTORS’S proprietary virus triage detection system for the H1N1 swine flu virus. The patents can also be applied to detection systems for other viruses and biological threats such as Methicillin-resistant Staphylococcus aureus (MRSA). The company believes that being granted rights to these patents, which are the cornerstone of the virus detection technology, will be a key factor in the evolution of PositiveID Corp. Shares gained $2.07 on the week to close at $3.22.

Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord, announced last week that its Investigational New Drug (IND) application has been granted approval by the U.S. FDA, and that the company has been given clearance to commence Phase I trials to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells. Neuralstem is the first company to be given FDA clearance to commence stem cell trials to treat Lou Gehrig’s, a fatal neurodegenerative disease for which currently there is no effective treatment or cure that affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year. The trial will study the safety of Neuralstem’s cells and the surgical procedures and devices required for multiple injections of Neuralstem’s cells directly into the grey matter of the spinal cord; the approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans. Shares lost seventeen cents on the week after retreating from a high of $2.95 to close at $1.70.

Volume Alert: Shares of CEL-SCI Corporation (AMEX: CVM), a vaccine developer and late stage cancer immunotherapy company, surged 20% on over three times average volume following the announcement last week that it has retained the services of a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment. The news comes on the heels of the announcement the week prior that the FDA had approved CEL-SCI to proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients. The study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS-H1N1 investigational therapy in order to assess the cells’ response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol. In order to be considered for the next stage of clinical trials, CVM must submit a detailed follow-up regulatory filing with extensive additional data. In order to accomplish this in as expeditious a manner as possible, the company plans to work closely with the FDA to ensure that they complete the steps necessary to gain approval for the next Phase of testing. Shares gained twenty eight cents on the week to close at $1.63.

IceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, announced last week that it has been chosen by a Canadian governmental agency to provide MLP Server Appliances for the Integrated Security Unit (ISU) for the 2010 Winter Olympics scheduled to be held in Vancouver. The company expects that this order will expand on the existing installations with the Canadian Agency and allow greater security and communications for the ISU in meeting their critical mission of protecting the 2010 Vancouver Games. In other news last week, IWEB announced that it is participating in the U.S. government’s cloud computing initiative that was discussed in a press conference by the Obama Administration on Tuesday, September 15th. The company has been providing products and services to the government for several years, and plans to participate in the Cloud Computing Initiative very actively, as their Iplicity products are an enabling technology for the adoption of Cloud based Data Storage, one of the key areas of need that this initiative addresses. Management believes that the company’s existing products and services are a natural fit for this new government effort and believe that IWEB can gain a significant amount of new, highly profitable business as a result. Shares gained two cents on the week to close at $0.09.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it has completed humanization, a process designed to increase acceptance of antibodies by host immune systems, for two of its antibodies, ICT-37 and ICT-109. Humanization was completed in collaboration with Antitope, a privately held, UK based biotechnology company providing services in the areas of immunogenicity testing, antibody humanization and protein engineering for the purpose of reducing immunogenicity with therapeutic monoclonal antibodies, and resulted in two novel antibodies targeting CEACAM5 alone and CEACAM5 and CEACAM6, two commonly expressed genes present in malignant cells specific to colon cancer, small cell lung cancer and pancreatic cancer. The company plans to explore partnering opportunities with companies that may be interested in small cell lung, pancreatic and colon cancer targeting opportunities as they continue to seek the fastest path to FDA approval for these potentially revolutionary therapies. Shares lost nine cents on the week to close at $1.13.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated to the powersports industry, announced last week that as a result of the expansion of its Municipal Lease Product to include several new types of vehicles in addition to police motorcycles, it has received a number of requests from local governmental agencies asking Sparta to finance vehicles such as armored tactical trucks, electric/hybrid passenger busses and police cruisers, as well as other essential equipment used by those municipal agencies. In response to this increased demand, the company is currently examining options that would allow it to finance the expanding needs of its municipal clients, in addition to the previously announced relationship with Armet Armored Vehicles, and ongoing contracting discussions to lease police cruisers to multiple agencies. Shares lost just over a penny to close at $0.056 on the week.

Volume Alert: Shares of Steel Vault (OTCBB: SVUL), an emerging provider of identity security products and services, surged 102% on over ten times average volume last week on the aforementioned news that its acquiring partner VeriChip had been granted patents related to a swine flu diagnostic technology. The company also announced preliminary results for the quarter ending September 30, 2009 and provided an update on its operations last week. The company expects revenue for the period of $550,000 to $650,000, compared to revenue of $343,000 for the quarter ended June 30, 2009, and no revenue for the quarter ended September 30, 2008; the subscriber base at September 30, 2009 is projected to be approximately 14,000. In other news last week, the company announced that it had formed a strategic marketing partnership with OPEN Sports, a leader in sports news and fantasy sports, and FOX Sports to drive subscriber growth for Steel Vault’s services. The partnership is designed to leverage exposure from FOX Sports marketing power to create interest in the company’s online offering, and additionally, players who participate in FOX Fantasy Quick Challenge and Fantasy Live, will receive a free credit report and score from NationalCreditReport.com, which also includes a seven-day free trial to its Safeguard Credit. Shares gained fifty three cents on the week to close at $1.05.

Volume Alert: Shares of XsunX (OTCBB: XSNX), a developer of advanced, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, gained ten percent on almost twice average volume following the announcement last week that it has entered into a Joint Business Agreement with Intevac, Inc. a leading provider of magnetic media deposition equipment to the hard disk drive (HDD) industry. The companies plan to collaborate in the development of techniques and equipment for the production of commercially marketable CIGS (copper indium gallium selenide) thin-film solar cells. They plan to use their cross-industry expertise to develop a new breed of TFPV manufacturing techniques to produce thin-film solar cells, combining Intevac’s unparalleled expertise and years of technological improvements developed for the sophisticated HDD manufacturing industry with XsunX’s experience in the TFPV industry. The two companies are adapting high-rate production tools from the disk drive industry with process knowledge from the CIGS and thin-film industry, which they expect will produce a technology that is cheaper to manufacture than standard silicon cells and more efficient than other TFPV cells currently available. Shares gained just under two cents on the week to close at $0.154

Advanced Cell Technologies (OTC: ACTC), a company engaged in the development of regenerative therapies utilizing stem cells, provided an update on pre-clinical activities in preparation of its first IND filing with the FDA for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. In the next few weeks, the company will be completing the preclinical work necessary for filing the IND. In various preclinical tests using the cells on animal models, no adverse events have occurred, leaving the company optimistic that human embryonic stem cells (hESCs) can serve as a potentially safe and inexhaustible source of RPE for the treatment of a range of macular degenerative diseases . The results will be part of the IND application which Advanced Cell expects to submit to the FDA prior to the end of the year. In other news last week, the company announced that Dr. Robert Lanza, its Chief Scientific Officer, was featured on “Explorations in Science” with Dr. Michio Kaku, an hour long radio program on science, technology, politics, and the environment that is broadcast each week on public radio in New York City (WBAI 99.5 FM), and re-aired in Los Angeles, San Francisco, Tampa, Houston, and stations across the country. The show focuses on Dr. Lanza’s research on cloning, stem cells, and his new book “Biocentrism.” Dr. Lanza is also scheduled to appear on Dr. Kaku’s commercial radio show “Science Fantastic,” a program focusing on the future of science, which airs in 127 cities around the country, making it the largest nationally syndicated science radio show on commercial radio. Shares remained unchanged at $0.13 on the week.

September 21st CEOcast Weekly Newsletter

Monday, September 21st, 2009

Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, ENZ, IMUC, IWEB, PHC, SVUL, SRCO, SVUL, XSNX

Markets extended their winning streak yet again this week, as all ten sectors of the S&P 500 finished in positive territory and markets hit fresh highs for the year once again, despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow ended up 2.2% on the week, gaining 214 points to close at 9820 on the week, up 11.9% on the year. The Nasdaq performed slightly better, gaining 2.5% on the week, closing at 2132, up 35.2% on the year, while the S&P 500 and Russell 2000 gained 2.5% and 4.1% respectively, up 18.3% and 23.7% on the year.

While it was a relatively quiet week as far as headlines were concerned, there were some positive economic developments in the form of significantly better than expected Retail Sales (2.7% vs. expectations for 1.7%). Industrial Production managed to narrowly beat forecasts for 0.6% growth, coming in at 0.8%, while Empire manufacturing came in at 18.9 versus estimates for 15.0. Further empirical evidence of a recovery in the manufacturing sector was added by the Philadelphia Fed business outlook survey which showed an increase of 14.1 versus forecasts for 8.0.

Despite the encouraging economic news, which also included comments from Fed Chairman Ben Bernanke, who stated that the recession is, “very likely over,” there were some notable earnings misses from some big names that helped keep a damper on bullish enthusiasm, as Best Buy (NYSE: BBY), Oracle (NASDAQ: ORCL) and FedEx (NYSE: FDX) all failed to live up to expectations. All ten sectors of the S&P 500 finished the week in positive territory, led by Materials at 4.7% and Financials at 4.5%.

What should investors look for this week? Earnings releases will be light again, but look for results from Carnival Cruise Lines (NYSE: CCL) and ConAgra (NYSE: CAG) before the bell on Tuesday, followed on Wednesday morning by General Mills (NYSE: GIS). Thursday morning Rite Aid (NYSE: RAD) reports, followed after the bell by Research in Motion (NASDAQ: RIMM).

Economic releases for the week begin with August Leading Indicators, due out at 10:00am on Monday. On Tuesday, FHFA US Housing Price Index figures for July are expected out at 10:00am, with weekly crude inventories to be released at 10:30am Wednesday and the FOMC Rate Decision at 2:15pm that same day. Weekly initial jobless claims and continuing claims are due out at 8:30am Thursday, along with Existing Home Sales for August at 10:00am. The week wraps up on Friday with Durable Orders for August at 8:30am, followed by revised Michigan Sentiment for September at 9:55am and New Home Sales for August at 10:00am.

Conference schedules will be fairly busy again this week. Things kick off on Monday with the two day Bank of America Securities Mid Cap Conference in Boston. Enzo Biochem (NYSE: ENZ) will present at the three day UBS Global Life Sciences Conference in New York on Monday. On Tuesday, look for the two day Bank of America Securities Power & Gas Leaders Conference in New York, followed on Wednesday by the Canaccord Adams Healthy Living Conference in New York, and the RBC Capital Markets Financial Institutions Conference in Boston.

Volume Alert: Shares of stem cell company Neuralstem (AMEX: CUR) jumped 58% on almost five times average volume last week closing at their highest level since December. The company had previously said that it expected to hear from the FDA prior to the end of the summer on whether it would receive clearance to file an IND to commence Phase I trials for its stem cell platform studying the effect on Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. If the company is correct on the timing, the FDA could notify it this week. Recently, the FDA placed a clinical hold on stem cell company Geron conducting a Phase I study of subjects with Spinal Cord Injuries. Shares gained sixty nine cents on the week to close at $1.87.

Volume Alert: Shares of Verichip Corporation (NASDAQ: CHIP), a provider of radio frequency identification systems for healthcare and patient-related needs, which recently acquired identity security provider Steel Vault to form PositiveID Corp, a provider of identification technologies and tools for consumers and businesses, surged 58% on over 8 times average volume last week, following the announcement that the companies will now fund a partnership with Receptors LLC to continue the development of a triage detection system for detection of the H1N1 virus. The commitment marks a continued relationship between Verichip and Receptors, and it is expected that the companies will release more specific details of the functionality and the timing of the triage detection system next week. For those investors seeking an under-the-radar way to play a potential swine flu epidemic, CHIP could quickly begin to get on the screens of traders. VeriChip is expected to merge with Steel Vault Corporation (OTCBB: SVUL) later this year. Shares gained forty two cents on the week to close at $1.15.

Volume Alert: Shares of vaccine developer CEL-SCI (AMEX: CVM) surged 103% on almost seven times average volume last week, highlighted by a 13% increase on Friday on the third highest trading volume in the company’s history (first two were earlier in the week) after the company said that the U.S. Food and Drug Administration (FDA) indicated that the company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients. The company also further strengthened its balance sheet by raising $20 million. Net proceeds from the offering will be used to commence a pivotal Phase III clinical trial with its cancer drug Multikine and to conduct human studies for the treatment of hospitalized H1N1 patients. Shares gained 82 cents on the week to close at $1.61.

Volume Alert: Shares of Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, surged 13% on Friday more than 4 times average volume, with the stock closing above $7 for the first time since October. This week, company executives will be presenting at both industry and investor events. Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will be presenting at the UBS Tenth Annual Global Life Sciences Conference on Monday, September 21, at 8:30 AM ET at the Grand Hyatt in New York City. Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27th Annual Lab Institute ’09 in Arlington, VA on Wednesday, September 23. Dr. Krenitsky will present at a panel discussion entitled “Going Inside the Boardroom: What’s the Bottom Line for Labs During a Time of Economic, Policy and Market Flux?” Among the meeting’s keynote speakers will be the Hon. Newt Gingrich, former Speaker of the U.S. House of Representatives, and Rep. Pete Stark (D-CA), Chairman, House Ways and Means Health Subcommittee. Shares gained $1.56 on the week to close at $7.08.

Healthcare services company Pioneer Behavioral Health (AMEX: PHC) announced results for its fourth fiscal quarter and year ended June 30, 2009 last week. During the period, the company managed to increase net revenue from continuing operations to $11.7 million for the three months ended June 30, 2009 from $11.5 million for the three months ended June 30, 2008. Income from operations was $381,661 for the 2009 fiscal fourth quarter compared to $97,540 for the 2009 fiscal third quarter, and $394,571 for the fiscal 2008 fourth quarter. Net income before taxes for the 2009 fiscal fourth quarter improved approximately $305,000 sequentially to $317,086. PHC attributes the improved results to strong demand at its Capstone and Seven Hills Behavioral Facilities, which it expects to continue. Demand could be further boosted by Seven Hills receiving CMS Medicare certification, which could increase census. The company also said on its conference call that it expected sequential quarterly revenue and profitability to continue to improve. Shares gained four cents on the week to close at $1.53.

Volume Alert: Shares of ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, surged 22% on almost eight times average volume following the announcement last week that it has been featured in an in-depth report by Griffin Securities highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments. The report summarizes how understanding these cells may be a crucial component of preventing, diagnosing and treating the diseases, highlighting two of the company’s therapeutic programs ICT-121 and ICT-109, which was recently licensed to Roche in a deal that could generate as much as $32 million in milestone payments, as potential approaches to harnessing the immune system in the fight against cancer. Shares gained twenty two cents on the week to close at $1.22.

iceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, announced last week that the company has been awarded a key contract by a Federal Agency to provide its Iplicity Unified Storage Platform to support a VMware Virtual Desktop Infrastructure deployment. The initial award is for a 16 terabyte platform and will enable the agency to commence testing within their research and development laboratory prior to full deployment. If the testing phase is successful, the contract may be expanded to procure Iplicity systems to support in excess of 8000 VDI images and home directories. In other news last week, the company announced that it has launched the Iplicity Cloud Storage Appliance product line. Iplicity Cloud Storage Appliance is the first commercially available Cloud Storage device geared toward allowing its users, businesses of any size, to simply attach a pre-configured appliance to their network and immediately begin serving vast amounts of file and data storage space to local, remote, internet or VPN connected users and applications. This appliance allows corporations to gain all of the benefits of Cloud Storage without assuming the risks of putting priceless company data in the hands of third party providers. Shares lost two cents on the week to close just above $0.07.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it will host a conference call on Monday, September 21 at 10:00am to discuss results for its 2010 first fiscal quarter which are scheduled to be released before the bell that day. Shares remained unchanged at $0.08 on the week.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated to the powersports industry, announced last week that it has formed a strategic alliance with Dairyland Cycle Insurance, a recognized leader in the motorcycle insurance industry. The newly formed alliance will enable Sparta’s nationwide network of powersports dealerships to provide an expedited means of securing personal vehicle insurance covering new and pre-owned powersports vehicles for their customers, adding further value to customers seeking to acquire powersports vehicles through the company. Customers who are financing their new or used powersports vehicle purchases through Sparta have the option to receive a free, no-obligation insurance quote from Dairyland Cycle while submitting their credit application online using Sparta’s proprietary credit decisioning and underwriting software. In other news last week, Sparta announced the appointment of Bill Kenney as Vice-President, Client Development; Mr. Kenney has over sixteen years of experience in the financial services sector of the powersports industry, most recently with GE Money, where he served as National Program Manager since 2001. Sparta believes that the relationships which he has developed over his tenure will be very valuable to the organization, as they include some of the largest powersports manufacturers and their dealer networks. Shares remained unchanged at $0.07 on the week.

Advanced Cell Technologies (OTC: ACTC), a company engaged in the development of regenerative therapies utilizing stem cells, announced last week that shareholders have approved each proposal in the company’s proxy statement dated August 5, 2009. As a result, the 2005 Stock Incentive Plan has been amended to increase the total number of shares available for issuance and the certificate of incorporation has been amended to increase the authorized shares eligible for issuance by the company. The company also indicated that it remains on schedule to submit an IND for its retinal pigment epithelial (RPE) program to the FDA for approval to commence a Phase I Clinical Trial prior to the end of the year. Shares remained unchanged at $0.13 on the week.

SPECIAL SITUATIONS:

XSUNX (OTCBB: XSNX) $0.14

Last summer’s staggering run up of energy prices led to worldwide acknowledgement of the need to find more efficient, sustainable sources that insulate global economies from speculative energy markets. As consumers were crippled in the wake of unthinkably high prices resulting from soaring energy costs, the importance of finding these alternative sources led many to look towards solar power as a solution, despite the lingering problems with the technology as a whole. XSUNX is a company seeking to make solar power a viable substitute by solving its technological limitations through focusing on efficiencies that will lower the cost per watt of electricity produced through two distinctive changes to photovoltaic cell production and design that the company expects will enable it to more cost effectively harness the power of the sun.

As a prospective comparison, traditionally the main problem with solar power versus fossil energy sources has been the higher per watt of electrical production capacity costs associated with installing a solar system versus building a coal fired power plant. However, the use of solar systems to produce power is rapidly becoming an economically viable alternative to traditional coal power plants. As electrical demand has continued to climb the costs to build a new power plant today has risen from $1.40 per watt of production capacity in 2000 to $3.50 per watt today with costs anticipated to continue to increase. These costs also do not include operating and fuel costs, and the costs to the environment through green house gas emissions which are yet to be fully realized or accounted for. Conversely since 1970 the solar industry has seen a 100 fold decrease in the cost per watt for a solar system. Today residential costs vary from $6 to $10 per watt (unsubsidized costs), and large multi-megawatt utility size solar installations are approaching $4 per watt installed in the Southwest Untied States. What’s needed to drive solar costs even further down is more efficient solar cell manufacturing processes and mass production systems that can be easily and inexpensively deployed.

While the solar industry has achieved substantial cost reduction gains the two most widely employed methods of converting the sun’s power each have their own set of unique limitations which leave significant room for improvement. Silicon based cells are the most common form of solar conversion technology currently being employed, accounting for approximately 90% of all solar cells currently in use. They utilize banks of small silicon based photovoltaic cells, and although they convert energy efficiently, they are expensive to produce due to the large amounts of precious silicon used in production and are subject to drastic swings in price due to the volatility of silicon feedstock on the open market. In response to the high cost of producing silicon based solar cells, many companies have begun to focus on a lower cost production method which, although less expensive to produce, has its own set of limitations. Thin-film photovoltaic cells, while significantly less costly to produce, do not harness the power of the sun nearly as efficiently as their more expensive silicon counterparts. This creates a whole new set of inefficiencies relating to the vast amounts of these cells required to produce the same amount of energy as silicon cells. These more inefficient cells are typically large sheets of glass that are coated with multiple layers of reactive materials in order to convert sunlight into energy. The ungainly, large cell sizes required to produce as much energy as a small bank of the more efficient, but more costly silicon based panel’s leads to a technology that requires vast amounts of space, making it largely inapplicable in any instance other than solar farms. Additionally, there is a loss of the cost affectivity which makes them an attractive alternative due to the need for larger numbers of cells to obtain the same amount of energy as would be produced with silicon based cells.

XSUNX is currently developing a technology that bridges the gap between high efficiency and low cost, which, although still in its early paces, has shown significant improvements on the limitations posed by its predecessors. The company has taken a two pronged approach to improving solar technology, choosing to focus on improving efficiencies in both the production of the cells, and the mass manufacturing system behind them as well. Their plan is to improve production efficiencies through a rather ingenious method; using idle space in existing factories that produce hard disk drives to produce photovoltaic cells, since the technologies have significant similarities that allow them to be manufactured in the same space with minimal process adaption. This allows for a significant reduction in production cost due to the elimination of the need to build separate facilities to produce the cells. In addition to their plans to streamline the production process in order to obtain lower costs per unit, XSUNX is also planning to increase the energy conversion efficiency per unit through a combination of technological advancement and common sense. One of the most efficient thin film solar technologies currently available is Copper Indium Gallium Selenide (CIGS), which has gained popularity among companies operating in the solar energy space. The problem with these types of cells is that they display much higher efficiency levels in laboratory testing than they do in commercial applications. This is primarily due to the loss of efficiency associated with taking a small area proven laboratory processes and attempting to scale the manufacturing process on to large sheets of glass needed to generate meaningful amounts of solar product. XSUNX has chosen to focus its production on what allows for the high conversion efficiencies obtained in laboratory CIGS testing; small cell sizes rather than large sheets which are typical of the arrays produced by the majority of the competition in the space. By building smaller, more efficient cells which can be assembled together to form larger arrays, similar to how silicon cells are used, they have come up with a technology that is closer to the efficiencies generated by the costly silicon arrays, and as cheap to produce as the less effective thin-film cells. Thanks to these improved efficiencies in production and design, the company expects that it will be able to reduce the cost of energy produced to much less than $1 per watt for the solar module. Providing low cost and high power production per unit area which in turn can reduce other installation costs this solar technology may allow utility scale installations to effectively reduce per watt solar system costs to below that of new coal power plants.

With an extremely promising technology operating in a robust multibillion dollar market that epitomizes the green movement, XSUNX appears extremely well positioned to capitalize on the shift in consumer preference away from fossil fuels and towards alternative energy sources. While the company is still in preproduction, its technology has garnered enough attention to generate almost $42 million in preorders, despite the fact that they are still in development phases. Add to that a management team comprised of industry veterans with significant connections within governmental agencies such as the National Renewable Energy Laboratories (NREL), which the company is establishing a relationship with as a third party validator of their technology, and you begin to see the type of potential that XSUNX has. The stock is currently trading at its 52 week low making now an interesting time to consider investing, as the company’s technology and the popularity of the movement towards alternative energy make this an intriguing prospective investment, especially at current levels.

September 14th CEOcast Weekly Newsletter

Monday, September 14th, 2009

Companies featured in this edition of the newsletter: CUR, CVM, ENZ, IMUC, MBCI, ONEZ, PHC, SVUL

Markets finished in positive territory yet again during this holiday shortened week despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow gained 164 points to close at 9605, up 1.7% on the week and 9.4% on the year. The Nasdaq gained 3.1% on the week, closing at 2080, up 32% on the year, while the S&P 500 and Russell 2000 gained 2.6% and 4.0% respectively on the week, up 15.4% and 18.8% on the year.

It was a slow week on the corporate side, but there were some healthy signals from the technology sector, as Texas Instruments raised its Q3 outlook, guiding for EPS of between $0.37 and $0.41, up from previous forecasts of $0.29-$0.39. Fed Ex also guided higher, citing cost management and better than expected volume in international shipping, leading to an increased forecast calling for EPS of $0.58 versus earlier forecasts of $0.30-$0.45. Buying on the week was broad-based as nine of the ten sectors of the S&P posted gains, with industrials and energy both outperforming.

While there were little in the way of major economic developments on the week, what little news was generally favorable. Continuing claims fell to 6.08 million while weekly jobless claims fell to 526,000, besting consensus estimates expecting 560,000; while the improvements were certainly welcome, the numbers remain at elevated levels which will more than likely result in an increased unemployment rate when it is released later in the month. In other economic news, further support for a recovery was added by way of the Fed’s Beige Book report, which showed that the rate of economic decline is slowing and manufacturing is improving, despite continued weakness in the labor markets, consumer spending and construction.

What should investors look for this week? Earnings releases will be light again, but look for results from Best Buy (NYSE: BBY) before the market on Tuesday, followed by Adobe Systems (NASDAQ: ADBE) after the close that same day while Oracle (NASDAQ: ORCL) reports after the close on Wednesday. The week wraps up on Thursday with FedEx (NYSE: FDX) reporting before the open and Palm (NASDAQ: PALM) reporting after the close.

Economic releases for the week begin on Tuesday with PPI, Core PPI, and Retail Sales, all for August, released along with the Empire Manufacturing Index for September at 8:30am, with Business Inventories for July due out at 10:00am. On Wednesday, CPI and Core CPI for August are due out together at 8:30am, followed by Net Long-term TIC Flows at 9:00am, Capacity Utilization and Industrial Production for August at 9:15am, and weekly crude inventories at 10:30am. The week wraps up on Thursday with Building Permits and Housing Starts for August due out at 8:30am, along with weekly initial jobless claims and continuing claims, followed at 10:00am by minutes from the Philadelphia Fed’s September meeting.

Conference schedules will be full again this week. On Monday, Morgan Stanley hosts its two day Global Healthcare Conference in New York, along with the three day Deutsche Bank Securities Technology Conference and the four day ThinkEquity Growth Conference, both of which will be held in San Francisco. On Tuesday, look for the two day Barclays Capital Global Financial Services Conference in New York, the BMO Capital Markets Media & Telecom Conference in Toronto and the Jefferies & Co. Technology Conference in New York. Also beginning on Tuesday is the JP Morgan Diversified Industries Conference, the three day Goldman Sachs Communacopia Conference, the three day Credit Suisse Group Chemical Conference, and the UBS Global Paper and Forest Products Conference, all being held in New York. The week finishes up with the two day RBC Capital Markets Consumer Conference and the Roth Capital Partners Media/Software Investor Event, both of which are also being held in New York.

Earnings Preview: Behavioral healthcare services provider PHC, Inc. (AMEX: PHC) is scheduled to release fourth quarter and year-end results on Thursday before the market opens. Shares are up 24% since the company said in its third quarter results for the period ended March 30, 2009 that it had returned to operating profitability. The company recently extended its 1 million share stock repurchase program, which was scheduled to expire in June. Total net revenue from continuing operations increased 5.9% to $12.0 million for its fiscal third quarter but could receive a boost in coming quarters from a recently announced agreement in which its Highland Ridge Hospital, located in Salt Lake City, Utah will provide the Veteran’s Administration with eight psychiatric and detoxification beds. The initial term of the contract is nine months, with six-month renewal periods. PHC is guaranteed a minimum of $1.24 million under the initial term. Highland Ridge PHC also has the opportunity to receive additional revenue for providing care for patients beyond the allocated beds on a fee-for-service basis. Investors will likely pay even more attention to what the company says about prospects for CMS certification at its Seven Hills Behavioral Institute that provides adult inpatient and partial hospitalization programs for mental health and substance abuse issues in Henderson, Nevada. CMS Medicare certification would allow it to gain government reimbursement for many of the services it provides and would significantly increase census at the facility. Shares ended the week at $1.49, down 6 cents.

Enzo Biochem (NYSE: ENZ), a leading vertically integrated biotechnology company engaged in the research, development, manufacture and licensing and marketing of innovative health care products, technologies and services based on molecular and cellular techniques, announced last week that it had appointed Mohan Chellani, Ph.D., as Vice President of Scientific Affairs at its Enzo Clinical Labs subsidiary. Dr. Chellani was previously a senior manager with Quest Diagnostics, and will oversee all aspects of Enzo Labs’ Molecular Diagnostic strategy and implementation, including serving as a key interface with Enzo Life Sciences, another subsidiary. He has over 15 years experience in the clinical laboratory business, and most recently was Head of Science and Innovation Portfolio Development at Quest. Among his responsibilities were growing Quest’s esoteric testing business, introducing assays and regionalized tests, and directing product development collaborations with academic and industry partners. In other news last week, the company announced that it presented at the Thomas Weisel Partners 2009 Healthcare Conference in Boston last week. The conference brings together top institutional investors with senior management and healthcare industry experts in an environment designed to showcase dynamic emerging companies and investigate critical trends that are driving our economy. Shares gained ten cents on the week to close at $5.56.

New 52-week high: Shares of CEL-SCI Corporation (AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, continued their sizzling gains last week as investors continue to be attracted by the company’s potential solutions for infectious disease, and specifically the “swine” flu. During the past three weeks, the stock has gained 60% on more than five times average volume, culminating last week with a new 52-week on heavy volume, as the stock closed at $0.79, up 12 cents.

Volume Alert: Shares of Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord, gained 3.5% last week on over twice average volume last week, following the announcement that it had received notice of allowance from the United States Patent Office for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions.” The newly granted patent covers the company’s use of neural stem cells to treat degenerative conditions of the nervous system and is a crucial component of the company’s intellectual property portfolio. It will cover the manufacturing process of future products from all regions of the human central nervous system (brain and spinal cord) through July of 2026. Shares gained four cents on the week to close at $1.18.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group, one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. Under the terms of the agreement, IMUC will license to Roche the rights to investigate the potential of ICT-69 in the diagnosis and treatment of multiple myeloma (MM) and ovarian cancer for an upfront payment. Upon completion of the evaluation period, Roche has an option to acquire a commercial license for ICT-69 from IMUC, which would result in total payments due to the company of up to $32 million in the event that all developmental milestones are met. ICT-69 is one of several monoclonal antibodies currently being developed for multiple cancer indications by IMUC; preclinical data have demonstrated the ability of ICT-69 to target antigens specific to human MM cells without binding to healthy tissues, making it a strong potential candidate for therapeutic applications associated with MM as it directly targets malignant cells without corresponding damage to healthy cells. Shares lost a penny on the week to close at $1.00.

MabCure, Inc. (OTCBB: MBCI), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, announced last week that it has been featured in the September issue of GEN (Genetic Engineering & Biotechnology News), one of the most widely read biotechnology publications in the world. The article, which was written by MBCI’s CEO, Dr. Amnon Gonenne, describes how tumor-specific antibodies could positively impact diagnosis, imaging, and therapy. It discusses problems associated with diagnosing different types of cancer due to the clinical variety within each specific type of the disease, and examines how cancer-specific antibodies such as the ones which MBCI is developing may help change the molecular diagnosis and treatment of cancer. The article can be found in its entirety on the GEN website. Shares lost five cents on the week to close at $1.05.

ONE Holdings (OTCBB: ONEZ), an investment company owning majority equity interest in core operating assets in Biotechnology located in the Asia Pacific region, announced last week that it has signed a definitive agreement for the acquisition of 99.75% control of Trade Finance Solutions (TFS), a company that provides balance sheet financing solutions for domestic and international credit-worthy customers including accounts receivable, purchase order financing, fulfillment services and factoring or invoice discounting. TFS’s unaudited results for 2008 include sales, operating income and net income of $7 million, $330k and $302k respectively. This acquisition, in conjunction with the recently announced acquisition of Jianou Lvjian FoodsStuff Co. Ltd, which is expected to close prior to the end of the third quarter, increases combined revenue, EBITDA, and Net Income for ONE Holdings to $34 million, $10 million and $8 million respectively based on 2008 results for these companies. In addition to the immediate financial benefits received from the acquisition, ONEZ will benefit strategically by being able to use TFS as an internal financing arm dedicated to fund and facilitate the growth of the company’s core assets in bioengineering and technology. In other news last week, the company announced that its subsidiary Green Planet Bioengineering launched two natural extracts called Resveratrol and 5-HTP. The two new extracts are expected to contribute approximately $1.8 million to the company’s revenue during the third quarter, with $1 million in revenue already achieved since the extracts were launched. Shares gained a penny on the week to close at $1.15.

Volume Alert: Shares of Steel Vault (OTCBB: SVUL), an emerging provider of identity security products and services, surged 48% on over nine times average volume last week, following the announcement that it has been acquired by VeriChip Corp., a provider of radio frequency identification (RFID) systems for healthcare and patient-related needs. The newly formed entity will be called PositiveID Corporation, and will offer identification tools and technologies for consumers and businesses. In conjunction with the merger, VeriChip plans to change its name to PositiveID and continue to trade on the NASDAQ. PositiveID intends to change its ticker symbol to “PSID” upon closing of the transaction which is expected to happen in the fourth quarter of 2009. Under the terms of the agreement, Steel Vault stockholders will receive 0.5 shares of VeriChip common stock for every share of Steel Vault common stock held. The outstanding stock options and warrants of Steel Vault will also be converted at the same ratio. The transaction is currently pending regulatory approval and affirmative votes from shareholders of both companies. Steel Vault believes that the merger will provide value for both companies’ stockholders and enables them to offer customers a broader array of value-added services by putting people in control of their personal health records and financial security, bridging the gap between secure medical records and identity security. Shares gained nine cents on the week to close at $0.43.

September 8th CEOcast Weekly Newsletter

Tuesday, September 8th, 2009

Companies featured in the current edition of the newsletter: ACTC, CUR,CVM, ENZ, FMTI, ICLK, IMUC, IWEB, MBCI, OMCM, ONEZ, ORMP, SIHI, SRCO, SVUL

With bullish investor sentiment reaching levels not seen since just before previous market corrections, the rally, which is approaching six months, took a break last week. All of the major indices posted losses, with the Dow falling 102 points, or 1.1%, leaving it up 7.6% for the year. Each of the other indices followed suit, with the Nasdaq declining 10 points, or 0.5%, but still up 28%, the S&P 500 falling nearly 13 points, good for a 1.2% drop but higher for the year by 12.5% and the Russell 2000 falling 1.6%, leaving it up 14.2% on the year.

Has the market rally run out of steam, or is it merely pausing? Investors seemed to generally ignore weak data over the past several months, instead choosing to focus on favorable economic reports that helped to underpin the bullish bias. However, last week the major indices sold off sharply following a batch of better-than-expected data. All told, nine of the ten sectors in the S&P 500 fell, led by a decline of 3.6% in financials. A sharp decline in Chinese stocks (Shanghai Composite Index fell 6.7% on Monday) helped drag world indices lower. Even favorable reports suggesting that the ISM Manufacturing returned to the expansion stage along with better than expected Pending Home Sales were not enough to overcome the weaker sentiment.

Ironically, investors seemed to shrug off a disappointing Employment Report later in the week, as weak Initial Claims and ADP data ahead of Friday’s employment report were largely ignored, and investors brushed off a weak employment report, which showed unemployment had reached 9.7%, a level not seen in nearly 30 years, while downward revisions for nonfarm payrolls in June and July more than offset a slightly better-than-expected August nonfarm payrolls.

While the markets will be closed for Labor Day on Monday, we note that the holiday falls in September, which has historically been the worst-performing month for stocks. There is very little on the economic calendar other than the Federal Reserve’s Beige Book on Wednesday and the weekly Initial Claims data on Thursday to influence investors. With so little data to evaluate, interest may return to the Treasury auctions, where activity will be brisk. On Tuesday, $38 billion in three-year Notes will be offered, Sept. 8, there is a $20 billion 10-year Note offering reopening on Wednesday and a $12 billion 30-year Bond offering reopening on Thursday. A disappointing offering could lead to fears that foreign investors are reevaluating their level of interest in U.S. investments.

There are no market-moving earnings announcements this week, but Texas Instruments (NYSE: TXN) provides a mid-quarter update on Wednesday after the market closes. The economic calendar is similarly light, with the Fed’s Beige Book on Wednesday, along with speeches from Fed executives Fisher and Evans. The Fed’s Lockhart and Kohn speak on Thursday, while Treasury Secretary Geithner testifies before the TARP Oversight Panel the same day.

The conference schedule will be busy this week, despite the holiday. Tuesday, the RBC Capital Markets Transportation Conference begins in Toronto. On Wednesday, the three-day Rodman and Renshaw Annual Global Investment Conference begins in New York. Steel Vault Corporation (OTCBB: SVUL) presents Wednesday at 12:30 pm. Enzo Biocehm (NYSE: ENZ) presents at 2:50 pm on Thursday, while Oramed Pharmaceuticals (OTCBB: ORMP) presents Friday at 10 a.m. along with ImmunoCellular Therapeutics (OTCBB: IMUC) at 2 pm. interCLICK, Inc. (OTCBB: ICLK) presents at 9:10 am on Friday, followed by Sinohub (NYSE AMEX: SIHI) at 3:40 pm that day. There is a Cleantech Forum in Boston on Wednesday. Barclays Capital holds a Back-To-School Conference in Boston and a CEO Energy/Global Power Conference in New York the same day. Credit Suisse Group hosts its Automotive & Transportation Conference in New York on Wednesday. Thomas Weisel Partners hosts a three-day Healthcare Conference in Boston beginning Wednesday. Keefe, Bruyette & Woods holds a two-day Insurance Conference starting Wednesday. Kaufman Brothers holds its 12th Annual Investor Conference in New York on Wednesday, while Jefferies & Co. holds a Shipping & Offshore Services Conference the same day. Robert W. Baird & Co., Inc. also holds a Health Care Conference that day in New York. Citi has its 16th Annual Global Technology Conference with many of the large-cap technology companies presenting on Wednesday. Goldman Sachs holds a Retailing Conference in New York on Wednesday. Deutsche Bank Global Emerging Markets has a One-on-One Conference Wednesday in New York. BMO Capital Markets holds a North American Real Estate Conference in Chicago on Wednesday. Bank of America Securities holds a two-day Media, Communications & Entertainment Conference in Marina Del Ray, California. On Friday, Sidoti & Company holds its Eighth Annual West Coast Emerging Growth Institutional Investor Forum on Friday in San Francisco.

Life sciences company Enzo Biochem (NYSE: ENZ) filed its form 10-Q for the period ended April, 2009 late Friday. The filing could remove concerns that may have kept the stock from moving higher after the company reported Q3 results in mid-July. With a market cap of approximately $200 million, which included more than $55 million in cash as of its last filing, the company appears well positioned to continue the growth at Enzo Life Sciences and the turnaround at Enzo Clinical Labs. The stock could receive a lift on Tuesday from the filing. Shares rose 5% on Friday ahead of the filing, ending the week at $5.46.

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced last week the elimination of Series K convertible notes. The notes, which had an initial principal value of $8.3 million, were issued in August 2006, and were convertible into common stock. The news reflects the significant improvement the company has made in its balance sheet, as the company has recently raised more than $10 million in capital, as well as investors focus on CVM’s platform technology and its potential to address swine influenza. Shares ended the week at $0.67 down 4 cents.

Volume Alert: Shares of stem cell company Neuralstem, Inc. (AMEX: CUR) jumped 3.5% on Friday on more than two times average volume. The company recently said it was focusing its near-term international efforts on commencing a clinical trial for stroke in Taiwan in the first half of 2010, with spinal cord injury trials in China and India commencing thereafter in 2010. It also continues to work with the U.S. Food & Drug Administration to refine the protocol for its Investigational New Drug Application for ALS. Shares ended the week at $1.14, up 4 cents.

Volume Alert: Shares of life sciences company Forbes Medi-Tech Inc. (NASDAQ: FMTI) jumped 28% on Friday on more than four times average volume. The company recently announced that it had extended its supply and licensing contract with Pharmavite LLC until mid 2010 for the continued sale of Reducol, plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally.

interCLICK, Inc. (OTCBB: ICLK), a rapidly growing ad network, said last week that it had increased its credit facility with Crestmark Commercial Capital Lending LLC from $5.5 million to $7.0 million. As part of the amendment to the credit facility, Crestmark also agreed to reduce the monthly servicing fee the company was previously paying from 0.575% to 0.375%, which translates to a 300 basis point reduction in the company’s effective annualized cost of capital. This represents the third time this year that the company has increased the size of its revolver to accommodate its growth. Recently, ICLK raised its full-year revenue forecast to exceed $44 million, an increase of at least 96% compared to 2008. Shares ended the week at $1.70, down 10 cents.

New 52-week high: Shares of ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, surged to a new 52-week high continuing their sizzling performance which has seen the stock more than double over the past 10 days. Shares ended the week at $1.01, up 11 cents.

Storage solutions provider iceWEB (OTCBB: IWEB) said last week that Murphy Analytics, an equity research group, had initiated coverage of the company. In the report entitled “IWEB Targeting Significant Opportunities in Cloud Computing and Data Storage,” Murphy notes that “With the divestiture of the IceWEB Solutions Group subsidiary, a reseller of low-margin software and hardware products, IWEB is positioned to focus on data storage solutions and hosted software applications. IWEB in its last quarter reported, reported, according to the research provider: significantly higher margins at over 50% versus 12.2% for the prior year’s quarter; the acquisition of over 30 new clients; a decline in selling / general / administrative expense from $2.4 million to $1 million; a decline of approx. $6 million in both current liabilities and total debt from 9/30/08. Shares ended the week at $0.09, down 1 cent.

MabCure, Inc. (OTCBB: MBCI), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, said last week that it had been featured in the August edition of Biotechnology Focus, Canada’s oldest and most successful magazine serving the Canadian life science industry. The piece titled “Tumour-Specific Markers: The Holy Grail of Cancer Diagnostics†illustrates the advantage of MabCure’s pipeline of cancer specific antibodies compared to some current cancer diagnostics such as prostate-specific antigens (PSA) for prostate cancer, CA-125 for ovarian malignancies, which suffer from a lack of specificity and sensitivity. MabCure’s (MAbs) are being developed against difficult-to-pinpoint tumor-specific antigens. In the article MBCI’s CEO noted that while more than 90% of cancers are curable if caught early, the challenge of early detection lies in the lack of clearly identified disease markers. Shares ended the week at $1.11, up 1 cent on heavy volume.

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture solutions for clinical trials said last week that three additional clinical research organizations (CRO) have joined its rapidly expanding partnership program, the CRO Preferred Program. The partnership allows CROs in the program to offer their clients OMCM’s TrialMaster, for clinical trials. The CRO Preferred Program’s benefits include fixed pricing with no hidden fees, complete sales and marketing support from OmniComm, a dedicated hosted environment and comprehensive training and support for TrialMaster. Shares ended the week unchanged at $0.24.

Sparta Commercial Services, Inc. (OTC.BB: SRCO), a provider of consumer financing and leasing for powersports products, said last week approximately $4.2 million of notes and accrued interest held by the company’s existing stockholders had been converted into shares of common stock. As a result of these conversions, Sparta shareholders’ equity increased by over $4.2 million. Additionally, holders of approximately $1.8 million in notes and accrued interest have agreed to convert their notes and accrued interest into shares of common stock thereby increasing shareholders’ equity by an additional $1.8 million for a potential total increase in shareholder equity of over $6 million. Shares rose 1 cent for the week to close at $0.069.

Shares of Advanced Cell Technology (OTC: ACTC) surged 20% on Friday, perhaps in anticipation of the company’s call on Tuesday, where it will addresses questions that shareholders raised in connection with its proxy vote, scheduled for Thursday. Shares ended the week at $0.158, up 2 cents.

On the Wires: ONE Holdings, Corp. (OTCBB: ONEZ), an investment company owning a majority equity interest in a biotechnology company located in the Asia Pacific region, named current interim President Marius Silvasan as its new CEO and Vice Chairman of the Board.

SPECIAL SITUATION:

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) $0.59

One of the biggest medical challenges and opportunities today is to develop a solution for the problems presented by diabetes. Today, for millions ofdiabetics, needle sticks have become a way of life. The opportunity to deliver insulin orally has been attempted by many companies, while many are aware of some of the high-profile failures, few may be familiar with the work being done by a small biotechnology company based in Israel. Oramed Pharmaceuticals, through its lead compound an oral insulin capsule, ORMD 0801, has a promising capsule in development that it believes has the potential to succeed where so many have failed, delivering insulin orally.

Established in 2006, ORMD 0801 is the product of a technology platform based upon more than 25 years of research from leading scientists at Jerusalem’s Hadassah Medical Center. ORMD 0801 has already completed both Phase I and Phase IIa studies in Israel, which showed that the capsule was safe and well-tolerated, with no adverse events discovered during the two studies. The company expects to complete a Phase IIb trial in South Africa, which would likely be a larger study, and to file an Investigational New Drug (IND) application in the United States, which would allow it to begin clinical activities here.

How does the company’s technology work? After a person swallows the capsule, insulin travels from the gastrointestinal tract via the portal vein into the bloodstream. Oramed has conducted numerous studies in animals that have confirmed the feasibility of lower blood glucose levels using its capsule. The technology has been receiving growing recognition from the scientific and academic communities. Last year, Professor Avram Hershko of the Technion, who won the 2004 Nobel Prize in Chemistry, joined the company’s Scientific Advisory Board. Recently, it received the 2009 Frost & Sullivan European Oral Drug Delivery Technology Innovation Award, which recognizes companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. In August of this year, Oramed was awarded a government grant amounting to a total net amount of NIS 3.1 million ($828,000), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.

At this point, one might ask why so many have spent so much trying to develop a novel approach to treating diabetes. The answer is quite simple. According to the American Diabetes Association, in 2007 more than $27 billion was spent on the direct treatment of diabetes. Perhaps even more alarming is the rate of growth of the disease. By 2025, according to data from the International Diabetes Foundation, more than 380 million people are expected to be diagnosed with the disease. At the same time that the incidence of disease is soaring, compliance rates for injection have been declining. With an oral delivery system, compliance rates would likely increase, and allow millions to be able to better control their diabetes. The potential for a company that can find an alternative way to deliver insulin to the method currently available could be substantial.

Oramed, in addition to its advanced diabetes program, is currently in a Phase Ia clinical trial for rectal delivery of insulin (ORMD 0802). In a proof of concept study in eight healthy volunteers, rapid insulin absorption was demonstrated and reactive glucose lowering effect. There were no adverse events.

The company also has an oral GLP1-analog that is currently in Phase I clinical trials Despite the large market opportunity and promising technology, the company still has a relatively nominal $33 million valuation, which is much less than some of the other companies in the sector such as Generex Biotechnology ($115 million) and MannKind (more than $800 million). Shares have performed well this year, with the stock up 51% so far, including rallying 13% on Friday on more than three times average volume. With a potential IND filing in the U.S. expected later this year, and a promising way to orally deliver insulin, Oramed Pharmaceuticals could continue to gain investor interest.

August 31st CEOcast Weekly Newsletter

Monday, August 31st, 2009

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with last week’s better than expected housing data left many investors speculating that a bottom in the housing market may be near. Positive news was also received in the form of an increase in consumer confidence, as the figures for August rose more than expected, coming in at 54.1, well above consensus estimates calling for 47.9. Labor data left little room for positive interpretation however, as new unemployment claims came in higher than expected and continuing claims fell, but the decline is more likely a reflection of workers exhausting their benefits rather than a rebound in job markets.

In corporate news, Intel raised its Q3 revenue guidance to $9 billion citing stronger than expected demand for microprocessors and chipsets. The company’s previous forecasts were for revenue to exceed $8.5 billion. In other corporate developments, Dell reported a 23% decline in its second quarter profit, but still managed to beat EPS estimates calling for $0.23 per share, posting a gain of $0.28 per share.

What should investors look for this week? Earnings releases will be few and far between, but look for results from Sun Microsystems (NASDAQ: JAVA) on Monday before the bell.

Economic releases for the week begin with Chicago PMI for August, due out on Monday at 9:45 am. On Tuesday, look for July Construction spending, released with the ISM Index for August at 10:00 am, with Truck and Auto Sales following at 2:00 pm that same day. ADP Employment Change is due out at 8:15 am Wednesday morning, followed by Revised Q2 Productivity figures at 8:30 am, Factory Orders for July at 10:00 am, weekly crude inventories at 10:30 am, and FOMC minutes from the August 12th meeting at 2:00 pm. On Thursday, weekly initial jobless claims will be released at 8:30 am, followed by ISM Services for August at 10:00 am. Friday will be a busy day for labor data, as Average Workweek, Hourly Earnings, Nonfarm Payrolls, and the Unemployment Rate, all for August, will be released together at 8:30 am.

Conference schedules will be light again this week, but look for the two-day Morgan Stanley Global Industrials Unplugged Conference beginning on Tuesday in New York, and the three day Lazard Capital Markets Retail & Apparel Conference which is being held in Las Vegas beginning on Sunday.

Volume Alert: Shares of late stage cancer immunotherapy company and the developer of vaccine to treat and fight infectious diseasesCEL-SCI Corporation (AMEX: CVM), surged 48% on almost four times average volume last week on growing concerns regarding the potential threat of swine flu emerging as the traditional flu season approaches. The company recently announced that it had expanded the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as future mutations, and has indicated that it expects to provide an update on its operations regarding the current form of the virus within the next month. Shares gained twenty three cents on the week to close at $0.71.

Pioneer Behavioral Health (AMEX: PHC), a leading provider of inpatient and outpatient behavioral health services, announced last week that it has been awarded a contract by the Salt Lake City Veteran’s Administration Medical Center (VA) to provide behavioral health services at the company

s Highland Ridge Hospital in Salt Lake City, Utah. The initial term of the contract is nine months, with six month renewal periods. PHC is guaranteed a minimum of $1.24 million under the initial term, with revenue for each six-month contract extension bringing in $792,000. Highland Ridge will provide the VA with eight psychiatric and detoxification beds. PHC also has the opportunity to receive additional revenue for providing care for patients beyond the allocated beds on a fee-for-service basis. Shares gained sixteen cents on the week to close at $1.58.

Xcorporeal, Inc. (AMEX: XCR), a development stage medical device company that is developing an extra-corporeal platform of products that might be used in devices to replace the function of various human organs, announced last week that it has received notice that its shares will be delisted from trading on the NYSE Amex Exchange. The company plans to seek listing on the Over the Counter Bulletin Board which it feels will offer significant savings resulting from a reduction in fees associated with being traded on a national exchange. Shares lost three cents on the week to close at $0.19.

interCLICK (OTCBB: ICLK), a leading internet advertising network, announced last week that it has appointed Kurt Munzinger as senior vice president of sales for the west coast region. Mr. Munzinger has a decade of proven success at top ad networks including Specific Media and Advertising.com, and will oversee the west coast sales team with an emphasis on driving market development, and establishing new client and industry relationships to continue interCLICK’s rapid growth. He joins interCLICK from Specific Media where as the vice president of advertising sales, west coast, he built out its sales force and grew revenue by 1000% over a three year period. The company is excited to have retained the services of someone with the experience level of Mr. Munzinger and expects that he will be instrumental in implementing the aggressive growth strategy that it has laid out for 2010. Shares lost eight cents on the week to close at $1.80.

IceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, announced last week that optional software modules are now available for Iplicity allowing organizations to virtualize underlying storage for Virtual Machines. The Iplicity VM Data Center add-in module, priced at $1,900 is available immediately for Iplicity 2.1 users, and will allow them to virtualize the underlying storage for all of their servers. This latest platform upgrade allows IWEB to capitalize on the growing trend of organizations migrating from physical computer servers to virtual server environments, a more cost effective, time saving and environmentally friendly storage option. Shares gained a penny and a half on the week to close just above $0.095.

Volume Alert: Shares of MabCure (OTCBB: MBCI), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, surged 41% on over 14 times average volume last week, following the announcement that it had been featured in the June 4, 2009 edition of BioWorld Today, a highly respected news source within the biotech industry. The company was featured in a cover story titled “MabCure’s Revamped Hybridoma Approach Seeks Cancer Antigens,” and describes the company’s “new take on a classic drug discovery technology,” detailing how MabCure is developing monoclonal antibodies against difficult-to-pinpoint tumor specific antigens for the diagnostics market. The article focuses on the company’s ability to successfully differentiate amongst specific types of melanomas to recognize both advance and early ocular melanomas, and how the development suggests that the MabCure technology could potentially generate antibodies that can recognize early disease in other cancers as well. The article went on to note that MabCure is gearing up for clinical testing in prostate and ovarian cancers and that the company intends to seek a commercial partner in the diagnostic field for those programs. Shares gained thirty two cents on the week to close at $1.10.

OmniComm (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced last week that their EDC tool, TrialMaster(TM), has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization (CRO) with European operations in the U.K., to provide eClinical services to its customers engaged in two separate studies examining the use of ophthalmic medical devices. The partnership is expected to generate more than $1 million to OmniComm over the next few years, and represents a continuation of an ongoing collaboration between the two companies. Shares remained unchanged at $0.24 on the week.

Volume Alert: Shares of ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, surged 73.6% last week on more than six times average volume, establishing a new 52-week high in the process. At ASCO earlier this year, the company reporting promising clinical data from a Phase I trial evaluating ICT-107, IMUC’s dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma. Seven of the 16 newly-diagnosed patients demonstrated stable disease with median progression-free survival of 64 weeks, and three of these seven patients have progression-free survival of over two years. The median progression-free survival time of newly-diagnosed glioblastoma patients is historically 30 weeks. Shares rose 41 cents for the week to close at $0.90.

ONE Holdings (OTCBB: ONEZ), an investment company owning majority equity interest in core operating assets in Biotechnology located in the Asia Pacific region, announced last week that it has elected Michael Weingarten as Chairman of the Board. Mr. Weingarten has over 30 years of international business experience, having successfully led a multitude of companies ranging from early stage development to multimillion dollar corporations worldwide while participating in over 40 mergers and acquisitions in his career and raising millions to fund both organic growth and acquisitions. The company expects that his experience and leadership abilities will prove critical as they continue to acquire, fund and grow biotechnology and health-related companies in the Asia-Pacific region. Shares gained seven cents on the week to close at $1.12.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated to the powersports industry, announced last week that it has entered into a strategic agreement with Armet Armored Vehicles, Inc, a worldwide leading manufacturer of custom designed armored vehicles. Under the agreement, Sparta will offer its Lease Purchase Financing Product to municipalities throughout the U.S. that purchase units from Armet’s line of tactical armored vehicles. Sparta’s Lease Purchase Financing allows municipalities to purchase vital equipment and property through installment lease payments, with no large, up-front cash outlays required. While SRCO remains dedicated to providing financing for the powersports industry, it expects that this latest deal will significantly increase the volume of business in the company’s Municipal Leasing Program which, although originally focused on leasing fleets of police motorcycles, is designed for virtually any type of vehicle, as well as other equipment. Shares lost half a cent on the week to close just below $0.065.

Steel Vault (OTCBB: SVUL), an emerging provider of identity security products and services, announced last week that it has entered into a strategic media and marketing partnership with the Miami Hurricanes and Hurricane Sports Properties designed to increase subscribers for Steel Vault’s services. The partnership includes exclusive in-stadium advertising of NationalCreditReport.com and CanesCreditReport.com powered by NationalCreditReport.com at all Miami Hurricanes regular season home football, baseball, and men’s and women’s basketball games, plus other campus sports including regular season home women’s soccer, men’s and women’s track and field, and men’s and women’s tennis, for a minimum of 80 events. The partnership also includes online advertising at HurricaneSports.com and sponsorship of the daily Official Sports Report sent to season ticket holders and other supporters. The company believes that the partnership has significant marketing and revenue potential as it will greatly expand the awareness of its service offering to a large population at the University of Miami, a world-class academic and athletic institution. Shares remained unchanged at just over $0.24 on the week.

i2 Telecom (OTCBB: ITUI), a leading developer of award-winning patented and innovative high-quality mobile applications and services, announced last week that it has appointed Richard H. Roberson as the company’s Chief Financial Officer. Mr. Roberson has 26 years of experience in business, finance, public accounting and enterprise leadership, and most recently served as Senior Vice President and Chief Financial Officer of Excel Telecommunications, a telecom company based in Dallas, Texas. The company is pleased to have added an industry veteran with as much as experience as Mr. Roberson has, and believes that he will be an invaluable member of the team as they continue to grow their business and transition from research and development to an operating company. Shares gained half a cent on the week to close at $0.055.

SPECIAL SITUATIONS:

Next 1 Interactive (OTCBB: NXOI) $1.85

Since the beginning of the global economic slowdown, many advertisers have begun looking for alternative ways to reach consumers that focus more on return on investment and less on big budget mass marketing campaigns. As budgets were slashed in the wake of the slowdown, advertisers have been forced to shift towards more highly targeted solutions that focus on bringing their message directly to their target demographics without the waste associated with the larger campaigns. Next 1 Interactive is a company that is well positioned to capitalize on the shifting expectations of advertisers looking to maximize their marketing dollars by offering a highly targeted network of media assets centered around the real estate and travel/leisure markets.

The company’s strength lies in its simple, straightforward business model that provides advertisers with a number of options for directly reaching consumers in their target demographics by operating in two divisions, travel and media. The travel division operates NextTrip.com, a travel site that includes professional and user-generated content, social networking, a directory of travel affiliate links, and travel business showcases. The website also offers live 24/7 travel talk radio, travel articles, destination guides, and travel deals, and allows advertisers such as hotels, airlines, cruise lines, and tour operators to place banner ads and showcases, providing a highly targeted advertising opportunity to marketers by connecting them with consumers interested in their businesses who are actively seeking the very opportunities that they are marketing. The media division operates a 24 hour digital cable TV network that provides advertising solutions for local realtors and an Internet radio station that includes 6 hours of travel- talk shows, further providing advertisers with highly targeted high return on investment marketing solutions.

In addition to their assets in the traditional media space, the company has also recently acquired The Resorts & Residence Network, one of the first interactive TV networks, offering the consumer the ability to control where, when and how they access content on TV with supporting solutions for web and cellular devices. The Network combines targeted lifestyle programming with interactive advertising and transactional shopping components that enable viewers to request information, make reservations and get an in-depth look at products and services all through their remote control. The network is scheduled to launch to 25 million households this fall through Direct TV, AT&T, Verizon and select Comcast and Capital Broadcast markets. The goal is to reach 40 million households by the first quarter of 2010.

With a strong portfolio of media assets offering highly targeted marketing opportunities to advertisers, Next 1 Interactive appears poised to capitalize on the shift towards higher ROI marketing strategies that have begun to dominate the industry. The recent acquisition of the Resorts & Residence Network and the scheduled launch through Direct TV make now an excellent time to consider investing in the company as its profile is sure to be raised significantly among both consumers and marketers. As more and more advertisers continue to seek out the highest possible return on their investment, companies such as Next 1 Interactive could see increased profits as a result of their ability to deliver highly targeted, consumer specific marketing opportunities to companies seeking the most bang for their buck.

August 24th CEOcast Weekly Newsletter

Monday, August 24th, 2009

Companies featured in this edition of the newsletter: CUR, CVM, DKAM, ICLK, IMUC, IWEB, OMCM, ONEZ, SVUL, TAGS

Markets managed to extend their run this week, hitting fresh highs for ‘09 despite coming under pressure from negative economic reports and a significant two week correction in Chinese equity markets. All told, the Dow ended up 2.0%, gaining 184 points to close at 9505, extending its yearly gains to 8.3%. The Nasdaq finished the week up 1.8%, closing back above 2000 at 2020, up 28.1% on the year, while the S&P 500 and Russell 2000 managed to post gains of 2.2% and 3.1% respectively, bringing their yearly gains to 13.6% and 16.4%.

Concerns stemming from weakness in Chinese markets which have surrendered 20% in the past two weeks after climbing 109% from October lows spooked many investors expecting a similar correction in US markets early in the week. US markets demonstrated their resiliency however, reversing a decline on Monday to close in positive territory for the week and allay the fears of many expecting a correction similar to those demonstrated in China. Buyers stepped in again on Wednesday to reverse opening declines and stocks surges higher despite the lack of any significant catalyst; by the end of trading Friday, all ten sectors of the S&P were in positive territory on the week despite the absence of any major market moving developments.

Bullish sentiment remained strong on the week, as even negative economic developments were discounted. Larger than expected declines in housing and employment data were largely shrugged off, as July Housing Starts came in at 585,000 versus expectations for 599,000 and building permits dropped more precipitously than expected, coming in at 560,000, against expectations for 577,000. Poor jobs numbers were also largely overlooked, as weekly initial claims came in at 576,000, well above estimates of 551,000. The only piece of economic news that investors seemed to trade on this week was the announcement on Friday that Existing Home Sales were up by significantly more than expected, coming in at 5.24 million versus expectations for 5.0 million, which led to a 1.9% gain in the S&P following the news.

What should investors look for this week? Earnings will be light again with the majority of companies with market moving potential having already reported, but look for reports from Burger King (NYSE: BKC), Medtronic (NYSE: MDT), Staples (NASDAQ: SPLS) and Sun Microsystems (NASDAQ: JAVA) Tuesday before the bell. Also keep a look out for reports from home builder Toll Brothers (NYSE: TOL) Thursday morning and Dell (NASDAQ: DELL) after the close that same day.

Economic releases for the week begin with the S&P Case-Shiller Home Price Index for June at 9:00am Tuesday, followed by Consumer Confidence for August at 10:00am. On Wednesday, look for Durable Orders for July at 8:30am, followed by New Home Sales for July at 10:00am. Weekly initial jobless claims, weekly crude inventories, Preliminary Q2 GDP, Q2 GDP Deflator and Q2 Core PCE will all be released together at 8:30am Thursday. Friday morning Personal Income and Spending for July will be released with PCE Core, also for July, at 8:30am, followed at 9:55am by revised Michigan Sentiment for August.

Conference schedules will be light again this week, but look for the Piper Jaffray Semiconductor Summit in Chicago, beginning on Tuesday. Jefferies & Co. will hostan investor conference in New York from Tuesday through Thursday, while Medtronic will hold its annual shareholder meeting in Minneapolis on Thursday.

Tarrant Apparel Group (NASDAQ: TAGS), a design and sourcing company for private label and private brand casual apparel, announced last week that its shareholders have approved the proposed merger between Tarrant, Sunrise Acquisition Company, LLC, and Sunrise Merger Company. The proposition was approved by 74% of the company’s outstanding shares; under the terms of the agreement, all of the outstanding shares of common stock of Tarrant, other than shares held by Sunrise Acquisition Company, LLC and two controlling shareholders will be acquired for $0.85 per share in cash. Shares remained unchanged on the week at $0.84.

Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord, announced last week that its compliance plan to remain listed on the NYSE AMEX exchange has been accepted and the company has been granted an extension until December 6, 2010 to become compliant. Shares lost eight cents on the week to close at $1.09.

CEL-SCI Corporation (AMEX: CVM), a late stage cancer immunotherapy company and vaccine developer, announced last week that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units -with each unit consisting of one of the company’s common shares and 0.50 warrants to purchase one share of common stock- for gross proceeds of approximately $4.4 million. The investors have agreed to purchase the units at a purchase price of $0.45 per unit, with warrants, representing the right to acquire 4.85 million common shares, exercisable at any time on or after February 20, 2010 and prior to the 5-year anniversary of the closing of the transaction at an exercise price of $0.55 per share. The transaction is expected to close on or about August 25, 2009, subject to satisfaction of customary closing conditions. In other news last week, the company announced that it has expanded the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as future mutations. The company’s scientists believe that the combination of various non-changing regions on the virus in one treatment or vaccine will allow for a greater ability to treat and protect against the current H1N1 virus and any possible future mutation. CEL-SCI currently has two on-going research programs directed towards the H1N1 virus; the first is directed against a future mutated form of the virus while the second aims to treat those already infected with the current strain of the virus. The company has indicated that it expects to provide an update on its operations regarding the current form of the virus within the next month. Shares lost a penny on the week to close at $0.45.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, announced last week that it has entered into a definitive financing agreement, which could raise $5 million, from which the proceeds will be used to fund operations and working capital needs. Based on the terms, certain market conditions and thresholds of the investment, the company may drawdown funds from the investor through the issuance of Series B Preferred Stock and five year warrants exercisable for shares of the company’s common stock having a value of 135% of the drawdown amount. Management is pleased to have completed the transaction and plans to use the funds to finance production of current brands and provide the capital needed to launch Kid Rock’s ‘American Badass Beer’, which is off to a very strong start in Michigan, its first launch market. In other news last week, the company announced that it has entered into a distribution agreement with Golden State beverage, a newly formed wine and spirits distribution and marketing company operating in California. Golden State Beverage has formalized a deal with Drinks Americas Holdings to take on the distribution of such high profile brands as award winning Trump® Super Premium Vodka, Trump® Premium Flavored Vodkas, Willie Nelson’s Old Whiskey River Bourbon, Olifant Premium Vodka from Holland and Damiana Liqueur from Mexico. Shares lost half a cent on the week to close at $0.125.

interCLICK (OTCBB: ICLK), a leading ad network, announced last week that it has joined the BlueKai Premier Partner Program. BlueKai is the online industry’s first intent-focused data exchange and online marketing’s largest source of user intent data, and is expected to enhance ICLK’s technology platform which is specifically designed to leverage 3rd party data to consistently deliver top results for advertisers. The company believes that BlueKai will make its data supply chain much more efficient, enabling them to run more scalable campaigns and optimize toward advertiser goals more quickly than before. Marketers working with program members will be able to tap experts who have long and extensive experience working with BlueKai data and who have deeper product integration with the company. Shares gained twelve cents on the week to close at $1.88.

Immunocellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it participated in the Southern California Investor Conference held in Newport Beach, CA on Tuesday, August 18. The conference brings together officers from 30 of Southern California’s leading growth oriented companies operating across a breadth of enterprises, including the life sciences, technology, media, and real estate/financial industries with retail and institutional investors from all over the nation. Shares lost one cent on the week to close at $0.49.

IceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, reported results for its third quarter ended June 30, 2009 last week. Among the highlights were revenue margins for the IceWEB family of products eclipsing 50% for the first time ever, compared to 12.2% in the same period in fiscal 2008, attributable to the company exiting their lower margin reseller business earlier in the year to focus on the sales of high-margin proprietary storage solutions. As a result of this decision to divest the lower margin business which the company expects will lead to higher profitability over the balance of the year, revenue for the period was $826,000 compared to $6.0 million for the same period in fiscal 2008. Third quarter total operating expenses were $1.2 million, which included $322,000 of non-cash items, compared to $2.8 million in the year-earlier period, while EBITDA for the period was a loss of $396,000, compared to a loss of $617,000 in the previous year. In other news last week, the company announced that its wholly owned subsidiary, INLINE Corporation, and Spot Image Corp., a leading supplier of geospatial information, have signed a commercial partnership agreement giving INLINE rights to distribute imagery data to the entire U.S. Federal and Commercial market. The U.S. market represents one of the largest user-bases of SPOT imagery in the world, which is used for many applications including homeland security, agriculture, geology, forestry, regional planning, education, intelligence and warfare. Shares lost two cents on the week to close at $0.08.

OmniComm (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced last week that it has been selected to provide eClinical data management solutions for two more organizations engaged in clinical research. The first deal involves Amarex, a Mid-Atlantic based Contract Research Organization, which will be conducting an upcoming Phase III trial investigating the use of a medical device for wound healing. The study will be conducted at over 30 sites and will recruit up to 300 patients over the course of two years. Amarex also joined OmniComm’s CRO Preferred Program, which will allow them to offer OmniComm’s flexible, robust electronic data capture solution, TrialMaster(TM), to their clients. The second deal announced this week will involve studies for Impax Pharmaceuticals, a California based organization conducting an international Phase III study in patients with Parkinson’s Disease. Shares gained a penny on the week to close at $0.24.

ONE Holdings (OTCBB: ONEZ), a rapidly growing company focused on the acquisition of core operating assets in the Asia Pacific and greater China region, announced last week that it has signed a letter of intent to acquire Jianou Lvjian FoodsStuff Co., an award-winning green-technology enterprise that specializes in the highly profitable production of organic products and fertilizers based on bamboo. JLF is the third largest bamboo producer in China and is the first bamboo company in China to gain food safety certification from both Japan and Europe; it operates nearly 6,635 acres of bamboo land in Fujian Province, one of China’s largest bamboo growing areas. ONEZ has indicated that upon completion of the acquisition it expects combined revenue, EBITDA, and net income for ONE Holdings would be increased to $27 million, $10 million and $7.7 million respectively based on 2008 results. In related news last week, the company announced results for its subsidiary, Green Planet Bioengineering for the second quarter of ’09. Second quarter revenue was $2,169,748, with EBITDA of $920,085 and operating income of $841,466; net profit reached $615,857. For the first two quarters of ’09, the company reported $4,467,369 in revenues while EBITDA reached $2,131,764. YTD 2009 operating income and net income came to $1,981,689 and $1,458,582 respectively. Green Planet managed to maintain margins for the period of over 59%, and expects that the results for their next two periods will be stronger as the first half of the year is traditionally much slower. Shares remained unchanged at $1.05 on the week.

Steel Vault (OTCBB: SVUL) an emerging provider of identity security products and services, announced last week that its Chief Executive Officer, William J. Caragol, appeared in an interview on the NBC news affiliate in West Palm Beach on Tuesday, August 18,. Mr. Caragol described how the company’s services, offered through its NationalCreditReport.com subsidiary, can help protect people’s credit and shield them from identity theft. A replay of the broadcast can be found on the affiliate’s website. Shares lost half a cent to close at $0.295.

August 17th CEOcast Weekly Newsletter

Monday, August 17th, 2009

Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, FMTI, ICLK, IMUC, IWEB, OMCM, ONEZ, SIHI, TAGS

Markets took pause from their four week run this week, as some less than encouraging economic reports coupled with profit taking led to slight declines in all of the major indices. All told, the Dow ended the week down 0.5%, surrendering 48 points to close at 9321, bringing its YTD gains to 6.2%. The Nasdaq was off 0.7%, closing at 1985, up a healthy 25.9% on the year, while the S&P 500 and Russell 2000 were down 0.6% and 1.5% respectively, paring their yearly gains to 11.2% and 12.9%.

Disappointing economic data relating to inventories and consumer sentiment soured the mood for much of the week, as worse than expected declines in retail sales, consumer sentiment, and business and wholesale inventories gave investors cause for concern. Retail sales figures, excluding autos, showed a 0.6% decline versus expectations for a 0.1% gain and July retail sales dropped 0.1% against expectations for an increase of 0.8%, mostly on consumer concerns regarding job security and weakness in wage growth. These unexpected declines combined with worse than expected consumer sentiment readings and inventory reports helped set the stage for a broad based sell off that saw all ten sectors of the S&P finish the week in the red.

The news wasn’t all bad however, as July CPI met expectations and Q2 productivity and July industrial production were all better than expected. In addition to these developments, signs of improvement in the global economy in the form of unexpected GDP expansion in France, Germany and Hong Kong, helped temper the selling pressures. Further balance was added by the FOMC announcement that rates would remain at historic lows due to its expectation that inflationary pressures will remain subdued and economic recovery is likely to remain weak for some time.

What should investors look for this week? Earnings reports continue to wind down slowly, but look for reports from CIT Group (NYSE: CIT) and Lowe’s (NYSE: LOW) Monday morning, followed on Tuesday morning by Cardinal Health (NYSE: CAH) and Home Depot (NYSE: HD), with Hewlett-Packard (NYSE: HPQ) reporting after the bell. On Wednesday before the bell, Deere (NYSE: DE) reports, followed on Thursday morning by Barnes & Noble (NYSE: BKS), HJ Heinz (NYSE: HNZ), and Sears Holdings (NASDAQ: SHLD). The week rounds out with Gap (NYSE: GPS) reporting Thursday after the market.

Economic releases for the week begin on Monday with the Empire Manufacturing Index for August due out at 8:30am, followed by Net Long Term TIC Flows for June at 9:00am. On Tuesday, keep an eye out for Building Permits, Core PPI, Housing Starts and PPI, all for July, released together at 8:30am. Weekly Crude Inventories will be released at10:30 am on Wednesday, with weekly Initial Jobless Claims due out at 8:30am Thursday, followed by Leading Indicators for July and Philadelphia Fed minutes from August at 10:00am. The week wraps up with Existing Home Sales for July at 10:00am on Friday.

Conference schedules will be light this week, but look for the Southern California Investor Conference being held in Newport Beach, CA on Tuesday in which ImmunoCellular Therapeutics (OTCBB: IMUC) will participate, and the Pritchard Capital Partners Mini Conference, which will be held in Dallas that same day.

Forbes Medi-Tech Inc. (NASDAQ: FMTI), a life sciences company focused on evidence-based nutritional solutions, reported results for its second quarter ended June 30, 2009 last week. For the period, FMTI generated revenues of $1.02 million Canadian versus revenue of C$2.69 million in the corresponding year ago period. Gross margin for the period improved from $524,000 in Q2 ’08 to $1.16 million in the current period. The significant increase in gross margin is attributable to decreased cost of sales of the company’s nutraceutical products, which fell from $2.2 million in the year ago period to $749,000 in the period ended June 30, 2009. As a result, FMTI managed to post net income of $113,000, or $.02 per share for the period, a significant improvement over the net loss of $3.03 million, or $0.63 per share in the period ended June 30, 2008. The company also said that that it has extended its supply and licensing contract with Pharmavite LLC until mid 2010 for the continued sale of Reducol, which it expects to favorably impact operating results in the coming quarters. Shares remained unchanged at $0.34 on the week.

Tarrant Apparel Group (NASDAQ: TAGS), a design and sourcing company for private label and private brand casual apparel, announced results for the quarter ended June 30, 2009. TAGS reported total net sales of $41.0 million in the second quarter of 2009, a 20.0% decrease compared to $51.3 million in the same period in 2008, mostly attributable to weak Private Label sales resulting from decreased demand from consumers and bankruptcies of significant retail customers such as Mervyn’s. The decrease was partially offset by an increase in sales to Wal-Mart of $7.4 million in the second quarter of 2009. Gross profit decreased by $1.4 million, or 12.9%, to $9.6 million in the second quarter of 2009 from $11.0 million in the second quarter of 2008, primarily resulting from the overall decrease in net sales. Income from operations in the second quarter of 2009 was $505,000 or 1.2% of total net sales, compared to loss from operations of $5.4 million or 10.5% of total net sales, in the second quarter of 2008. Net income was $219,000, or $0.01 per basic and diluted share for the 2009 second quarter, compared to net loss of $5.3 million, or $0.16 per basic and diluted share for the 2008 second quarter. Shares gained a penny on the week to close at $0.84.

Neuralstem (AMEX: CUR), a company targeting major central nervous system diseases using neural stem cells of the human brain and spinal cord, announced last week that it has submitted a plan to address its non-compliance with NYSE Amex listing requirements. Shares lost four cents on the week to close at $1.18.

CEL-SCI Corporation (AMEX: CVM), a late stage cancer immunotherapy company and vaccine developer, reported results for the period ended June 30, 2009 last week. The company’s loss from operations for the quarter ended June 30, 2009 was $3.7 million, or $0.05 per share versus a loss of $2.2 million, or $0.02 per share during the same quarter in 2008; the most current period loss includes $2.6 million in non-cash expense. R&D expenses during the most current period were $1.6 million compared to $1 million during the corresponding year ago period. The company feels that it has emerged from this period of disrupted capital markets stronger than ever and anticipates completing the validation of its manufacturing facility which it hopes will enable it to accelerate the pivotal Phase III test for its lead product candidate Multikine, a next-generation, comprehensive immunotherapy that targets newly diagnosed head and neck cancer. Shares gained a penny on the week to close at $0.49.

SinoHub (AMEX: SIHI) a company providing world-class supply chain management services with transparent information access for participants in the electronic components supply chain in China, reported results for the three months ended June 30, 2009 last week. Among the highlights was a nearly six-fold increase in net income and revenue growth of more than 137%, compared with the 2008 second quarter. Net income for the 2009 second quarter grew substantially to $3.2 million, or $0.13 per fully diluted share based on 25.2 million weighted average shares outstanding, from $540,000, or $0.03 per fully diluted share based on 19.6 million weighted average shares outstanding, in the year-ago quarter (the increase in shares outstanding was the result of a private placement in September of ’08). Total revenue for the 2009 second quarter rose significantly to $31.4 million from $13.2 million for the 2008 second quarter. Revenue from electronic component sales, including procurement-fulfillment and spot component sales, increased more than 130% to $29.1 million for the 2009 second quarter from $12.6 million for the same period last year. Revenue from the company’s supply chain management services business increased to $2.3 million for the second quarter of 2009, from $569,000 last year. The company attributes its impressive results to increased recognition of SIHI’s value offering to manufacturing clients within Chinese markets which has been enhanced by the company’s decision to target second tier mobile phone sector of the Chinese electronics industry where suppliers and manufacturers are looking to SinoHub to expand the flexibility of their supply chains. Shares lost seven cents on the week to close at $3.90.

Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, will hold a conference call on Tuesday, August 18th to discuss results for fiscal year 2009 which are to be released that same day. The company also plans to discuss the progress of Kid Rock’s American Badass Beer, its pending export sales to Israel, key market distributor additions, and a recap of the Olifant Vodka Concert Series. Shares lost a penny on the week to close at $0.13.

interCLICK (OTCBB: ICLK), a leading behavioral targeting company, reported record results for the quarter ended June 30, 2009 last week. Among the highlights was record revenue of $10.6 million which rose 128% from 2008 second quarter revenue of $4.7 million, and increased 26% sequentially from the 2009 first quarter, attributable to increased demand from existing advertisers as well as strong penetration into new key accounts. Gross profit of $5.0 million grew 235% from pro forma 2008 second quarter gross profit of $1.3 million, and increased 26% from 2009 first quarter gross profit of $4.0 million. Gross margin of 47.2% compared with pro forma gross margin of 27.0% in the year-earlier period and 47.3% in the prior quarter. The company attributes its significant increases in gross margin to supply chain management improvements and efficiencies generated through its advanced proprietary technology platform. EBITDA was $0.2 million, compared to an EBITDA loss of $1.6 million in the year-earlier period. Net loss for the period was $1.0 million, or $0.03 per share, compared to a net loss of $3.9 million, or $0.11 per share in the year earlier period. ICLK expects third quarter revenue to exceed $12.5 million and gross margin to approach 50%. The company raised its full-year revenue forecast to exceed $44 million, an increase of at least 96% compared to 2008. Previously, the company forecast that revenue would exceed $40 million. Shares lost seven cents on the week to close at $1.84.

IceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, announced last week that its wholly owned subsidiary, INLINE Corporation, was recently awarded a contract by the Department of Defense (DoD) to develop innovative storage solutions to accommodate the government’s growing need for data storage in connection with defense applications. Under the agreement, INLINE Corporation will provide data storage to one of DoD’s Combatant Commands. The company’s TruEnterprise 444 model, a scalable data center grade product, will be deployed by the DoD to build an initial 48TB repository for geospatial imagery data. DoD plans to scale the overall solution to accommodate growth of this GIS data to upwards of 200TB’s. Shares lost a penny on the week to close at $0.10.

OmniComm (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced last week that it has been selected to provide eClinical data management solutions for two more organizations engaged in clinical research. The first deal involves two Phase I HIV studies for a large west coast based biotechnology company that will handle over 100 patients over the course of approximately seven months. The second deal involves a pivotal Phase III trial in Rheumatoid Arthritis for a large European based Contract Research Organization (CRO), which is expected to enroll close to 300 patients over the course of 48 months at 20 sites in Europe. The company believes that organizations within the clinical research space have become increasingly aware of the high value and tailored solutions that OMCM offers to clients thanks to its recent acquisition of the EDC assets of eResearch and Logos Technologies. Shares gained three cents on the week to close at $0.23.

Advanced Cell Technologies (OTC: ACTC), a company engaged in the development of regenerative therapies utilizing stem cells, announced last week that Dr. Robert Lanza, its Chief Scientific Officer, was featured on Deepak Chopra’s Wellness Radio on Sirius/XM Stars, Channels 102 and 55. The channel is the flagship talk station on the Sirius/XM network and boasts a listenership of approximately 9 million people. The show focuses on Dr. Lanza’s research at ACTC and his new book “Biocentrism.” Chopra is a prolific author of over fifty-five books on topics ranging from health to consciousness and quantum mechanics, and was heralded by Time Magazine as one of the top heroes and icons of the century. In other news last week, ACTC announced that it has hired Edmund Mickunas as Vice President Regulatory. Mr. Mickunas will be in charge of spearheading the company’s effort to translate its cutting edge research into FDA approved therapies ready for clinical trials. Specifically, Mr. Mickunas will work with Dr. Robert Lanza and ACT’s Development Team to finalize and submit an IND for the RPE program to the FDA for approval to commence a Phase I Clinical Trial. Mr. Mickunas has over 28 years of experience across a breadth of disciplines including the biotechnology, medical device and pharmaceutical fields. Shares remained unchanged at just under $0.15 on the week.

Special Situation:

ONE Holdings, Inc. (OTCBB: ONEZ) $1.05

As economic growth resumes following the global recession, many investors have begun to look towards opportunities in emerging markets where growth is expected to resume at higher rates. ONE Holdings is a rapidly growing company focused on the acquisition of core operating assets in the Asia Pacific and greater China region that is positioning itself to capitalize on the strong growth expected to characterize the region as it leads the global economy out of recession. The company pursues fast growing, cash flow positive leaders in the biotech and technology industries where management has a long history of operating experience; it seeks to acquire companies with proprietary technology, high barriers to entry, repeatable and sustainable revenue streams and synergies with its current operating assets. Their strategy is to support the growth of operating subsidiaries by providing strong managerial direction and adequate financing aimed at promoting sustainable, long term growth fostered by the robust markets which the company has chosen to operate in.

While it may sound complex, the company’s business model is fairly simple and very sound strategically; find profitable, high growth companies operating in strong emerging markets, acquire them and help them continue to grow by providing managerial guidance and financing. In addition to a sound business model, ONE Holdings benefits from an affiliation with Abacus Global Investments, a business advisory firm assisting small to midsize companies in reaching their full potential, which recently purchased a controlling interest in the company with plans to refocus its business strategy on accretive acquisitions and delivering value to shareholders. Abacus identifies best in class midsize private companies and transforms these companies into fast growing public entities by assisting them in raising capital for growth in addition to providing sound strategic guidance.

The company’s first operating subsidiary in a series of planned strategic acquisitions is Green Planet Bioengineering, a fast-growing, high-tech bioengineering company operating in China that uses proprietary processes to extract highly profitable health supplements, fertilizers, and pesticides from waste tobacco. Green Planet posted revenues of $10.4 million in FY’08, with EBITDA of $5.0 million and net income of $3.3 million, with FY ’09 forecasts for revenue of $13.5 million and EBITDA and net income of $6.9 million and $4.8 million respectively. The company’s proprietary processes and exclusive access to raw materials allow it to generate gross margins in excess of 50%, illustrating the type of opportunities that ONE Holdings targets.

With future plans for further accretive acquisitions in the works that the company has indicated that it expects will bring substantial value to shareholders, ONE Holdings appears extremely well positioned to capitalize on the renewed growth spurred by the slowing of recessionary pressures. Their strong business model and strategic focus on fostering growth within already high growth markets makes them an intriguing prospective investment as more and more investors continue to scour emerging markets in hopes of finding higher return on investment than is available stateside. The company’s aggressive acquisition strategy combined with a strong, high growth target market and focus on providing value to shareholders makes ONE Holdings an enticing play on emerging Asia that appears to provide significant value at present levels. The prospect of forthcoming acquisitions alluded to by management in a recent public filing provides the possibility for potential catalysts on the horizon, making now an opportune time to think about investing as the company is operating largely under the collective radar of investors for the time being.

August 10th CEOcast Weekly Newsletter

Monday, August 10th, 2009

Companies featured in this edition of the newsletter: CBAI, ICLK, ITUI, IWEB, MBCI, OMCM, SIHI, SRCO

Markets continued their torrid pace this week on the strength of encouraging reports from two of the most beleaguered economic sectors, which led to gains in all of the major indices following the week’s activities. All told, the Dow ended the week up 2.2%, gaining 198 to close at 9370, bringing its YTD gains to 6.8%. The Nasdaq gained 1.1% on the week, bringing its yearly gains to 26.8% while the S&P 500 and Russell 2000 posted gains of 2.3% and 2.28 % respectively, bringing their yearly gains to 11.9% and 14.6%.

Economic news stole the spotlight this week as earnings season wound down, leaving investors with a more definitive picture of the overall state of recovery than in many weeks prior. The good news started early in the week, as the ISM Manufacturing Index posted its seventh straight gain, beating expectations in the process and suggesting that the manufacturing sector is rebounding more sharply than anticipated. Good news was also extrapolated from the housing sector, where construction spending for June surprised many by rising 0.3% versus expectations for a 0.5% decline. Pending home sales were also surprisingly more positive than anticipated, rising 3.6% in June and beating expectations for an increase of 0.7%.

The long awaited employment figures that were released on Friday served to add more fuel to the rally as the report was generally better than expected, although it indicated that employers are still shedding jobs. Employers cut 247,000 jobs in June which was better than expectations calling for 325,000. The amount of job losses fell to the lowest level in nearly a year as the unemployment rate receded to 9.4%, down from 9.5% in June. Corporate developments took a back seat to economic data, but there were still some notable developments as AIG (NYSE: AIG) managed to report its first quarterly profit since 2007 and Cisco (NADAQ: CSCO) reported an 18% drop in profitability year over year, which was in line with expectations and reflected the weakness remaining in consumer demand, which was further enforced by the tepid July same store sales reports from retailers.

What should investors look for this week? Earnings releases slow considerably, but look for reports from Sysco (NYSE: SYY), before the bell on Monday, followed on Wednesday morning by Macy’s (NYSE: M). Wal-Mart (NYSE: WMT) will report before the bell on Thursday, with Blockbuster (NYSE: BBI) reporting that afternoon along with Nordstrom (NYSE: JWN). The week wraps up on Friday morning with JC Penney (NYSE: JCP).

Economic releases for the week begin on Tuesday with Q2 Preliminary Productivity and Unit Labor Costs, due out at 8:30am, followed by Wholesale Inventories for June at 10:00am. On Wednesday, look for June Trade balance data at 8:30am, weekly crude inventories at 10:30am, Treasury Budget for July at 2:00pm, and the FOMC’s Interest Rate Decision, which is expected at 2:15pm. On Thursday, Import and Export Prices for July, weekly initial jobless claims, and Retail Sales for July will be released together at 8:30am followed by Business Inventories for June at 10:00am. The week finishes up on Friday with CPI and Core CPI for July at 8:30am, followed by Capacity Utilization and Industrial Production for July at 9:15am; Preliminary Michigan Sentiment finishes things up at 9:55am.

Conference schedules pick up this week with earnings season largely behind us; things kick off with the three-day CanaccordAdams Global Growth Conference in Boston on Tuesday, alongside the two day Oppenheimer & Co. Communications, Technology and Internet Conference which is also being held in Boston. Credit Suisse will host their E2M2 Investment Banking Conference in New York on Tuesday, while Jefferies & Co. will hold their Industrial CEO Summit in Chicago on Wednesday. UBS will hold their Engineering & Construction One-on-One Conference in Chicago that same day.

Earnings Preview: SinoHub (AMEX: SIHI) a provider of supply chain management services, is scheduled to report results for its 2009 second fiscal quarter on Friday before the market opens for the period ended June 30, 2009. Since the announcement of first quarter results, the stock has surged 58%. Highlights from the first quarter included a 56% increase in revenue, rising from $11.6 million to $18.1 million, and an increase in net income of 83% from $1.1 million in the corresponding year ago period to $2.0 million in Q1 of ’09. The company announced during its first quarter conference call that it expects top line organic revenue growth of as much as 50% in FY ’09. Investors are expected to focus on the company’s ability to continue to grow revenue and net income, especially as China emerges out of the global economic downturn. In other news last week, the company announced that it has been granted approval to begin trading on the NYSE Amex Exchange. The move from the OTC Bulletin Board to the AMEX should provide the company’s stock with expanded visibility and improved liquidity; it will trade under the symbol SIHI. Shares lost three cents on the week to close at $3.97.

Volume Alert: Shares of IceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, surged 71% on over three times average volume last week, following the announcement late last week that its Chairman and CEO had acquired the remaining 626,667 shares of Series B Convertible Preferred Stock for $75,000, or approximately $0.12 per share. Following that acquisition, there was more insider buying this week, as the company’s CFO made multiple open-market purchases. IWEB also announced last week that its storage subsidiary has begun commercial shipment of its new MLP ManPac III portable Geospatial Information Server. The device, along with new optional expansion storage accessories is available to commercial and federal clients and Channel Partners immediately. The Shares gained five cents on the week to close at $0.12, their highest level since Septmber.

Earnings Preview: interCLICK (OTCBB: ICLK), a leading behavioral targeting company, is scheduled to report second quarter results for the period ended June 30, 2009, after the bell on Tuesday. For the first quarter of ‘09, ICLK reported record results, with revenue of $8.4 million, up 136% from pro forma 2008 first quarter revenue of $3.6 million. The company also managed to post its first quarter of profitability, reporting net income of $0.03 million. Gross profit of $4.0 million grew 366% from pro forma 2008 first quarter gross profit of $0.9 million while expanding 24% from 2008 fourth quarter gross profit of $3.2 million. The company also managed to report gross margin of 47.3%, its highest margin ever, thanks in large part to improvements in its supply chain management. ICLK previously released a preliminary second quarter outlook in which it said that it expects record revenue to exceed $10.5 million, an increase of at least 124% compared to the year-earlier period and 25% sequentially, raising guidance from its previous forecast for quarterly revenue to exceed $9.5 million. Investors will likely focus on the company’s ability to retain profitability and continue to grow revenues, as this is traditionally a busier period seasonally. Shares gained three cents on the week to close at $1.93.

I2 Telecom (OTCBB: ITUI), a leading developer of award-winning patented and innovative high-quality mobile applications and services announced last week that the company has converted approximately $5.5 million in Promissory Notes into preferred stock of its wholly-owned subsidiary i2Telecom IP Holdings, Inc. The exchange was required as part of a financing of ITUI’s Series F Convertible Preferred Stock, which required the exchange of a minimum of eighty-five percent of the company’s $6.3 million in total debt related securities. In connection with creation of the new subsidiary, substantially all of the company’s intellectual property has been transferred to the subsidiary, with ITUI owning all common stock in the newly formed entity. The Preferred Stock provides for an accruing dividend of 12 percent per annum, and a special dividend for up to two years in the event that the IP Subsidiary Preferred Stock has not been redeemed. Shares remained unchanged at just over $0.05 on the week.

OmniComm (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced last week that it has acquired the EDC assets of UK based, clinical software provider, Logos Technologies, Ltd. The software is used to collect data gathered while conducting Phase I clinical trials, aiding in all aspects of the Phase I process from subject recruitment and clinical workflow management to laboratory sample management. This latest acquisition serves as a complement to OMCM’s TrialMaster software which is primarily used to collect data for later stage trials, and now allows the company to provide a complete range of EDC software solutions for clinical trials from Phase I through Phase IV, making it an extremely valuable service to all types and sizes of organizations conducting clinical research. In other news last week, OMCM announced that it has signed a licensing deal with a west coast based Clinical Research Organization (CRO) expected to generate more than $1.1 million from licensing, maintenance, hosting, and consulting fees over the next three years. The company expects that its latest acquisition will aid in signing more deals with companies seeking to streamline and more efficiently manage their clinical data collection efforts. Shares gained four cents on the week, surging 25% to close at $0.20.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated exclusively to the powersports industry, announced last week that it has completed a transaction to provide financing in the amount of $172,000 for the leasing of eight 2009 BMW police motorcycles for the City of Charlotte, North Carolina. The company believes that the difficult economic climate which has tightened municipality budgets will enable the company’s Fleet Leasing operations to continue to grow, even as it continues to focus its efforts mainly on its consumer financing and leasing operations. Shares lost $0.004 on heavy volume on the week to close at $0.076.

Cord Blood America, Inc. (OTCBB: CBAI), an umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced last week that it had retired $2.53 million of long term debt. The debt was related to the company’s acquisition of CorCell, the first licensed family cord blood banking company in the United States which allowed the company to establish itself as one of the largest domestic stem cell storage companies. The notes were scheduled to mature on February 28, 2010 and were paid off ahead of schedule as part of the company’s plan to increase shareholder value by strengthening its balance sheet through retiring debt. Shares remained unchanged at less than a penny on the week.

SPECIAL SITUATIONS:

MabCure, Inc. (OTCBB: MBCI) $0.87

Much of the focus of the biotech and pharmaceutical industries over the past several decades [or 50 years] has been on trying to develop cures for cancer. As billions of dollars have been pumped into potential treatments and preventative measures, one aspect of the fight has been largely overlooked; providing early, definitive diagnoses that enable treatments to achieve 5-year survival of more than 90% in most cancers. MabCure is a company devoted to using its proprietary technologies to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer. These MAbs have shown extremely encouraging results in early studies. MBCI’s business model centers on serving the vast and growing cancer markets that have been the focus of so much attention and funding, but does so by concentrating on the much less competitive niche of diagnosing these deadly diseases rather than mixing it up in the highly competitive business of attempting to treat them. This allows them to offer a product which potentially has just as much importance to the multibillion dollar market, but without the significant risks associated with going toe to toe with the major pharmaceutical and biotech companies vying for supremacy in the treatment space, making them an intriguing early stage play on an enormously robust market.

MabCure’s current focus is on early cancer detection, which it feels should lead to significant reductions in overall mortality and morbidity. Its portfolio currently includes highly specific MAbs targeted to diagnose three lethal human malignancies: melanoma, ovarian cancer and prostate cancer. The company’s ultimate goal is to remedy the glaring lack of diagnostic tests that can reliably detect many types of cancers in the blood or urine, when they are at their earliest and most curable stages. This could change the reality of cancers as largely incurable diseases by diagnosing them before they spread to other tissues, when the rate of curing the diseases is often greater than 90%. By detecting these diseases in their most curable stages, the company hopes to allow patients to be treated effectively with conventional therapies and significantly prolong their disease free survival.

In preclinical studies, a single anti-melanoma MAb was able to correctly identify 100% of different melanoma tissue specimens, while cross reacting with both early and metastatic tissue specimens, demonstrating its potential to detect early cancerous growths. Similarly positive data were observed in a pilot clinical trial using an anti-ovarian cancer MAb which detected active disease in the blood of thirteen out of thirteen patients; it also diagnosed six patients judged to be in remission to still have the disease, suggesting that the MabCure antibody is more sensitive than the standard diagnostic marker or test, CA-125, in detecting patients with residual disease. Plans are underway to begin the first full scale clinical study of patients at high risk for ovarian cancer and an additional clinical study for diagnosing prostate cancer in high risk patients. In addition to melanoma, prostate and ovarian cancers, which all serve multi-billion dollar markets, the company has also begun work on diagnostic antibodies for colon cancer, with plans for other types of cancer with similarly large markets to follow.

As money continues to be poured into researching more effective treatments for cancer, it appears that perhaps a shift in strategy such as the one which MabCure is currently focusing on may be the more prudent course of action in combating these terrible diseases. By focusing on improving our ability to detect these maladies before they advance beyond the point of no return, patients are given a much greater chance at survival which is essentially what the majority of companies working towards more efficient treatments are attempting to do. By choosing to work away from the pack and focusing on early diagnosis, MBCI provides investors with an opportunity to invest in a company engaged in crucially important research that should be able to command significant market share in the extremely lucrative cancer space once they have gained approval to market their portfolio of highly targeted, advanced diagnostic tools designed to provide physicians with a window of opportunity to effectively treat cancer patients through early detection of these terrible and deadly diseases.

August 3rd CEOcast Weekly Newsletter

Monday, August 3rd, 2009

Companies featured in this edition of the newsletter: ACCP, CBAI, CICS, CUR, CVM, DKAM, EMDH, ESYM, ICLK, IWEB, OMCM, SRCO

Markets hit fresh highs for ’09 this week on modest gains across all of the major indices despite profit taking from the two week rally which has seen the S&P 500 increase by 11%. All told, the Dow gained 0.9% on the week to close at 9171, up 78 points, bringing its year-to-date gain to 4.5%. The NASDAQ managed to post a 0.6% gain, closing at 1965, up 25.5% on the year, while the S&P 500 and Russell 2000 finished up 0.8% and 1.5% respectively, bringing their yearly gains to 9.3% and 11.5%.

Earnings were once again the subject of investors’ collective attention, but despite being generally positive, failed to spur the type of buying that has characterized the past two weeks as there were fewer bellwether names with market moving potential releasing results. Buyers met with profit taking from the previous two-week run up which led to markets trading mostly sideways on the week, with the exception of Thursday which saw triple digit gains in the Dow despite the lack of any significant market driving announcements. Financials led the way with a 4.4% gain on the week while Utilities were the laggard, losing 2.0%.

Economic news on the week was mixed and had a muted result on the week’s trading activity. The highlight of the week with regards to economic developments was the advanced second quarter GDP reading, which came in at a better than expected decline of 1.0% versus expectation for a drop of 1.5%, suggesting that the economy is contracting at a slower rate than forecast. Housing data was mostly positive on the week as well, as New Home Sales managed to beat expectations and the S&P/Case-Shiller Home Price Index also declined less precipitously than forecast. However, these positive developments were offset by disappointing Consumer Confidence figures for July and mixed Durable Goods Orders for June, leaving the exact state of overall recovery open to interpretation.

What should investors look for this week? Earnings will once again be in focus, but to less of a degree as the majority of market driving names have already reported. Investors are likely to keep a close eye on unemployment data for July which is due out Friday morning.

Earnings season begins to wind down this week, but on Monday morning, expect reports from Loews Corp (NYSE: L), Marathon Oil (NYSE: MMP) and Tyson Foods (NYSE: TSN). On Tuesday before the bell, Archer-Daniels (NYSE: ADM), CVS Caremark (NYSE: CVS), while Kraft Foods (NYSE: KFT), News Corp (NYSE: NWS) and Whole Foods (NASDAQ: WFMI) are expected to release after the close. On Wednesday, Procter & Gamble (NYSE: PG) reports before the open, with Allstate (NYSE: ALL) Cisco Systems (NASDAQ: CSCO), Prudential (NYSE: PRU), and Sunoco (NYSE: SUN) to release after the close. Thursday morning look for releases from Comcast (NASDAQ: CMCSA), DirecTV (NYSE: DTV), Sirius XM Radio (NASDAQ: SIRI), Thomson Reuters (NYSE: TRI), and Wendy’s (NYSE: WEN) followed by American International (NYSE: AIG) and CBS Corp. (NYSE: CBS) after the close.

Economic reports for the week begin with Construction Spending for June and ISM Index for July due out together on Monday morning at 10:00am, with Auto and Truck Sales for July to be released at 2:00pm that afternoon. On Tuesday, Personal Income and Spending for June will be released at 8:30am, followed by Pending Home Sales for June at 10:00am. On Wednesday, look for ADP Employment Change figures at 8:15am, followed by Factory Orders for June and ISM Services for July at 10:00am; Weekly Crude Inventories follow at 10:30am. Weekly Initial Jobless Claims will be released Thursday at 8:30am, while Average Workweek, Hourly Earnings, Nonfarm Payrolls and the Unemployment Rate, all for July, will be released together at 8:30am Friday. Consumer Credit for June rounds out the week at 2:00pm.

Conference schedules for the week will be light once again as earnings will dominate most calendars, but BMO Capital Markets will host their 2009 Focus on Healthcare Conference beginning on Tuesday in New York.

Volume Alert: Shares of CEL-SCI Corporation (AMEX: CVM), a late stage cancer immunotherapy company and vaccine developer, surged 17% on three times average volume, following a report last week by BioMedReports, a news portal covering the biomedical and financial sectors. The report focused on the H1N1 swine flu pandemic and concluded that CVM is positioned to help combat the virus after diligently preparing for the worst case scenario with promising results. The article focused on the company’s preclinical studies which have demonstrated that vaccines utilizing the company’s proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology can potentially induce protection against illnesses such as the swine influenza, including potential mutations which the virus might undergo as we continue to close in on the traditional flu season. Shares gained seven cents on the week to close at $0.50.

Volume Alert: Shares of Access Pharmaceuticals, Inc. (OTCBB: ACCP), an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients, jumped 11% on almost three times average volume last week, following the announcement that its European partner, SpePharm, has commenced commercial launch of MuGuard, Access’ proprietary formulation for management of oral mucositis, a painful side effect of radiation therapies. The news comes on the heels of recent commercial launches in the UK, Germany, Italy and Greece, with plans to launch in France, Spain and the Benelux countries within the next 12 months. Access also announced that it is currently evaluating its options for commercialization of MuGuard in North America, where demand for the product is greater than previously estimated. The company has retained the services of Frank Jacobucci, formerly President & CEO of Milestone Biosciences, who will assist with ongoing reimbursement, manufacturing and commercial launch activities at Access, while discussions with potential licensee and co-promotion partners is ongoing. Shares gained forty five cents on the week to close at $4.30.

Earnings Preview: interCLICK, Inc. (OTCBB: ICLK), a rapidly growing ad network, is scheduled to announce second quarter financial results for the period ended June 30, 2009 on Thursday after the market closes. Shares have more than doubled since late-May, helped by the company raising full-year guidance for revenue to exceed $40 million, which would be an 80% increase from the year-earlier period. The company also recently raised Q2 expectations, saying that it expects revenue to exceed $10.5 million, an increase of at least 124% compared to the year-earlier period and 25% sequentially. ICLK previously said it expected quarterly revenue to exceed $9.5 million. For the 2008 second quarter for the period ended June 30, 2008, interCLICK had revenue of $4.7 million. The company also announced last week that it had launched an important update to its ad serving platform, increasing scalability and effectiveness of its behavioral platform. The latest platform upgrade centers on reporting and delivery tools that improve the predictability data and inventory requirements. The goal of the upgrade is to provide advertising clients with improved transparency regarding exactly where advertising dollars are being most effectively utilized, which is designed to further increase ROI across the company’s network. Shares remained unchanged at $1.90 on the week.

Cord Blood America, Inc. (OTCBB: CBAI), an umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said in an interview of its CEO last week that the company’s recent acquisition of a new stem cell laboratory would reduce its cost of storing stem cells and allow it to begin a research and development program and to seek government and other grants. Cord Blood recently announced it is opening a state-of-the-art laboratory, one of the largest in the U.S., for the storage of multiple stem cell products, including adipose tissue, peripheral blood stem cells and umbilical cord blood stem cells. Shares remained unchanged at less than a penny on the week.

Volume Alert: Shares of beverage distributor Drinks Americas (OTCBB: DKAM) jumped 15% on over twice average volume last week perhaps driven by interest in the company’s Kid Rock American Badass Beer. DKAM had previously indicated that it expects the launch to be immensely successful due to its association with Kid Rock, a popular Midwestern musician; the company has focused their initial roll outs on Michigan markets where he grew up, with successive launches in coming months in other markets nationwide. Shares gained two cents on the week to close at $0.15.

Emerging Media Holdings (OTCBB: EMDH), a company that operates television broadcasting and infrastructure companies in Moldova and Romania, issued guidance for its fiscal year ended December 31, 2009 last week. EMDH said it expects full year revenue to be between $20 million and $25 million, with EBITDA, a non-GAAP measure, of between $5 million and $6 million. The earnings are expected to come from the recent acquisition of a 60% interest in Genesis International, a leading Eastern European infrastructure company whose results are expected to be consolidated in the third quarter of ’09 and a 25% increase in earnings from its media operations. Shares lost ten cents on the week to close just above $0.40.

IceWeb (OTCBB: IWEB), a storage technology company specializing in Geographic Information Systems (GIS) that provides services to bureaucratic and corporate organizations, announced last week that it has entered into a definitive agreement under which the company has secured a $3 million investment available for drawdown through issuance of Series C preferred stock. IWEB believes that the investment will provide adequate funding to finance the company’s operations, research & development and sales efforts until it is able to reach sustainable profitability. In other news last week the company announced that it has seen increased demand for its Iplicity 2.0 software from both commercial clients and governmental agencies. The company feels that its upgraded platform provides features and functionality well beyond that which is currently offered by competitors and expects that the enhanced software will be extremely popular as clients recognize the significant value and superior performance offered by the newest version. Shares lost just under half a cent on the week to close at $0.066

OmniComm (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced last week that it has been selected by a Midwestern contract research organization (CRO) to provide eClinical solutions in connection with two of the CRO’s Phase IV studies covering approximately 27 sites and more than 700 subjects. The company attributes the recent increase in demand for its services to the recent acquisition of eResearch Technology’s data capture unit, which has greatly expanded the breadth of service offerings that the company provides to clients of all sizes in all phases of clinical development. Shares lost a penny on the week to close at $0.16.

Sparta Commercial Services (OTCBB: SRCO), a nationwide financial services company dedicated exclusively to the powersports industry, announced last week that it has entered into a definitive agreement under which it has secured up to a $5 million investment which can be accessed through issuance of Series B preferred stock. In addition to securing financing, the company also converted its short term notes into equity in a move designed to strengthen its balance sheet and meet the criteria necessary to begin initial drawdown on its $25 million revolving credit facility. Management believes that this credit facility, in combination with the recent $5 million financing, will be sufficient to dramatically grow its powersport leasing and installment loan activities. Shares remained unchanged at $0.08 on the week despite active trading.

EcoSystem Corp. (OTCBB: ESYM), a company innovating industrial-scale applications of bioreactor technology that are designed to resolve compelling ecological challenges while producing value added carbon neutral products, announced last week that it has executed agreements for the sale of EcoSystem preferred stock and warrants to five investment funds for $76 million. Funding is expected to occur prior to August 5, 2009; the proceeds will be held in a restricted EcoSystem account and will be available for use according to the use of proceeds schedule and other conditions specified in the agreements. The company plans to use the funds to acquire distressed ethanol production facilities, to acquire other strategically-compatible assets, and to develop and integrate EcoSystems’ Cellulosic Corn technologies into EcoSystem’s planned ethanol production facilities. ESYM plans to achieve an annualized renewable fuel production rate of 500 million gallons within the next three years. Shares ended the week below a penny.

Carbonics Capital Corporation (OTCBB: CICS), a company that provides applied engineering and technology transfer services based on clean technology and process innovations that enhance manufacturing efficiencies, improve resource utilization and minimize waste, announced last week that the company has entered into an exclusive license with GreenShift Corporation (OTCBB: GERS) for use of its algae bioreactor technologies in municipal and industrial applications excluding ethanol production. GreenShift’s patented and patent-pending bioreactor technologies rely on thermophillic cyanobacteria to consume carbon dioxide emissions and to produce carbon-neutral products in addition to having the potential to reduce the costs and technical barriers to managing the flow resources into, through and out of the bioreactor in a compact and cost-efficient way as compared to other algae bioreactor technologies. The company’s wholly owned subsidiary Sustainable Systems, Inc., was recently awarded a $375,000 grant from the Montana Department of Commerce Research and Commercialization Technology program and plan on pursuing additional funding to apply towards further commercialization of the newly acquired technology. Shares closed the week under one cent.

SPECIAL SITUATIONS:

Neuralstem, Inc. (AMEX: CUR) $1.16

The allure of stem cells as a potential therapeutic option are the seemingly limitless possibilities; imagine one day being able to return function to someone who is paralyzed, or the victim of a devastating stroke and you begin to see the potential for applications that Neuralstem, a Maryland-based biotherapeutics company is exploring. Neuralstem is using a patented process to grow neural stem cells of the human brain and spinal cord in commercial quantities. The company’s focus is on incurable neurodegenerative conditions that are typically associated with severely debilitating side effects such as paralysis, muscular atrophy and even death. CUR’s focus is on commercialization of its Human Neural Stem Cell technology through optimizing delivery of its neural stem cell therapies to patients. It expects to demonstrate this therapy in a Phase I clinical trial for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) later this year. Few stem cell companies are currently in the clinic, which could generate significant interest in the company’s platform.

Neuralstem’s lead product candidate is a spinal cord stem cell line which has shown encouraging results in animal models, extending the lives of rats with ALS and reversing paralysis in animals with ischemic spastic paraplegia. The company filed an IND in December of ’08 with the FDA and is currently addressing various technical issues with the agency concerning the novel surgical techniques and devices required to deliver this first in human therapy. Expectations are that a Phase I trial of the company’s spinal cord cells in patients with ALS, a debilitating condition in which degeneration of motor neurons leads to a loss of voluntary motor control, will commence sometime in the latter half of 2009. In addition to ALS, Neuralstem will be testing its spinal cord cells as therapies for Huntington’s disease and traumatic spinal cord injuries. The company’s technology has been extensively studied through collaborations with major research centers including the University of California at San Diego and Johns Hopkins, in addition to the previously described Phase I clinical trial which is scheduled to occur under the guidance of world renowned ALS researchers at Emory University in Atlanta.

Aside from its proprietary neural stem cells, what differentiates Neuralstem from many of its competitors is its intended launch in foreign markets, in jurisdictions such as Aisa, which could facilitate a more rapid commercialization of the company’s therapies. The company has formed partnerships in Taiwan with China Medical University Hospital for clinical trials to treat Stroke and in several Asian countries through a commercialization agreement with CJ CheilJedang Corp, one of South Korea’s largest conglomerates. Under the terms of the arrangement, CJ CheilJedang purchased an option to negotiate for an exclusive license to the company’s products which could result in exclusive rights in Korea, Indonesia, the Phillipines, Malaysia, Singapore and Vietnam. Partnerships have also been formed in Germany with the Albert-Ludwigs Universitat Freiburg for a Huntington’s trial, in addition to the recent addition of former US Senator and Ambassador to China, James Sasser to the company’s Advisory Board which could increase the company’s development and commercialization efforts in China.

Neuralstem’s unique portfolio of therapies supported by favorable preclinical animal data that demonstrate the safety and efficacy of the cells for treatments to reverse certain types of paralysis, and its commercialization strategy focused on exploiting international opportunities providing more tolerant clinical pathways provide two reasons why the company is poised for growth as markets continue to rally. Despite this, CUR’s stock is currently trading just above its 52- week low as it has begun to rebound from its March bottom along with the broader market; with the FDA’s IND concerns currently being addressed, the next logical catalyst for the stock would be the announcement of Phase I trials which the company has indicated that it expects to begin in the second half of 2009, making this an intriguing time to consider the stock, as investors could see opportunities for gains similar to those of other stem cell stocks we have covered such as Advanced Cell, Cord Blood Partners and Pluristem.

July 27th CEOcast Weekly Newsletter

Monday, July 27th, 2009

Companies featured in this edition of the newsletter: ACCP, ACTC, CBAI, ITUI, SIHI, SRCO, SVUL

Markets once again displayed strength this week, spurred on by a number of better than expected earnings reports which led to gains in all of the major indices. All told, the Dow ended the week up 4.0%, gaining 349 points on the week to close above the 9000 mark at 9093, bringing it back into positive territory on the year, up 3.6%. The Nasdaq posted a 4.2% gain, closing at 1886, up 24.7% on the year while the S&P 500 and Russell 2000 gained 4.1% and 5.6% respectively on the week, bringing their yearly gains to 8.4% and 9.8%.

Earnings once again took center stage this week and for the second time in as many weeks, provided investors with all the reason that they needed to jump back into the markets. Out of 142 S&P 500 components reporting, 111 managed to beat expectations while only 21 missed estimates. The best performing sectors on the week were materials, up 8.1%, and energy and utilities, both up 5.6%. While the week’s strong performance was hailed as a sign of better things to come by many, there are still some who viewed the results with some degree of skepticism, as the majority of the consensus besting reports came as a result of strong cost cutting measures on the part of companies rather than increases in revenue.

Markets benefited further from news earlier in the week that CIT Group had reached an agreement with bond holders to secure $3 billion in rescue financing. Although this was certainly an encouraging development, there are still concerns surrounding CIT’s future solvency. Economic reports were light last week, but weekly initial jobless claims once again provided some relatively positive news as they came in at 554,000; just below consensus estimates which were calling for 557,000. The latest figure brought the four week moving average to 566,000, which is down from 585,000 but still well above normal levels.

What should investors look for this week? Earnings season continues; on Monday morning, look for reports from Honeywell (NYSE: HON), Radioshack (NYSE: RSH), and Verizon (NYSE: VZ). On Tuesday morning, expect reports from Amgen (NASDAQ: AMGN), BP (NYSE: BP), Office Depot (NYSE: ODP), Pepsi Americas (NYSE: PAS), US Steel (NYSE: X), Valero Energy (NYSE: VLO), and Viacom (NYSE: VIA). Wednesday before the bell, look for reports from Aetna (NYSE: AET), Arcelor Mittal (NYSE: MT), Coca Cola Enterprises (NYSE: CCE), Conoco Phillips (NYSE: COP), General Dynamics (NYSE: GD), Hess (NYSE: HES), Sprint Nextel (NYSE: S), Time Warner (NYSE: TWX), and Wellpoint (NYSE: WLP), with Visa (NYSE: V) reporting after the close. Thursday will be a busy day; before the bell, expect reports from AmerisourceBergen (NYSE: ABC), AstraZeneca (NYSE: AZN), Colgate-Palmolive (NYSE: CL), Dow Chemical (NYSE: DOW), Eastman Kodak (NYSE: EK), Exxon Mobil (NYSE: XOM), Goodyear Tire (NYSE: GT), Kellogg (NYSE: K), MasterCard (NYSE:MA), Motorola (NYSE:MOT), OfficeMax (NYSE: OMX), Royal Dutch Shell (NYSE: RDS), and Sony (NYSE: SNE), with First Solar (NASDAQ: FSLR), MetLife (NYSE: MET), and Walt Disney (NYSE: DIS) reporting after the close. The week wraps up with Chevron (NYSE: CVX) reporting before the bell on Friday.

Economic releases for the week begin with New Home Sales for June at 10:00am Monday, followed on Tuesday by Consumer Confidence for July and the S&P/Case-Shiller Home Price Index for May due out together at 9:00am. On Wednesday, look for Durable Orders for June due out at 8:30am, followed by weekly crude inventories at 10:30am, with the Fed’s Beige book due out at 2:00pm. On Thursday look for weekly initial jobless claims at 8:30am. The week finishes up on Friday with Advance Q2 GDP, Q2 Core PCE, Advance Q2 Chain Deflator, and Q2 Employment Cost Index, all due out together at 8:30am, followed by Chicago PMI for July at 9:45am.

There are no conferences of note scheduled once again this week due to earnings season.

Volume Alert: Shares of Access Pharmaceuticals, Inc. (OTCBB: ACCP), an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients, rocketed 83% on 5 times average volume last week, following the announcement that its European partner, SpePharm, is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK showing prevention of oral mucositis. Out of 280 total patients expected to participate in the study, the first 140 enrolled have shown no signs of oral mucositis following treatment with MuGuard; the results are extremely encouraging considering that the typical rate for mucositis in patients undergoing radiation treatment for head and neck cancer is roughly 100%. The condition ranges from moderate discomfort up to Levels 3 and 4, where symptoms are typically so debilitating that patients have to discontinue radiation treatment. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth, providing protection against the discomforting blisters and sores that form as a result of the condition. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis. Shares gained $1.75 on the week to close at $3.85.

Volume Alert: Shares of Chinese supply chain management company SinoHub (OTCBB: SIHI) surged 55% on almost twice average volume last week, as investors have become increasingly aware of the strong fundamentals and robust market that the company serves. The company posted impressive Q1 results for the period ended March 31, 2009, with revenue and net income up 56% and 83%, respectively, over the three months ended March 31, 2008. Total revenues for the 2009 first quarter rose to $18.1 million from $11.6 million in the first quarter of 2008. Net income for the 2009 first quarter advanced to $2.0 million, or $0.08 per fully diluted share, from $1.1 million, or $0.06 per fully diluted share, in the year earlier period. Shares ended the week at $4.25, up $1.51.

Steel Vault (OTCBB: SVUL) an emerging provider of identity security products and services, announced preliminary results for its fiscal quarter ended June 30, 2009 last week. During the period, SVUL managed to generate revenues of over $350,000, representing an increase of over 500% from the prior quarter. The company also highlighted some of its achievements over the quarter, among them; subscriber receipts for the month of June exceeded $200,000 -the highest in the company’s history, successful completion of a private placement totaling $500,000, and strong customer retention as SVUL ended the quarter with 15,564, active subscribers, a sequential increase of 53% from May, and an increase of 253% from 4,415 subscribers at the end of March 2009. The company attributes this solid performance to the marketing campaign which it implemented in February which has seen significant traction since its inception. Shares gained five cents on the week to close at $0.32.

Advanced Cell Technologies (OTC: ACTC), a company engaged in the development of regenerative therapies utilizing stem cells, announced last week that it filed results for its 2009 first quarter for the period ended March 31, 2009. As a result of the filing, the company become current in its filings, which could allow it to file for relisting on the Over-the-Counter Bulletin Board. A listing on the Bulletin Board could increase investor interest in the company’s science. ACTC plans to file an IND for its retinal pigment epithelium cell therapeutic program for treatment of diseases of the eye with the FDA in the second half of this year. Shares lost half a penny on the week to close just above $0.16.

Cord Blood America, Inc. (OTCBB: CBAI), an umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, provided an update on its accomplishments over the first half of 2009, which have been the most significant in the company’s history. The company has managed to significantly improve their balance sheet through a number of debt reduction measures, in addition to expanding sales into Europe, Central America and the Caribbean, in addition to obtaining a new laboratory facility which was recently the topic of an interview on a local Fox affiliate in Las Vegas. CBAI’s CEO, Matthew Schissler, was featured last week in a television interview on KVVU Fox News Las Vegas, in which he discusses the 17,000 square foot facility in Las Vegas, Nevada that it recently leased to develop a state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells. CBAI has seen significant interest from companies wishing to partner with the company since announcing that it has obtained the laboratory space last month. Shares remained unchanged at less than a penny on the week.

i2Telecom (OTCBB: ITUI), a leading developer of patented and innovative mobile applications and services, announced last week that it has entered into an agreement with Ztar Mobile, a leading Mobile Network Enabler (MNE), to become the company’s preferred international long-distance discount provider. Ztar offers global wireless solutions that enable retailers, affinity groups and brand name labels to deliver private brand wireless services to their customers. Under the terms of the agreement with Ztar Mobile, all international calls will be powered by i2Telecom’s MyGlobalTalk™ network. ITUI expects to benefit greatly from the arrangement by capitalizing on Ztar’s existing market penetration which it feels will further enhance consumer awareness as to the features and significant value offered by its MyGlobalTalk™ application. Shares remained unchanged at $0.05 on the week.

SPECIAL SITUATIONS:

SpartaCommercial Services (OTCBB: SRCO) $0.08

The global economic crisis has left indelible marks on the way the world does business, and will continue to do so as we progress down the road to recovery. Lending requirements have been forever altered which will have lasting effects on not only businesses, but the way in which consumers obtain the goods and services that they require on a daily basis. Sparta Commercial Services is a company operating largely under the radar that provides financing to consumers and municipalities seeking motorbikes and other alternative forms of conveyance that is poised to capitalize on two increasingly secular trends brought about by the global slowdown; the shift away from automobiles in response to rising energy prices, and the tightening of lending standards in the wake of the sub-prime melt down.

Sparta is currently the only nationwide full-service, independent web based finance company offering lease solutions in combination with traditional loans to the Powersports industry. The industry itself has been growing rapidly, with sales of scooters and dual sport bikes up 50% and 30% respectively in 2008 alone, largely in response to the record run up of energy prices last summer as consumers have shifted preferences away from gas guzzling automobiles and towards more economical modes of transportation. The combination of its significant dealer network and proprietary web based application processing platform that allows dealers to instantly approve or deny financing on the spot, provides Sparta with significant advantages over competitors in the space, who typically do not offer the breadth of services that Sparta does to its customers.

Sparta’s full spectrum of direct and indirect leasing and financing products include programs for all major brands of motorcycles 550cc and up, virtually all semi customs, most utility ATV’ , and select scooters, financing as many as 30 different brands with a dealer base of over 2300 nationwide, in sharp contrast to their competitors who typically specialize in one brand or category of bike. SRCO has been benefiting further as a result of tightened lending restrictions and other adverse effects of the global financial meltdown, which have led to competitors either significantly tightening their underwriting criteria, or exiting the space entirely, as many of the company’s closest competitors, such as Capital One, HSBC and GE Capital, have chosen to refocus their efforts towards enterprises that are more in line with their core businesses, leaving significant market share in the Powersports financing space for the taking.

The strength of Sparta’s business model lies in the demographics behind the variety of machines that they finance; they tend to target brands which are sought after by stable consumers -typically homeowners- with substantial positive credit histories. By choosing to serve individuals with less likelihood of defaulting on their obligations, Sparta is able to almost halve the delinquency rates on payments typical of the industry, boasting a percentage of outstanding balances over 30 days of 3.10% in FY ’08 versus a major competitor who reported delinquencies of almost double that rate in the same period. In addition to their strong consumer portfolio performance, they have also chosen to serve an almost recession proof market which further strengthens their balance sheet and has helped the company grow revenues by 258% in the four years ended April of ‘08.

In addition to their consumer financing operations, the company also offers Municipal Leasing and Commercial Fleet Leasing services which further extend Sparta’s breadth of service offerings. Originally designed to facilitate the leasing of fleets of police motorcycles, the Municipal Leasing services arm has been extended to include all types of police and emergency vehicles and has served 72 jurisdictions in 16 states in its first 14 months in operation. The Commercial Fleet Leasing product provides commercial, non-governmental, non-consumer leases, rentals and other customized financing arrangements, and recently completed its first commercial fleet leasing transaction with a major Harley dealer. Sparta expects that this business will add significant value to shareholders as more dealers become aware of the option which will enable them to increase inventories without affecting existing credit arrangements with suppliers.

With a sound business model serving a robust industry poised for continued growth in response to the shift in consumer preferences towards more fuel efficient modes of transportation, Sparta Commercial Services seems extremely well positioned to capitalize on the credit crunch which has left the vast majority of its competitors essentially unable, or unwilling, to lend. Add to this the fact that Sparta was recently approved for an expandable $25 million revolving credit facility with a large German bank, and it appears that the company is poised to continue the impressive growth which it has demonstrated over the past four years. As both the private sector and municipalities continue to demand alternative forms of transportation, yet are unable to procure the necessary financing, companies such as Sparta will surely grow along with that increased demand as they fill the void left in the wake of the credit freeze and enable consumers to finance their growing needs.

July 20th CEOcast Weekly Newsletter

Monday, July 20th, 2009

Companies featured in this edition of the newsletter: ACCP, DKAM, FMTI, ICLK, IMUC, ITUI, MNDL, OMCM, PHC

The markets came roaring back this week on the strength of earnings reports from several notable companies and some surprisingly positive economic data which provided investors with all the reason that they needed to jump headlong back into equities. The Dow posted an impressive 7.3% gain on the week to close at 8743, up 597 points on the week, cutting its yearly loss to 0.4%. The Nasdaq also managed to post sizable gains, ending the week at 1756, up 7.4% on the week and 19.6% on the year while the S&P 500 and Russell 2000 finished the week up 7.0% and 8.0%, bringing their yearly gains to 4.1% and 4.0%.

Earnings were sharply in focus this week and did not disappoint; nearly every company of note reported earnings well above consensus estimates to the delight of investors. The stage was set on Monday when Goldman Sachs received an upgrade from bearish analyst Meredith Whitney who raised her outlook and commented that she felt that it was possible for financials to rally by as much as 15% in the short run. Goldman’s report did not disappoint, as the company shattered estimates and raised the bar for other financial stocks reporting later in the week, including JP Morgan which also managed to handily outperform forecasts. By Friday, financials were up 9.4% on the week. Intel’s drubbing of estimates later in the week added more fuel to the bullish fire as it helped to allay fears that the recession would hinder tech growth.

Economic developments on the week were largely positive as well, headlined by the largest ever drop in continuing jobless claims, which fell by 642,000 to 6.273 million. Inflation reports came in a bit higher than expectations with both the CPI and PPI showing the effects of higher energy prices, but the core consumer inflation figures, which exclude energy and food costs were in line with acceptable levels. Positive news from housing markets in the form of stronger than expected housing starts and building permits served to further soothe the minds of anxious investors as they look forward to next week and more earnings reports.

What should investors look for this week? Earnings season will be in full swing and is expected to command investors’ full attention. On Monday morning, look for reports from Halliburton (NYSE: HAL) and Johnson Controls (NYSE: JCI), followed that afternoon by Boston Scientific (NYSE: BSX) and Texas Instruments (NYSE: TI). Things pick up considerably on Tuesday morning with Blackrock (NYSE: BLK), Caterpillar (NYSE: CAT), Coca Cola (NYSE: KO), Continental Air (NYSE: CAL), DuPont (NYSE: DD), Lockheed Martin (NYSE: LMT), Merck (NYSE: MRK), Schering-Plough (NYSE: SGP), Southwest Air (NYSE: LUV), UAL Corp. (NASDAQ: UAUA), United Technologies (NYSE: UTX), and United Health (NYSE: UNH). After the bell on Tuesday, expect reports from Advanced Micro (NYSE: AMD), Apple (NASDAQ: AAPL), Starbucks (NASDAQ: SBUX), and Yahoo (NASDAQ: YHOO). Wells Fargo (NYSE: WFC) reports Wednesday morning, followed that afternoon by Boeing (NYSE: BA), Delta Airlines (NYSE: DAL), Eli Lilly (NYSE: LLY), Morgan Stanley (NYSE: MS), PepsiCo (NYSE: PEP), Pfizer (NYSE: PFE) and Qualcomm (NASDAQ: QCOM). On Thursday before the bell look for reports from 3M (NYSE: MMM), Bristol-Myers (NYSE: BMY), Ford Motor (NYSE: F), Kimberly-Clark (NYSE: KMB), McDonalds (NYSE: MCD), Northrop Grumman (NYSE: NOC), Phillip Morris (NYSE: PM), Radioshack (NYSE:RSH), Raytheon (NYSE: RTN), UPS (NYSE:UPS), US Air (NYSE: LCC), and Wyeth (NYSE: WYE), with Amazon.com (NASDAQ: AMZN), American Express (NYSE: AXP) and Microsoft (NASDAQ: MSFT) reporting after the close. The week wraps up on Friday morning with Ingersoll-Rand (NYSE: IR) and LM Ericcson (NASDAQ: ERIC).

Economic reports will be few and far between but look for Leading Indicators for June due out at 10:00am Monday morning. On Wednesday, expect Weekly Crude Inventories at 10:30am, followed on Thursday by Weekly Initial Jobless Claims at 8:30am and Existing Home Sales for June at 10:00am. The week finishes up on Friday with Revised Michigan Sentiment Index for July at 9:55am.

There are no notable conferences scheduled for the week due to earnings reports, but keep an eye on developments from Chairman Bernanke’s testimony on monetary policy which is expected on Tuesday and Wednesday, as investors will surely look for signs that the Fed is beginning to slow its implementation of quantitative easing measures.

Volume Alert: Shares of behavioral healthcare services provider Pioneer Behavioral Health (AMEX: PHC), surged 30% on almost twice average volume last week, following news the week prior that the company has expanded capacity at its Capstone Behavioral Facility in Detroit, Michigan, in response to increased demand for its services in the region, and anticipation that the company could receive CMS certification for its Seven Hills Behavioral facility in Nevada. PHC previously said that it believed it was “close” to receiving certification at the Nevada facility and has demonstrated strong growth in demand for its services in Michigan markets which has been coupled with strong performance within the healthcare sector in the past few weeks. Shares gained forty one cents on the week to close at $1.74.

Volume Alert: Shares of Drinks Americas Holdings (OTCBB: DKAM), a company that develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned iconic celebrities, jumped 8% on over two times average volume before retreating last week, following the announcement that it has launched Kid Rock American Badass Beer at Comerica Park in Detroit Michigan during Kid Rock concert dates on July 18th and 19th. DKAM has planned roll outs in Michigan markets immediately following the concert dates, with the beer being available initially in kegs and 12 oz. and 22 oz. bottles shortly thereafter. A newly formed sales team will begin selecting distributors and filling orders in the Michigan market, where initial interest in the beer has been high. In other news last week, the company announced that the Olifant Vodka brand, supported by headline sponsorship of the Blazed and Confused Tour featuring Snoop Dog and Slightly Stoopid, is driving year over year sales growth in current markets, and that sales have expanded into additional concert venue markets where Olifant was not previously sold including California, Utah, Idaho, Washington, Oregon, New Mexico and Nevada. The company believes that sales at the distributor level will increase by close to 40% thanks to the increased brand awareness raised by the Tour. Shares ended the week up 2% to close at $0.1325.

Forbes Medi-Tech Inc. (NASDAQ: FMTI), a life sciences company focused on evidence-based nutritional solutions, announced last week that the Nasdaq has extended the suspension of its bid price minimum listing requirement, extending the company’s compliance deadline to January 4, 2010. In order to regain compliance, Forbes must achieve a minimum closing bid of $1 or greater for ten consecutive trading days before the deadline. The company is currently working to retain its listing on the Toronto Stock Exchange (TSX) as well, and has until August 12, 2009 to regain compliance with the TSX’s minimum $3 million market capitalization threshold. Given current trends and trading patterns, the company has said that it does not expect to regain compliance with the TSX’s requirements by the deadline stated, but plans to seek listing on another Canadian exchange should its shares be delisted following the August deadline. Shares lost two cents on the week to close at $0.30.

i2Telecom (OTCBB: ITUI), a leading developer of award-winning patented and innovative high-quality mobile applications and services, announced last week that its MyGlobalTalk application now allows users in 31 countries to save on international calls, marking a significant expansion from the first generation application which only allowed users within the US to access the MyGlobalTalk network. The application is now available in overseas markets via local access numbers which allow users in the 31 nations to have their international phone calls routed through the MyGlobalTalk network at significant cost savings versus traditional international calling plans. The app is also available on Smartphones and works wherever mobile service is available, providing high-quality service without the need for a Wi-Fi connection with no contracts, connection fees or call minimums. Shares closed the week at $0.0475.

Volume Alert: Shares of internet advertiser interCLICK, Inc. (OTCBB: ICLK), surged 14% on almost twice average volume last week, as the company again raised guidance for its preliminary second quarter revenue for the period ended June 30, 2009. ICLK now expects revenue to exceed $10.5 million, an increase of over 124% compared to the year-earlier period and 25% sequentially, raising guidance from its previous forecast for quarterly revenue to exceed $9.5 million versus $4.7 million in the corresponding year ago period. The company previously increased its 2009 full-year revenue forecast on June 4th, for revenue to exceed $40 million, which would represent an increase of at least 80% compared to 2008 revenue of $22.4 million. ICLK attributes its strong performance to its proprietary behavioral targeting system which has allowed the company to deliver significant return on investment to its advertising clients. In other news last week, ICLK announced that it has appointed Steven D. Rubin to its Advisory Board. Mr. Rubin is a member of The Frost Group, LLC, a successful private investment firm based in Miami that recently purchased a large position in ICLK. Mr. Rubin has extensive experience across a breadth of industries and will add a great deal of perspective and experience to the Board. Shares gained twenty cents on the week to close at $1.60.

ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers, announced last week that it has retained the services of the Torrey Pines Institute for Molecular Studies in San Diego, CA, to evaluate the immunogenicity of peptides to target cancer stem cells (CSCs) relating to the company’s lead product candidate ICT-121. The evaluation will be conducted by Dr. Clemencia Pinilla, a specialist in immune response mechanisms and their role in the prevention and cause of human disease with over 100 publications and multiple patents to her credit. IMUC expects that this is the beginning of a collaborative relationship which will serve to increase the efficacy of their existing portfolio and could lead to development of more commercially viable vaccines in the future. Shares gained ten cents on the week to close at $0.40.

Mandalay Media (OTCBB: MNDL), the owner of new media distribution and content companies, reported results for its fourth fiscal quarter and fiscal year ended March 31, 2009 last week. MNDL managed to report its first quarter of positive adjusted EBITDA, posting $0.9 million, an improvement of approximately $1 million sequentially, while revenue for the quarter was approximately $9.9 million. Revenue for the fiscal year ended March 31, 2009 was $31.3 million with an EBITDA loss of approximately $2.0 million. The company also provided guidance for FY ’10, where it expects to generate revenues in excess of $40 million with EBITDA of $3.5 million as a result of expected increases in M&A activities, expansion into new markets in Europe, North America and Latin America, and plans to expand its product offerings to capitalize on the growing Smartphone market. Shares remained unchanged at $0.55 on the week.

On the Wires: Access Pharmaceuticals, Inc. (OTCBB: ACCP), an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients, announced last week that it has been invited to present at the Jessup & Lamont 2009 Growth Stock & National Sales Conference to be held at the Waldorf Astoria Boca Beach Club on July 30th, 2009 in Boca Raton, Florida. Shares gained twenty six cents on the week to close at $2.10.

SPECIAL SITUATION:

OmniComm Systems (OTCBB: OMCM) $0.20

Over the course of the past few months, we have profiled a number of companies operating in industries that have been overlooked by investors in the wake of the global economic slowdown that are now poised to resume growth as markets continue to right themselves. The biotech industry has been one of the sectors hardest hit by the slowdown, where companies with insatiable demand for investment capital necessary to push product portfolios through the capital intensive FDA approval process were denied funding as a result of the capital market freeze, making it all but impossible to acquire the financing necessary to push product portfolios through the FDA approval process and onto commercialization. With the beginning of recovery, these companies have begun to be able to satisfy their demands for fresh capital resulting in the sector beginning to resume growth, despite being largely overlooked by investors searching for value in the broader market. OmniComm is a company that is poised to capitalize on the renewed growth spurred by access to capital markets which has allowed many biotechs to resume their clinical programs by facilitating and streamlining management of the massive amounts of data necessary to promote clinical programs through the FDA process. They are an eClinical software and services company dedicated to helping the world’s pharmaceutical, biotechnology, contract research (CROs), and medical device organizations to maximize the value of their clinical research investments through the use of innovative and progressive technologies.

Despite sounding complex, OMCM’s business model is fairly straightforward; they provide customer driven Internet data management solutions to companies conducting potentially life altering clinical trial research across the globe. The company itself is one of the fastest growing entities in the Electronic Data Capture (EDC) and Clinical Trial Management Systems (CTMS) markets, ranking in the top 150 fastest revenue growth technology companies in North America during the last five years. At the center of OMCM’s success is its TrialMaster web based software platform which allows clinical trial sponsors and investigative sites to easily and securely collect, validate, transmit, and analyze clinical study data including patient histories, patient dosing, adverse events and other clinical trial related information via an intuitive user interface. TrialMaster eliminates the need for endless stacks of documents and makes them available instantly to agencies all across the globe, greatly reducing the costs and time constraints associated with clinical processes. Since its inception in 1997, OMCM has facilitated the enrollment of over 10,000 patients in North America, Asia, Europe, Australia, Africa, India and South America, with successful implementation of TrialMaster in over 40 countries and close to 300 clinical trials from Phase I through IV, with a number of customers having received FDA approval using the TrialMaster system.

In addition to its strong technology platform and superior customer service offering that enables facilitation of all phases of clinical development, OMCM has also recently acquired the EDC business of eResearch Technology, a key competitor in the space which should significantly enhance the company’s bottom line by providing OMCM with 44 new clients. eResearch’s EDC business generated $5.9 million in FY ’08 with revenues of $1.4 million in the first quarter of this year, and OMCM expects that the acquisition will further facilitate growth and increase their position as a leader in the EDC business. Despite their strong business model and recent acquisition activity, and like many companies operating in the space, OMCM has recently seen its shares punished as a result of the difficult capital markets which have severely hampered clinical activities for all but the most well capitalized companies. Prior to the slowdown, OMCM posted back to back to back record quarters, but that impressive growth was stunted with the significant decreases in clinical activities resulting from the slowdown. With renewed access to capital markets resulting in a resurgence of clinical activity, OMCM seems well positioned to reap the benefits as companies again recommence going through the FDA approval process, which could see the company resume its growth.